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ABSTRACT
CBX7, 
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chromobox homolog 7, is a chromobox family protein encoding a novel 
Polycomb protein, component of the Polycomb repressive complex 1 (PRC1). 
The Polycomb group (PcG) proteins are epigenetic transcriptional repressors 
involved in the control of cellular proliferation and oncogenesis. CBX7 protein 
levels show a progressive reduction, well related with the malignant grade of 
the thyroid neoplasias. Indeed, its expression decreased in an increasing 
percentage of cases going from benign adenomas to papillary, follicular and 
anaplastic thyroid carcinomas.
To elucidate the function of CBX7 in carcinogenesis, we searched for CBX7 
interacting proteins by a proteomic analysis. By this approach, we identified 
several proteins among which we selected Histone Deacetylase 2 (HDAC2) 
that is well known to play a key role in neoplastic cell transformation and to 
downregulate E-cadherin expression, whose loss is a critical event in the 
Epithelial-Mesenchymal Transition, and therefore emerging as one of the 
caretakers of the epithelial phenotype.
 We confirmed by co-immunoprecipitation that CBX7 physically interacts with 
the HDAC2 and demostrated that is able to inhibit its activity. Then, we 
showed that both these proteins bind the E-cadherin promoter, and that CBX7 
is able to upregulate E-cadherin expression. Consistent with these data we 
found a positive statistical correlation between CBX7 and E-cadherin 
expression in human thyroid carcinomas. Finally, we demonstrated that the 
expression of CBX7 increases the acetylation status of the histones H3 and H4 
on the E-cadherin promoter. Therefore, the ability of CBX7 to positively 
regulate E-cadherin expression, by interacting with HDAC2 and inhibiting its 
activity on the E-cadherin promoter, would account for the correlation between 
the loss of CBX7 expression and a highly malignant phenotype in thyroid 
cancer patients. Thus, several important interacting proteins of CBX7 and the 
pathways in which they are involved strongly suggest that CBX7 can be 
considerated a very important regulator of thyroid malignant transformation. 
1. BACKGROUND 
1.1 CBX7 and thyroid carcinogenesis.
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The thyroid gland is the largest endocrine organ in humans (Kondo et al. 2006) 
and regulates systemic metabolism through thyroid hormones. It is located in 
the neck region, on the anterior surface of the trachea, and is formed by two 
distinct cell types, the follicular cells and the parafollicular or C cells (De 
Felice and Di Lauro 2004). However, more than 95% of thyroid carcinomas are 
derived from follicular cells (Kondo et al. 2006) and are the most common 
endocrine malignancies, with an estimated 25000 new cases diagnosed 
annually in the United States. Conversely, only 3% of thyroid tumors, referred 
to as medullary thyroid carcinoma, are of parafollicular origin. Thyroid tumors 
result from the accumulation of different modifications in critical genes 
involved in the control of cell proliferation. Thyroid neoplasms represent a 
good model for studying the events involved in epithelial cell multistep 
carcinogenesis, because they comprise a broad spectrum of lesions with 
different degrees of malignancy, which are diagnosed on the basis of 
histological and clinical parameters. In fact, follicular cell-derived thyroid 
tumors include: 1) benign adenomas, which are not invasive and very well 
differentiated; 2) carcinomas, which are divided into well-differentiated, poorly 
differentiated (PDCT) and undifferentiated (ATC). Well-differentiated thyroid 
carcinomas are papillary (PTC) that represent more than 70% of thyroid 
malignant tumors and follicular (FTC) that represent 10% of thyroid 
carcinomas. These tumors, being differentiated, have a good prognosis (Kondo 
et al. 2006; Saltman et al. 2006). PDTC and ATC seem to derive from the 
progression of differentiated carcinomas (Van der Laan et al. 1993). Although 
the ATC represent 2-5% of thyroid malignant tumors, they are one of the most 
lethal human neoplasms being rapidly–growing, very aggressive and always 
fatal. Finally, PDTC, representing 7% of thyroid carcinomas, are 
morphologically and behaviourally intermediate between well-differentiated 
and undifferentiated thyroid carcinomas. Although various therapeutic 
approaches are followed in clinical practice, most of them are not life-saving. 
Hence, the discovery of new approach to diagnose cancer at an early stage and 
to establish more effective therapies is a critical and urgent issue. To achieve 
this goal, identification and characterization of key molecules that participate 
in carcinogenesis are essential steps. 
Microarray studies are widely used to define diagnostic and prognostic 
signatures in cancers and they have led to the identification of a large list of 
carcinoma-regulated genes also in thyroid cancers (Delys et al. 2007). To 
identify the genes involved in the process of thyroid carcinogenesis we 
analysed the gene expression profiles using an Affymetrix HG_U95Av2 
oligonucleotide array. This study led to the identification of genes whose 
expression was up- or down-regulated in the carcinoma cell lines compared 
with 
altered 
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the primary cell culture of normal thyroid origin, assuming that the genes 
in their expression in all of the thyroid carcinoma cell lines might 
represent candidate genes involved in thyroid cell transformation (Pallante et 
al. 2005). Among the down-regulated genes, we identified CBX7 that resulted 
down-regulated about 20 fold in all the carcinoma cell lines analysed and that 
could be actively involved in the process of thyroid carcinogenesis. CBX7 is a 
chromobox family protein encoding a novel polycomb protein and its 
expression shows a progressive reduction, well related with the malignant 
grade of the thyroid neoplasias. Indeed, CBX7 protein levels decreased in an 
increasing percentage of cases going from benign adenomas to PTC, FTC, 
ATC. Moreover, correlation between low CBX7 expression and a more 
aggressive histotype seems to apply also to breast, ovary, and lung carcinomas 
and seems to reduce survival in colon carcinoma (Pallante et al. 2008).
1.2 CBX7, a novel Polycomb protein.
CBX7, which is located on chromosome 22q13.1, encodes a novel Polycomb 
protein (Pc) of 28.4 kDa and 251 amino acids that contains a highly conserved 
“chromodomain" (chromatin organisation modifier, CD) at N-terminal, 
between amino acids 10 and 46. This domain was originally identified in 
Drosophila melanogaster as a 37-amino-acid region of homology shared by 
heterochromatin protein 1 (HP1) and Pc proteins (Paro and Hogness 1991). 
Phylogenetic and sequence analyses of the chromodomain (figure 1A and B) 
revealed that CBX7 has a great similarity to other known or putative Pc 
proteins like CBX2 (Pc1), CBX4 (Pc2), CBX6 and CBX8 (Pc3). This 
similarity is less pronounced respect to the HP1 proteins, such as CBX1 
(HP1), CBX3 (HP1), CBX5 (HP1) and, moreover, CBX7 does not contain 
the “chromo-shadow domain” that, instead, is a hallmark of HP1 proteins. 
Despite a high degree of conservation, the CD display significant differences in 
binding histone H3 modification. Not all CDs in fact bind preferentially to tri-
methylated Lys 27 on histone H3 (H3K27me3); rather, some (Cbx2 and Cbx7)
display affinity towards both histone H3 tri-methylated at K9 (H3K9me3) and 
H3K27me3, one (Cbx4) binds K9me3 and some (Cbx6 and Cbx8) do not bind 
significantly to either modification suggesting that these CDs may bind to 
another methylation site not yet identified or tested (Bernstein et al. 2006). 
CBX7, in particular, displays strong affinity for both H3K9me3 and 
H3K27me3 and is developmentally regulated in its association with chromatin. 
CBX7 chromodomain contains Pc-specific residues that have been shown to be 
necessary both for Pc dimerization and recognition of H3K27me3 (Min et al. 
2003). In addition to the high homology within the CD, CBX7 has also 
homology to Pc proteins in a carboxy-terminal region (figure 1C) previously 
defined as the Pc box or C-box (Jones et al. 2000). 
8Figure 1. Identification of CBX7 as a Polycomb protein. A) Phylogenetic analysis 
of Chromobox (CBX) proteins. Lines grouped by open rectangles denote orthologs of 
a same CBX protein (name in the right). Full rectangles refer to proteins that cannot 
be considered purely orthologs of any of the CBX proteins. Pc proteins are shown in 
blue, and HP1 proteins in red. CBX7 and CBX6 are shown in black. B) Alignment of 
CBX7 chromodomain with that of other known and putative human Polycombs. 
Identical residues are shown in a yellow background, and similar residues are shown 
in a cyan background. C) Alignment of CBX7 Polycomb box with that of other known 
and putative human Polycombs. Background colours are as described in B  (from Gil 
et al. 2004).
It is known that the Pc box (aminoacids 231–243) and the CD (Jones et al. 
2000) are both necessary for CBX7 function. It was seen that a fusion protein 
between CBX7 and the DNA-binding domain of Gal4 is able to repress in a 
dose dependent manner, the transcription over a 4xGal4-tk-luc reporter, 
suggesting that CBX7 functions by repressing transcription (Gil et al. 2004). 
So, CBX7 seems to act like the others Pc proteins exerting its effect through 
transcriptional repression.
Mouse Cbx7 is, moreover, able to associate with facultative heterochromatin 
and with the inactive X chromosome, which indicates that CBX7 is really 
9involved in the repression of gene transcription (Bernstein et al. 2006). It has 
also been found in vitro that the CD of CBX7 can bind RNA and that, in vivo, 
the interaction of CBX7 with chromatin, and in particular with the inactive X 
chromosome, partially depends on its association with RNA (Bernstein et al. 
2006). These data suggest that the capacity of this mouse Polycomb homolog 
to associate with the inactive X chromosome, or any other region of chromatin, 
depends not only on its chromodomain but also on the combination of histone 
modifications and RNA molecules present at its target sites (Bernstein et al. 
2006). CBX7 has also been shown to initiate lymphomagenesis and cooperate 
with c-myc in tumor progression in vivo (Scott et al. 2007). Analysis of the 
CBX7 chromodomain showed that this protein can associate with repressive 
histone modifications, including dimethylated and trimethylated H3K9, as well 
as trimethylated H3K27 (Bernstein et al. 2006) suggesting that a CBX7-
containing complex may possess the ability to read histone modifications found 
in promoters of key genes, including those susceptible to cancer-specific DNA 
methylation.
CBX7 is also capable to interact with different Pc group members. In fact, 
similarly to other Pc proteins, CBX7 is able to inter-functions with itself and 
with the ring-finger protein Ring1 (Gil et al. 2004), as reported by the mean of 
Glutathione S-transferase (GST) pull-down experiments (Satijn et al. 1997, 
Satijn and Otte 1999). In addition, within the nucleus, CBX7 co-localizes with 
Ring1 to distinct foci-like structures termed Pc-bodies as demonstrated, in 
several cell lines, with immunofluorescence microscopy studies (Saurin et al. 
1998). However there is not association between CBX7 and other PcG 
proteins, such as Bmi1, EED or EHZ2 (Gil et al. 2004) so this let think that 
CBX7 is part of different complexes than Bmi1 and Pc2.
CBX7 is highly expressed in a number of different normal tissue types, 
including brain, kidney, heart and skeletal muscle and recent studies suggest 
that may play an important role in tumorigenesis. CBX7 was identified in a 
functional screen for genes involved in senescence bypass, at least partially via 
repression of expression of the tumor suppressor gene, p16, extending cellular 
life span in mouse embryonic fibroblasts and human prostate primary epithelial 
cell (Gil et al. 2004, Bernard et al. 2005). 
However, another study on ependymoma (Suarez-Merino et al. 2005) reported 
a consistent down-regulation of CBX7 in the tumor samples, in fact in this 
study is suggested the presence of a microdeletion at this site of 22q. The 
abnormal expression of CBX7 was due to allelic loss in 55% of cases, where 
underexpression was due to loss of one allele in 46% of cases and both alleles 
in 9% of cases. Moreover, none sequence alteration of the CBX7 coding region 
was identified, suggesting that other mechanisms, such as promoter 
methylation or histone deacetylation, may be responsible for the silencing of 
this gene in ependymoma samples. Also in thyroid carcinomas was detected 
LOH in 36.8% of PTC and 68.7% of ATC and no mutations were found 
(Pallante et al. 2008). Therefore, other epigenetic mechanisms associated with 
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an allelic loss might account for the reduced CBX7 expression in human 
thyroid carcinomas.
1.3 CBX7 and Polycomb Group proteins.
CBX7 is a part of the Polycomb Group proteins (PcG) (Gil et al. 2006). PcG, 
so named because of mutations that affect the patterning of the male sex combs 
in Drosophila, are transcriptional repressors that participate in distinct 
multiprotein complexes, the best characterized being Polycomb repressive 
complexes 1 and 2 (PRC1 and PRC2) (Sparmann and van Lohuizen 2006, 
Schwartz and Pirrotta 2007). The PRC2 complex has associated histone 
deacetylase and histone methyl transferase activities specific for lysine of 
Histone H3, H3K27, thus contributing to the establishment of histone 
repressive marks (Kuzmichev et al. 2002, Kirmizis et al. 2007). Between the 
known mammalian components of this complex are Enhancer of Zeste (EZH2), 
Early embryonic deficient (EED), Suppressor of Zeste (SUZ12) and other 
associated proteins. The prototypic PRC1 complex comprises stoichiometric 
amounts of Polycomb (Pc), Posterior sex comb (Psc), Polyhomeotic (Ph) and 
Sex combs extra (Sce) (Shao et al. 1999, Saurin et al. 2001). PRC1 binds to the 
H3K27me3 mark via the chromodomain of the Pc protein (Fischle et al. 2003, 
Bernstein et al. 2006) and catalyzes the mono-ubiquitylation of histone H2A on 
lysine 119, thereby shutting down transcription (Wang et al. 2004, Cao et al. 
2005, Sparmann and van Lohuizen 2006).
In mammalian cells, the formation of this complex is complicated by the 
presence of multiple orthologs of the archetypal PRC1 proteins. With five Pc 
proteins (CBX2, CBX4, CBX6, CBX7 and CBX8), six Psc proteins (BMI1, 
MEL18, MBLR, NSPC1, RNF159 and RNF3), three Ph proteins (HPH1, 
HPH2 and HPH3) and two Sce proteins (RING1 and RING2). There is 
enormous diversity for combinatorial association between these proteins (Gil 
and Peters 2006, Whitcomb et al. 2007) (figure 2). The reasons for such 
diversification and the interplay between the different family members remain 
unclear. Genetic ablation of specific PcG genes in mice has confirmed their 
role in embryonic patterning and Hox gene regulation but also pointed to more 
general effects on stem cell function. For example, Bmi-1 null mice have 
hematological and neurological defects that are traceable to a failure in the self-
renewal of the relevant stem cells (Lessard and Sauvageau 2003, Park et al. 
2003). 
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Figure 2. Transcriptional repression by the Polycomb group proteins. The PRC2 
complex, comprising Ezh2, Eed and Su(z)12, binds to Polycomb responsive elements 
(PRE) and establishes epigenetic marks in chromatin by tri-methylating histone H3 on 
lysine 27 (H3K27). This mark is recognised by the PRC1 complex, which mono-
ubiquitylates histone H2A on lysine 119, leading to transcriptional repression. 
Whereas the PRC1 complex in Drosophila comprises stoichiometric amounts of Pc, 
Psc, Ph and Sce, there are multiple orthologues of these proteins in mammalian cells, 
as indicated in the coloured boxes.(Gil et al.2006).
More recently, genome-wide ChIP analyses have identified over 1000 genes 
that are potential targets of PcG-mediated repression, many of which are 
implicated in the maintenance of pluripotency (Bracken et al. 2006, Tolhuis et 
al. 2006). Evidence is rapidly increasing that PcG genes are a novel class of 
oncogenes and anti-oncogenes, which may in future years become central to 
the development of novel cancer therapies based on epigenetic gene silencing 
(Nakao et al. 2004, Egger et al. 2004). Not only PcG genes such as BMI-1 and 
EZH2 are capable of cellular transformation, but are also essential for cell 
survival. To date, abnormal PcG genes expression has been described in most 
human cancers. Moreover, the correlation between PcG expression and 
biological behavior of clinically defined cancer subtypes suggests that these 
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genes play a central role in oncogenesis, and holds a promise for discovery of 
novel diagnostic markers (Raaphorst et al. 2004). Recent studies have shown 
that a large group of genes silenced in association with aberrant promoter DNA 
hypermethylation in cancer are frequent targets of the PcG repressive 
complexes in normal and neoplastic embryonic cells (Ohm et al. 2007; 
Schlesinger et al. 2007). These studies suggest a stem cell origin for cancer in 
which silencing of genes in adult cancer are linked to the epigenetic control of 
stem/precursor cell gene expression patterns regulated by PcG proteins. 
However, a direct link has not yet been established.  
CBX7, constituent of the PRC1 complex, has a direct association with gene 
repression and promoter DNA hypermethylation of genes frequently silenced 
in cancer (Mohammad et al. 2009). CBX7, in fact, is able to complex with
DNA methyltransferase (DNMT) enzymes, which leaded to explore a role for 
CBX7 in maintenance and initiation of gene silencing. Knock-down of CBX7 
was unable to relieve suppression of deeply silenced genes in cancer cells; 
however, in embryonal carcinoma (EC) cells, CBX7 can initiate stable 
repression of genes that are frequently silenced in adult cancers. Furthermore, it 
was observed the assembly of DNMTs at CBX7 target gene promoters.
Sustained expression of CBX7 in EC cells confers a growth advantage and 
resistance to retinoic acid–induced differentiation. In this setting, especially, 
there is increased promoter DNA hypermethylation for many genes. Indeed, 
DNA methylation is another well studied epigenetic mechanism. Methylation 
at the C-5 position of cytosine residues present in CpG dinucleotides by DNA 
methyltransferases (DNMTs) is generally considered to facilitate static long-
term gene silencing (Lund and van Lohuizen, 2004). Therefore CBX7 promote
the initiation of epigenetic changes involving abnormal DNA hypermethylation 
of genes frequently silenced in adult cancers (Mohammad et al. 2009).
To elucidate the function of CBX7 in carcinogenesis, we searched for CBX7 
interacting proteins by a proteomic analysis. By this approach, we identified 
several proteins among which we selected Histone Deacetylase 2 (HDAC2) 
that is well known to play a key role in neoplastic cell transformation and to 
downregulate E-cadherin expression, whose loss is a critical event in the 
Epithelial-Mesenchymal Transition.
1.4 Epithelial–Mesenchymal Transition.
Epithelial–Mesenchymal Transition (EMT) is an indispensable morphogenetic 
process which allows tissues and organs formation involving cell migration 
(Thiery and Sleeman 2006). This phenotypic change is known to take place, for 
example, in gastrulation, neural crest cell migration, and heart formation 
(Savagner 2001). EMT can be distinguished on the basis of morphological 
criteria including the loss of epithelial polarization and the acquisition of a 
flattened and elongated cell shape (Hay 1995). Cells that dissociate from 
primitive embryonic epithelia during tissue patterning often convert to a 
13
migrating, mesenchymal cell type. Crucial to the EMT process is the down-
regulation of cell-cell contacts, most notably E-cadherin-based adhesion 
(Savagner 2001). Epithelial and mesenchymal cells differ in various functional 
and phenotypic characteristics. Epithelial cells grow in layers and communicate 
through specialized membrane structures, such as tight junctions, adherens 
junctions, desmosomes and gap junctions. Epithelial cells are motile and can 
move away from their nearest neighbours, while remaining within the 
epithelial layer (Schock and Perrimon 2002). Mesenchymal cells, on the other 
hand, do not form an organized cell layer, nor do they have the same apical–
basolateral organization and polarization of the cell-surface molecules and the 
actin cytoskeleton as epithelial cells.
Epithelial cells can convert into mesenchymal cells by a process known as the 
EMT. The precise spectrum of changes that occur during EMT is probably 
determined by the integration of extracellular signals that the cell receives, 
although this is still unclear. It has also been reported the reverse process, 
known as mesenchymal-epithelial transition (MET) (figure 3).
Figure 3. The cycle of epithelial-cell plasticity. The diagram shows the cycle of 
events during which epithelial cells are transformed into mesenchymal cells and vice 
versa. The different stages during EMT (Epithelial–Mesenchymal Transition) and the 
reverse process MET (Mesenchymal–Epithelial Transition) are regulated by effectors 
of EMT and MET, which influence each other. Important events during the progression 
of EMT and MET, including the regulation of the tight junctions and the adherens 
junctions, are indicated. (Thiery and Sleeman 2006)
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The thyroid gland is unique among the endodermally derived organs that has 
no connection with the gut tube and is located rather distant from the site of 
embryological specification. The effector mechanisms regulating the 
dislocation of the thyroid anlage from the pharyngeal endoderm, its further 
migration, and the terminal differentiation of the follicular epithelium are 
largely unknown. Unexpectedly, during thyroid morphogenesis is not involved 
an EMT-like process, typically characterized by loss of E-cadherin and up-
regulation of N-cadherin. The finding of continuous expression of E-cadherin 
in thyroid progenitor cells, in fact, demonstrates that the epithelial 
differentiation is maintained throughout the entire morphogenetic process. 
Conversely, N-Cadherin expression, often associated with increased migrating 
capacity, was not detected in the thyroid primordium, but was expressed in the 
surrounding mesenchyme. These findings indicate the lack of EMT because, in 
thyroid progenitor cells, the epithelial phenotype is maintained throughout 
organogenesis, and suggest that translocation of the developing thyroid does 
not involve active migration of individual cells, but rather is secondary to 
movements of surrounding tissues (Fagman et al. 2003). Another classical 
cadherins that influences thyroid development is the R-cadherin. Its expression 
in late thyroid development, in fact, proposes a functional role in 
folliculogenesis and was maintained in the adult thyroid along with E-cadherin
(Fagman et al. 2003).
Modifications of cell-cell interactions similar to those abserved during 
development also occur in some pathological situations, such as during 
carcinogenesis, where the distruption of cell-cell contact is one of key events in 
tumor progression. EMT provides a new basis for understanding cancer 
progression towards dedifferentiated and more malignant states. In fact, during 
recent years, EMT has emerged as a central process during cancer progression 
and metastasization. In this process, cancer cells acquire a fibroblastoid 
invasive phenotype, down-regulate epithelial-specific proteins, such as 
adherens and tight junction proteins, induce various mesenchymal markers, 
such as vimentin, and finally migrate through the extracellular matrix 
(Savagner 2001, Huber et al. 2005). This results in changed adhesive 
properties, and the activation of proteolysis and motility, which allows the 
tumour cells to metastasize and establish secondary tumours at distant sites 
(Sleeman 2000).
Many effectors orchestrate the disassembly of junctional complexes and the 
changes in cytoskeletal organization that occur during EMT. The activation of 
signalling pathways also results in the activation of transcriptional regulators 
such as Snail (now known as SNAI1) (Ballaro-Gimeto and Nieti 2005) and 
Slug (now known as SNAI2), which regulate the changes in gene-expression 
patterns that underlie EMT.
A central target of these transcriptional regulators is the repression of the E-
cadherin gene, an important caretaker of the epithelial phenotype. Loss of E-
cadherin protein and/or transcriptional repression of its mRNA are hallmarks of 
EMT (Cano et al. 2000, Batlle et al. 2000). Several studies indicated that 
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down-regulation of E-cadherin is accompanied by upregulation of the 
mesenchymal N-cadherin expression, which correlates with invasion, 
metastasis, and EMT (Cavallaro and Christofori 2004). This dynamic and 
reciprocal change in E- and N-cadherin expression is known as “cadherin 
switching”. The intracellular domain of E-cadherin interacts with catenin 
proteins, called -, ß-, -, and p120-catenin, which connect the adhesion 
complex to the actin cytoskeleton (Thiery 2002). The interaction between the 
cytoplasmic tail of cadherins with the catenins and the actin cytoskeleton is 
critical for the establishment of stable and functional adherens junction (Rosanò 
et al. 2006). However, signals generated by intracellular cadherin-binding
proteins may also alter cellular behavior. This is most notable for ß-catenin, 
which, apart from linking cadherins to the cytoskeleton, is able to enter the 
nucleus and trans-activate target genes (Fagman et al. 2003).
1.5 E-cadherin.
Cadherins constitute a major class of adhesion molecules that support calcium-
dependent, homophilic cell-cell adhesion in all solid tissues of the body. The 
cadherins mediate cell-cell recognition events and, in association with the actin 
cytoskeleton, bring about morphological transitions that underlie tissue 
formation and maintain tissue architecture in the adult organism. In this way, 
five different sub-families can be considered: 1) type I, classical cadherins, 
mainly localised to adherens junctions; 2) Highly related type II cadherins; 3) 
Desmosomal cadherins (desmocollins and desmogleins) that form desmosomal 
junctions; 4) Protocadherins, mainly implicated in neural development; 5) 
Cadherin-related proteins, like the Flamingo (7Tm) and Fat-like cadherins 
(Peinado et al. 2004) (figure 4).
The classical cadherins typically consist of five tandemly repeated extracellular 
domains, approximately of 110 amino acids, single membrane-spanning 
segment and a cytoplasmic region. The N-terminal extracellular domains 
mediate cell-cell contact while the cytoplasmic region interacts with the 
cytoskeleton through the catenins. Specific adhesive binding is conferred by 
the cadherin ectodomain. Although the ectodomain alone possesses 
homophilic-binding properties (Brieher et al. 1996), stable cell adhesion 
requires the cadherin cytoplasmic tail and associated proteins (Nagafuchi and 
Takeichi 1988, Brieher et al. 1996). In the case of E-cadherin, specificity of the 
homophilic interactions was localized to the first N-terminal extracellular 
domains (Nose et al. 1990) (figure 4).
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Fifure 4. Schematic overview of the cadherin superfamily. The main structural 
domain and schematic structure of the different cadherin types are shown at the right. 
The human E-cadherin gene (CDH1) is located at the 16q22.1 locus and is 
comprised of 16 exons, spanning 99 Kb of genomic DNA. The mouse E-
cadherin gene (cdh1) has a similar exon-intron organization and is located on 
chromosome 8. The mouse E-cadherin promoter was first isolated in 1991. Its 
initial characterization showed that it was a TATA-less promoter containing 
several potential proximal regulatory elements, including a CCAAT box (-65), 
a GC-rich region (-30  to -58) and a palindromic element (-70 to -90) 
composed of two adjacent E-boxes flanked by four inverted nucleotides called 
E-pal (Faraldo et al. 1997) (figure 5). The proximal CCAAT box and GC-rich 
regions are required for basal E-cadherin expression and are recognized by 
CAAT-binding proteins and constitutive AP2 and Sp1 transcription factors, 
respectively (Behrens et al. 1991, Hennig et al. 1996, Faraldo et al. 1997).
The E-pal element was initially described as an epithelial-specific regulator 
(Behrens et al. 1991), but subsequent studies showed it to be an active 
repressor in E-cadherin deficient cells (Hennig et al. 1996, Faraldo et al. 1997, 
Rodrigo et al. 1999). Equally, the E-boxes in the proximal E-cadherin
promoter repress its expression (Batlle et al. 2000, Hajra et al. 2002). 
A study based on the yeast one-hybrid system has led to identification of 
several E-cadherin repressors. More than 90% of these identified factors, that 
specifically bound to the E-boxes, corresponded to transcription factors, of 
which, two in particular were highly represented: 49% corresponded to the zinc 
finger factor Snail and 32% to the class I bHLH factors, E47 (Cano et al. 2000, 
Perez-Moreno et al. 2001). The remaining factors corresponded mainly to an 
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additional class I bHLH factor, mITF2 (also called E2-2), while a single clone 
corresponded to another member of the Snail family, Slug (Bolòs et al. 2003). 
Functional characterisation of Snail, bHLH E47 and Slug have confirmed their 
ability to behave as E-cadherin repressors and to induce EMT when over-
expressed in epithelial cell line (Batlle et al. 2000, Cano et al. 2000). Other two 
factors have also been described as repressors of E-cadherin and are EF1 
(Zeb1) and SIP1 (Zeb2) of homeodomain and zinc finger family. In all these 
instances, these repressors silence E-cadherin binding to the proximal E-boxes, 
although some differences are observed between the mouse and the human 
promoters. While the factors that act on the mouse promoter seem to 
preferentially interact with the E-pal element (including Snail, Slug and E47) 
(Cano et al. 2000, Perez-Moreno et al. 2001, Bolòs et al. 2003), in the human 
promoter all three E-boxes or E-box 1 and 3 appear to be required for the 
interaction of Snail/Slug or EF1/ SIP1, respectively (Batlle et al. 2000, Hajra 
et al. 2002) (figure 5). These observations suggest that at least two of the three 
proximal E-boxes in the mammalian E-cadherin promoter are functionally 
similar in terms of recruiting repressors, regardless of their relative location. 
Interestingly, all of the E-cadherin repressors identified exhibit expression 
patterns in developing embryos compatible with this function.
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Figure 5. Schematic representation of the E-cadherin promoter region and E-box 
sequences in mouse, human and dog. A) The E-cadherin promoter region is 
represented with its representative proximal control elements in the proximal region 
(exerting either a positive or negative effect on E-cadherin expression). The CAAT, 
GC and E-box1/E-box3 are conserved in all three promoters, while the E-box 2 is only 
present in the mouse promoter region. An additional E-box (E-box 4) downstream of 
the transcription initiation site is present in the human promoter, but is not conserved 
in the region encompassing the mouse promoter. Binding of identified factors to the 
different E-boxes is shown in the lower part. B) Sequence of the E-boxes present in 
the proximal region of the mouse, human and dog E-cadherin promoter. Observe the 
high degree of conservation of E-box 1 and E-box 3. (Peinado et al. 2004).
1.5.1 E-cadherin implication in tumor progression.
The long-standing observation that tumor cells demonstrate decreased cellular 
adhesion, as well as the observation that E-cadherin expression is frequently 
lost in human cancers, led investigators to hypothesize that changes in the 
cadherin-catenin complex may play a causative role in cancer development and 
progression (Jiang 1996). In several cancer types, in fact, loss of either E-
cadherin or -catenin expression has been correlated with tumor 
A
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dedifferentiation, infiltrative growth, lymph node metastasis, and poorer patient 
prognosis. Immunohistochemical studies have demonstrated that loss of E-
cadherin expression is a frequent event in many types of carcinomas (Jiang 
1996, Papadavid and Katsambas 2001). Restoration of E-cadherin expression 
into highly invasive epithelial tumor cell lines of dog kidney or mouse 
mammary gland origin abrogates their invasive behavior, though reversion to 
the invasive phenotype is seen following treatment with anti-E-cadherin 
antibodies. Alternatively, a plasmid encoding E-cadherin-specific anti-sense 
RNA was introduced into noninvasive ras-transformed cells with high 
endogenous E-cadherin expression. The resulting down-regulation, albeit 
partial, rendered the cells invasive. These data have provided direct evidence 
that E-cadherin acts as an “invasion suppressor” (Vleminckx et al. 1991). 
Subsequent studies have shown that loss of E-cadherin expression is a common 
finding in a wide spectrum of human epithelial cancers (Birchmeier and 
Behrens 1994). Recent studies have provided more compelling evidence that 
E-cadherin inactivation does not simply reflect the cancer phenotype, but its 
inactivation has a causal role in the process (Gayther et al. 1998; Guilford et al. 
1998).
Although somatic mutations in the CDH1 gene have been identified in a small 
subset of tumors, in the majority of cancers the mechanisms underlying loss of 
E-cadherin expression are poorly understood. The CDH1 gene is located on 
chromosome 16q in a region that is frequently affected by allelic loss in several 
cancer types (Risinger et al. 1994). Somatic mutations in the CDH1 gene have 
been identified in more than 30% of gastric cancers of diffuse subtype, about 5-
10% of endometrial and ovarian cancer. Moreover, in many cancer types where 
expression is frequently lost, CDH1 mutations are rare or absent (Hirohashi 
1998). Proposed epigenetic mechanisms for E-cadherin loss include alterations 
in the expression and/or function of the trans-acting factors that regulate CDH1
gene transcription, hypermethylation of its promoter, and chromatin-mediated 
effects. In some cases, transcriptional mechanisms underlie loss of E-cadherin 
expression through its proximal promoter (Hajra et al. 1999), and E-box 
elements within this region have been proposed to be critical in the silencing of 
CDH1 transcription in cancer (Giroldi et al. 1997). 
Hypermethylation of the CDH1 promoter has been postulated to play a critical 
role in the loss of E-cadherin expression observed in some primary tumors and 
in cell lines without identified CDH1 mutations. Mechanisms other than 
repression by certain transcription factors and promoter hypermethylation have 
been suggested to inactivate CDH1 expression in cancer. In particular, 
chromatin condensation has been proposed to play a role in the silencing of 
CDH1 expression in carcinomas (Hennig et al. 1995). The various proposed 
mechanisms of CDH1 silencing in cancer may not be mutually exclusive. For 
instance, CDH1 promoter hypermethylation and chromatin remodeling may 
occur in concert with or as a specific consequence of the transcriptional 
repression effects of distinct trans-acting transcription factors targeted to the 
CDH1 promoter (Hennig et al. 1995).
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1.5.2 Mechanisms of E-cadherin repression: potential co-operation with 
epigenetic modifications.
The informations available regarding the different mechanisms involved in E-
cadherin silencing make it difficult to define a simple model where E-cadherin 
expression is regulated by just a single genetic, epigenetic or transcriptional 
control mechanism. Probably it seems more that a combination of different 
mechanisms is responsible for defining the status of E-cadherin expression 
during tumour progression.
Current evidence indicates that silencing of E-cadherin transcription requires 
the participation of several repressor factors that interact with specific E-box 
elements in the proximal promoter. The repression of gene expression either 
involves the local modification of chromatin organization through the 
recruitment of specific co-repressor complexes (Snail, Slug and potentially -
EF1/SIP1), or heterodimerization of repressors with specific partners (E47). 
The specific mechanisms by which Snail, and/or other repressors, mediates E-
cadherin silencing are still largely unknown. The modification of chromatin by 
the co-ordinated action of DNA and/or histone methylation, and acetylation, 
has emerged as one of the major mechanisms for regulating the transcriptional 
activity of different regulatory genes (Peinado et al. 2004). Very recently, 
details of the mechanism underlying Snail repression of E-cadherin were 
revealed, providing a link between transcriptional control and the epigenetic 
modifications of the E-cadherin promoter (Peinado et al. 2004). Snail 
repression of the E-cadherin promoter involves the recruitment of a repressor 
complex formed, at least, by the co-repressor mSin3A, HDAC1 and HDAC2 
(Peinado et al. 2004). The recruitment of this complex is mediated by the N-
terminal SNAG domain of Snail, previously thought to act as the repressor 
domain. The presence of this complex results in a net decrease in the amount of 
acetylated histones H3/H4 and an increase in methylated K9 of histone H3 in 
the endogenous E-cadherin promoter. In turn, this leads to a compact 
organisation of the chromatin (Peinado et al. 2004). A preliminary analysis in 
the mouse skin carcinogenesis model indicates that Snail expression is also 
associated with the hypermethylation and silencing of the E-cadherin
promoter, further supporting the notion of a connection between Snail and 
epigenetic modifications (figure 6). The molecular mechanisms involved in this 
link remain to be elucidated, but the implication of MBDs (methyl DNA 
binding protein) and HDACs is an interesting aspect of E-cadherin silencing 
for further study, since treatment with inhibitors of DNA methylation and 
HDACs promotes the re-expression of E-cadherin (Peinado et al. 2004).
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Figura 6. A model for the regulation of E-cadherin expression involving different 
repressors and epigenetic mechanisms
A schematic illustration of the putative epigenetic mechanisms involved in E-cadherin 
regulation is shown. In this model, active transcription is probably achieved through 
the interaction of several activators, and involves the acetylation of histone residues 
which promotes the chromatin to adopt an open conformation. Under the influence of 
the appropriate signals, several repressors and co-repressor molecules are recruited 
(depending on either the tissue or cellular context), attracting the repressor machinery 
which includes corepressor molecules, HDACs and methylases, and still unidentified 
molecules which will modify the acetylation and methylation status of chromatin, 
promoting E-cadherin silencing. (Peinado et al. 2004).
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1.6 Epigenetic control of gene expression.
The term “epigenetics” refers to mitotically and meiotically heritable changes 
in gene expression that are not coded in the DNA sequence itself (Egger et al. 
2004). 
The DNA of eukaryotic cells is compacted by basic histone proteins in a highly 
organized structure called chromatin to achieve compaction, enabling the entire 
genome to fit into the nucleus, and allowing DNA transcription, replication, 
and repair, when necessary. The nucleosome, the basic unit of chromatin, 
consists of 147 base pairs of DNA wrapped around the histone octamer, 
composed of two copies of each of the four core histones, H2A, H2B, H3, and 
H4 (van Holde 1988). Although the structure of the core nucleosome is well 
defined, the basic N-terminal histone tails protrude from the core nucleosome 
and show no defined structure (Luger et al.1997, Luger and Richmond 1998). 
These histone tail domains are subject to post-translational modifications, such 
as acetylation, methylation, phosphorylation, and ubiquitination. Recent 
observations indicate that histone modifications occur interdependently and 
create a pattern that might modulate the affinity of histone-binding proteins. A 
correlation between histone acetylation and increased gene expression was 
discovered earlier on (Alfrey et al. 1964). According to the current model, the
acetylation of lysine residues within the histone tails neutralizes the positive 
charge of -amino groups and thereby reduces the interaction between the N-
terminal tails of histones and the negatively charged DNA. Acetylation at the N 
termini of core histones is therefore believed to induce the local opening of 
chromatin structures. Reversible histone acetylation is controlled by histone 
acetyltransferases (HAT), which usually act as transcriptional coactivators, and 
histone deacetylases (HDACs), which repress transcription. Activator 
complexes containing HAT activity have been shown to contribute to 
transcriptional activation by recruitment of general transcription factors and 
RNA polymerase II (Carrozza et al. 2003, Torok and Grant 2004). In contrast, 
recruitment of repressor complexes with HDAC activity is considered to lead 
to deacetylation of histones, stabilization of nucleosome structure, and 
formation of a repressive chromatin state. Strahl and Allis proposed that 
distinct histone modifications, on one or more tails, act sequentially or in 
combination to form a 'histone code' that is read by other proteins leading to 
distinct downstream events (Strahl and Allis 2000). This theory states that post-
translational modifications can act through two mechanisms that are not 
mutually exclusive: 1) by structurally changing the chromatin fiber through 
internucleosomal contacts thus regulating the access of transcription factors to 
the DNA; 2) by generating docking sites for effector molecules that, in turn, 
initiate distinct biological processes. The histone code is part of the epigenetic 
information found into the cells. 
All the core histones are acetylated in vivo; however, modifications of histones 
H3 and H4 are much more extensively characterized than those of H2A and 
H2B (Struhl 1998, Annunziato and Hansen 2000). Acetylation of histone H3 is 
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primarily associated with transcription whereas H4 acetylation is associated 
with both transcription and with chromatin assembly (Struhl 1998, Annunziato 
and Hansen 2000). Steady-state levels of acetylation in the core histones result 
from the balance of the antagonistic activities of histone acetyltransferases and 
histone deacetylases (Grunstein 1997, Struhl 1998). In general, increased levels 
of histone acetylation are associated with transcriptional activity whereas 
decreased acetylation levels are associated with repression (Grunstein 1997, 
Struhl 1998). 
During the last decade, more than a dozen of histone deacetylases have been 
identified in mammalian cells. Based on sequence similarities, HDACs are 
divided into four functional classes: class I (HDAC1, HDAC2, HDAC3, and 
HDAC8), class II (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and 
HDAC10), class III (SIRT1 to SIRT7), and the recently described class IV of 
HDACs, which consists of HDAC11-related enzymes (Grozinger and 
Schreiber 2002, Gregoretti et al. 2004). 
HDAC inhibitors have been shown to induce cell cycle arrest, differentiation, 
or apoptosis in tumor cells, and some of these compounds are currently tested 
as antitumor drugs in clinical trials (Mei and Mahlknecht 2004, Dokmanovic 
and Marks 2005, Drummond et al. 2005). These inhibitors affect the catalytic 
activity of most class I and class II deacetylases. However, little is known 
about the individual roles of mammalian deacetylases in transcriptional control 
and the relevant target enzymes for HDAC inhibitors as antitumor drugs.
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2. AIMS OF THE STUDY 
Thyroid tumors are the result of the accumulation of different modifications in 
critical genes involved in the control of cell proliferation. Although various 
therapeutic approaches are followed in clinical practice, most of them are not 
life-saving. Hence, the discovery of new approach to diagnose cancer at an 
early stage and to establish more effective therapies is a critical and urgent 
issue. To achieve this goal, identification and characterization of key molecules 
that participate in carcinogenesis are essential steps.
CBX7 is a chromobox family protein encoding a novel polycomb protein, the 
expression of which shows a progressive reduction, well related with the 
malignant grade of thyroid neoplasias. The aim of this study has been to 
elucidate CBX7 function in normal cells and understand why it is drastically 
down-regulated in tumor thyroid cells. Thus, we investigated proteins 
interacting with CBX7, by a proteomic assay because the association of CBX7 
with partners involved in a particular mechanism might strongly suggesting the 
biological function of the protein (Monti et al. 2005). Thus, we try to elucidate 
the mechanisms by which the loss of CBX7 expression contributes to cancer 
progression by the identification and characterization of proteins that interact 
with CBX7 and might contribute to the transformation process of the thyroid 
follicular cells.
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3. MATERIALS AND METHODS
 3.1 Cell culture and transfections. 
In this study we have used HEK 293 cells (Human embryonal kidney), and 
HeLa cells maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) and 
RPMI medium respectively, supplemented with 10% fetal calf serum, L-
glutamine 10 mM, and penicillin/streptomycin 100 g/ml. The human thyroid 
carcinoma cell lines TPC-1 and NPA were grown as described elsewhere 
(Pallante et al. 2005). Normal human thyroid primary culture cells have been 
established and grown as already described (Curcio et al. 1994). PC Cl3 cell 
lines was cultured in modified F12 medium supplemented with 5% calf serum 
(Gibco Laboratories) and six growth factors (thyrotropic hormone, 
hydrocortisone, insulin, transferrin, somatostatin and glycyl-histidyl-lysine) 
(Sigma, St. Louis, MO) (Fusco et al. 1987). All cell lines were maintained at 
37°C under 5% CO2 atmosphere.
Cells were transfected using Lipofectamine reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. The transfected cells were 
selected in a medium containing geneticin (G418) (Gibco Laboratories, 
Carlsbad, CA). CBX7 inducible NPA cells were generated by trasfecting NPA 
cells with the pcDNA™6/TR regulatory vector (Invitrogen) that provides high 
level expression of the tetracycline repressor and with the expression vector 
which contains the CBX7 gene under the control of a tetracycline-regulated 
promoter. Cells, plated at a density of 90% in 100 mm dishes, were co-
transfected with pcDNA™6/TR and pCBX7-TetO2 and supplemented with 
Zeocin and Blasticidin (Invitrogen) 24 h later. Two weeks after the onset of 
drug selection, several resistant clones were picked, expanded and analysed for 
CBX7 expression after adding tetracycline to the medium. 
In the experiments performed in presence of trichostatin A (TSA) (Sigma) the 
cells were treated 24 h after transfection. TSA was dissolved in ethanol and 
added to the culture medium at 300 nM and a corresponding volume of ethanol 
was added to untreated cells. 
For the inhibition of CBX7 expression, rat cbx7 siRNA (SI01495795 and 
SI01495802, Qiagen, Hilden, Germany) and Nonsilencing Control siRNA 
(1022076, Qiagen) were transfected using Oligofectamine (Invitrogen) 
according to the manufacturer’s recommendations. siRNAs were used at a final 
concentration of 100 nM and 12x105 PC Cl3 cells/well were plated in a six-
well format plate. RNAs were extracted 48 h after siRNA treatment.
3.2 Plasmid constructs. 
CBX7 expression plasmid was constructed by cloning the human cDNA 
sequence in a pCRTMII TA Cloning® vector (Invitrogen, Carlsbad, CA). The 
primers used were: CBX7 forward 5’-ATGGAGCTGTCAGCCATC-3’ and 
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CBX7 reverse 5’-TCAGAACTTCCCACTGCG-3’. The inserted cDNA was 
then subcloned into the BamHI/XhoI sites of the mammalian expression vector 
pcDNA 3.1 (Invitrogen). 
V5-tagged CBX7 expression plasmid was generated by the insertion of he PCR 
product into the Gateway entry vector pENTR/D-TOPO and subsequently 
cloned into the destination vector pcDNA-DEST-40 Gateway Vector 
(Invitrogen) by using the pENTR/D-TOPO Cloning Kit (Invitrogen) according 
to the manufacturer’s instructions. Primers are as follows: CBX7-dest-forward 
5’-CACCATGGAGCTGTCAGC-3’ and CBX7-dest-reverse 5’-
GAACTTCCCACTGCGGT-3’. The expression of CBX7 was assessed by 
Western blotting. 
HA-tagged CBX7 expression plasmid containing the entire portion of the 
CBX7 coding sequence was obtained by PCR amplification and subcloned into 
the pCEFL-HA expression vector. CBX7-deletion mutants were cloned in 
pCEFL-HA: 
- for p-CEFL-HA-CBX7-CHROMO (1-100aa): CHROMO forward 5’-
GAGCTGTCAGCCATCGGC-3’ and CHROMO reverse 5’-
TCACTTCTCCTTGCCCTTGGC-3’; 
- for pCefl-HA-CBX7-NOCHROMO (55-251aa): CBX7-NOCHROMO 
forward 5’-GCCAAGGGCAAGGAGAAGTGAC-3’ and CBX7-
NOCHROMO reverse 5’-GTCAGAACTTCCCACTGCGG-3’.
E-cadherin-luc reporter construct, in which the luciferase gene was driven by a 
fragment extending from -1359 bp 5’ to +125 bp 3’ of the human E-cadherin
promoter and 5’ UTR of E-cadherin gene, was kindly provided by Dr ER 
Fearon, University of Michigan Medical School (Hajra et al. 1999, Ji et al. 
1997). Ather two reporter construct conteining E-cadherin promoter sequence 
were generated by PCR and subcloned into pGL2-Basic vector (Promega) 
upstream of the firefly luciferase gene. The sequences subcloned cover E-
cadherin promoter and 5’ UTR of E-cadherin gene from –601 bp to +125 bp 
(E-cadherin 601) and from -211 bp to +125 bp (E-cadherin 211). Primers used 
were: 601 forward: 5’-TGGGCAATACAGGGAGACAC-3’ and 601 reverse:  
5’-TCACAGGTGCTTTGCAGTTC-3’; 211 forward: 5’-
AACTCCAGGCTAGAGGGTCA-3’ and 211 reverse:  5’-
TCACAGGTGCTTTGCAGTTC-3’.
The identities of the sequences cloned for all constructs were confirmed by 
sequences analysis.
pEGFP expression vector (Clontech) was used as control in transfection 
experiments and as negative control in FRET experiment.
3.3 Protein extraction. 
For total cell extract (TCE) preparation, cells were harvested 48 h after the 
onset of transfection. Cells were then lysed in RIPA buffer (20 mM Tris-HCl 
pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% Nonidet P40, and a mix of protease 
inhibitors), and clarified by ultracentrifugation at 13000 rpm at 4°C for 30 min.
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For nuclear extract (NE), cells were washed twice in phosphate-buffered saline 
and resuspended in 3 volumes of a solution containing 10 mM HEPES pH 7.9, 
10 mM KCl, 1.5 mM MgCl2, 0.1 mM EGTA, 0.5 mM DTT (homogenization 
solution). The cells were disrupted by passage through a 26-gauge needle. 
Nuclei were collected by centrifugation at 1500 rpm and resuspended in a 1.2-
volume of extraction solution containing 10 mM HEPES pH 7.9, 0.4 M NaCl, 
1.5 mM MgCl2, 0.1 mM EGTA, 0.5 mM DTT, 5% glycerol, to allow elution 
of nuclear proteins by gentle shaking at 4°C for 30 min. Nuclei were pelleted 
again by centrifugation at 12000 rpm for 30 min and the supernatant was stored 
at -80°C until used. The protease inhibitors (leupeptin 5 mM, aprotinin 1.5 
mM, phenylethylsulfunilfluoride 2 mM, peptastatin A 3 mM, and benzamidine 
1 mM) were added to both homogenization and extraction solutions. Protein 
concentration was determined by the Bradford protein assay (BioRad).
3.4 Western blotting and immunoprecipitation assay.
Protein extracts and immunoprecipitated pellets were separated by SDS-PAGE, 
and then transferred onto Immobilon-P Transfer membranes (Millipore). 
Membranes were blocked with 5% non-fat milk proteins and incubated with 
antibodies (Ab) at the appropriate dilutions. To ascertain that equal amounts of 
protein were loaded, the western blots were incubated with antibody against the 
-tubulin protein (Santa Cruz Biotechnology Inc.). After the hybridization with 
primary antibody the filters were incubated with horseradish peroxidase-
conjugated secondary antibody (1:3000) for 60 min at room temperature. The 
signals were detected by Western blotting detection system (ECL) (GE 
Healthcare). 
For immunoprecipitation (IP) experiments, TCE was incubated for pre-clearing 
with protein A-sepharose or G-sepharose beads (Amersham) for 1 h at 4°C, 
then sample was centrifugated to 2000 rpm to eliminate beads and incubated 
overnight with antidoby. The day after the IP was incubated again with protein 
A-sepharose or G-sepharose beads for 1 h at 4°C. The beads were collected and 
washed five times with lysis buffer, and boiled in Laemmli sample buffer for 
immunoblotting analysis. The Abs used for IP and Western blotting were: anti-
CBX7 protein (Neosystem), anti-V5 (Sigma), anti-HDAC2 (Upstate), anti-HA 
(Roche), anti-Tubulin (Santa Cruz Biotechnology Inc.).
3.5 Samples preparation and immunoprecipitation for proteomic assay. 
For preparative gels, 8x107 cells were transfected with 10 g of empty vector 
or with CBX7-V5-His expression plasmid. The IP was performed with 1 mg of 
NE and the complex immunoprecipitated was recovered by competition with 
peptide V5 (Abcam). For immunoblotting analysis, 50 g of TCE or 
immunoprecipitated proteins were analysed by Western blotting.
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3.6 Electrophoresis fractionation and in situ digestion.
The IP and the control were fractionated by SDS-PAGE on a 12% bis-
acrylamide gel. The gel was stained by Colloidal Comassie (Pierce) and the 
corrisponding protein bands were excised from both lanes and digested in situ
with trypsin (Shevchenko et al. 1997). Peptide mixtures were extracted, freeze-
dried and resuspended in 10 l of 0.2% trifluoroacetic acid (TFA) for the 
Liquid Chromatography/Mass Spectrometry/Mass Spectrometry (LCMSMS) 
analysis.
3.7 Liquid Chromatography/Mass Spectrometry/Mass Spectrometry 
(LCMSMS) analysis.
Each peptide mixture was directly analysed by LCMSMS using an Agilent ion 
trap mass spectrometer LC/MSD Trap XCT Ultra integrated with a new 
microfluidic chip-based technology for nanospray LC/MS (Agilent) and 
coupled on-line with a nano chromatography system Agilent 1100. After 
loading, the peptide mixture (8 µl) was first concentrated and washed at 4 
µl/min onto a reverse-phase pre-column on the chip using 0.2% formic acid as 
eluent. The sample was then transferred and fractionated by reverse-phase 
chromatography onto a capillary column present on the chip at a flow rate of 
300 nl/min using a linear gradient of eluent B (0.2% formic acid in 95% 
acetonitrile) in A (0.2% formic acid in 5% acetonitrile) from 7 to 60% in 50 
min. The mass spectrometer was set up in a data-dependent MS/MS mode 
where a full scan spectrum (m/z acquisition range from 400 to 1600 Da/e) was 
followed by a tandem mass spectrum (m/z acquisition range until 1800 Da/e). 
The precursor ions were selected as the most intense peaks of the previous 
scan. LC/MSD Trap software, provided by the manufacturers, was used to 
analyse raw MS and MS/MS spectra and to generate a peak list which was 
introduced in the MASCOT MS/MS ion search software for protein 
identification.
3.8 Expression and purification of recombinant proteins/GST pull-down 
experiments.
GST fusion proteins were constructed by cloning the human cDNA sequence 
of CBX7 in a pGEX4T-1 (Promega). The primers used were: 
- for GST-CBX7: CBX7 forward 5’-GAGCTGTCAGCCATCGGC-3’ 
and CBX7 reverse 5’-GTCAGAACTTCCCACTGCGG-3’; 
- for GST-CBX7-CHROMO: CBX7-CHROMO forward 5’-
GAGCTGTCAGCCATCGGC-3’ and CBX7 reverse 5’-
TCACTTCTCCTTGCCCTTGGC-3’;
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- for GST-CBX7-NOCHROMO: CBX7-NOCHROMO forward 5’-
GCCAAGGGCAAGGAGAAGTGAC-3’ and CBX7-NOCHROMO 
reverse 5’-GTCAGAACTTCCCACTGCGG-3’.
GST fusion proteins were produced in Escherichia coli BL21 cells. Stationary 
phase cultures of E. coli cells transformed with the plasmid of interest were 
diluted 1000 ml in LB with ampicillin (100 mg/ml), grown at 30°C to an OD 
600 of 0.6 and induced with 1 mM IPTG. After an additional 2 h at 30°C, the 
cultures were harvested and resuspended in 10 ml of cold PBS, 140 mM NaCl, 
20 mM sodium phosphate pH 7.4, 1 mM phenylmethylsulfonyl fluoride 
(PMSF) and protease inhibitors (Boehringer). The cells were broken by French 
Press. For the GST proteins, the supernatant was then incubated at 4°C for 1 h 
with 250 l of glutathione-Sepharose beads (Amersham Pharmacia Biotech). 
The expression of recombinant protein of CBX7 was assessed by Coomassie.
The recombinant proteins were eluted with a buffer containing PBS, 10mM 
reduced glutathione, and 10% (v/v) glycerol. For GST pull-down the fusion 
proteins were incubated with TCEs in NETN buffer (20 mM Tris-HCl, pH 8.0, 
100 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40) for 2 h at 4°C. The 
resins were then extensively washed in the same buffer and then resuspended 
in Laemmli buffer. The bound proteins were separated by SDS-PAGE and 
analysed by Western blotting. 
3.9 HDAC activity assay.
HEK 293, HeLa and NPA cells were transfected with increasing amount of 
CBX7 expression vector and were used to assay the HDAC activity. 30 g of 
TCE were incubated with 5 µl of [3H]acetate-labeled histone H4 (1.8 nCi/µg) 
in 200 µl of activity buffer (25 mM Tris-HCl [pH 7.5], 10% glycerol, 1 mM 
EDTA, 125 mM NaCl) overnight at 37°C. The reaction was stopped by the 
addition of 50 µl of 1 N HCl-0.4 M acetate and the released [3H]acetate was 
extracted with 600 µl of ethyl acetate (Upstate). After centrifugation, 100 µl of 
the supernatant was counted in 5 ml of scintillation cocktail. All experiments 
were carried out three times, and samples were assayed in duplicate. The same 
protocol was used to analyse HDAC activity in TCE from human tumor 
samples.
3.10 Chromatin immunoprecipitation (ChIP) and Re-ChIP assays.
ChIP and Re-ChIP experiments were performed as reported elsewhere 
(Pierantoni et al. 2006). Briefly, after transfection, 5x106 HEK 293 and HeLa 
cells were cross-linked using 1% formaldehyde at room temperature for 10 
min, reaction was terminated with glycine (final concentration, 0.125 mol/L). 
Cells were lysed in 200 l of lysis buffer containing 10 mM EDTA, 50 mM 
Tris-HCl pH 8.0, 1% SDS and protease inhibitors and sonicated five times for 
30 sec at maximum settings, obtaining fragments between 0.3 and 1.0 kb. The 
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samples were cleared by centrifugation at 14000 rpm for 15 min. After 
centrifugation, 3% of the supernatants were used as inputs, and the other part 
of the samples diluted 2.5-fold in Ip buffer (100 mM NaCl, 2 mM EDTA pH 
8.0, 20 mM Tris-HCl pH 8.0, 0.5% Triton X-100 and protease inhibitors). 
After 2 h pre-clearing at 4°C with Protein A Sepharose or Protein G 
Sepharose/BSA/Salmon Sperm (Upstate), samples were subjected to IP with 
the following specific antibodies: anti-HA (Roche) and anti-HDAC2, anti-
H3K4m2, anti-H3K4m3, anti-H3K9me, anti-H3K9m3, anti-H4K20 (Upstate)
and with aspecific IgG (Upstate). After an over-night incubation with antibody, 
the proteins A/G were added again for the precipitation of chromatin 
complexes. The chromatin immunoprecipitated was removed from the beads 
through 15 min incubation with 250 l of 1% SDS, 0.1 M NaHCO3. 
For Re-ChIP assays, complexes from the primary ChIP were eluted with 10 
mmol/L of DTT for 30 min at 37°C diluted in 250 l of Re-ChIP buffer (20 
mmol/L Tris-HCl (pH 8.1), 1% Triton X-100, 2 mmol/L EDTA, 150 mmol/L
NaCl) followed by re-IP with the indicated second antibodies and were again 
subjected to the ChIP procedure. Crosslink was reversed by an overnight 
incubation at 65°C with 20 l of 5 M NaCl. Then were added 10 l 0.5 mM 
EDTA, 20 l 1 M Tris-HCl pH 6.5 and 20 g of Proteinase K, and incubated 
for 1 h at 45°C. DNA was purified by Phenol/CHCl3, and precipitated by two 
volumes of ethanol and 0,1 M NaOAc.
Semi quantitative PCR was performed using specific primers: 
pE-cadherin-F(-300)-L, 5’-GAACTCAGCCAAGTGTAAAAGCC-3’
pE-cadherin-R(+40)-R, 5’-GAGTCTGAACTGACTTCCGC-3’
p16-F, 5’-GCAGTCCGACTCTCCAAAAG-3’
p16-R, 5’-GGGTGTTTGGTGTCATAGGG-3’
pE2F1-F, 5’-CGTTGGCTGTTGGAGATTTT-3’
pE2F1-R, 5’-TTGCCTCACCCATGACATTA-3’
S100A4-ChIP-F, 5’-TCATCCAGTCCCCTGCTAGT-3’
S100A4-ChIP-R, 5’-AGAGCGGATACTGCCTTCCT-3’
GAPDH-F, 5’-TCCTGTTTCATCCAAGCGTG-3’
GAPDH-R, 5’-GACTGTCGAACAGGAGGAG-3’
Quantitative PCR(qRT-PCR) was performed using specific primers:
E-cadherin-F(-70), 5'-GAACCCTCAGCCAATCAGC -3'
E-cadherin-R (+54), 5'-GAGTCTGAACTGACTTCCGC -3'
3.11 Electrophoretic mobility shift assay (EMSA) and supershift assay.
For gel shift analysis, NE were prepared following the method of Dignam 
(Dignam et al. 1983). The double-strand oligonucleotides covered a region 
spanning from nucleotide –70 to +54 of the human E-cadherin promoter with 
respect to the transcription start site (TSS), were 32P labeled (TransCruz™ Gel 
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Shift Oligonucleotides) with 32[P]-ATP to 50,000 cpm/ng by using 
polynucleotide kinase. Binding reaction mixtures (20 l) were incubated for 20 
min at room temperature in 10 mM Tris pH7.5, 50 mM NaCl 1 mM 
dithiothreitol (DTT), 1 mM EDTA, 5% glycerol. Binding reaction contained 
DNA probe (50000 cpm), 5 µg nuclear extract and 1 µg poly dI-dC to inhibit 
non specific binding of the labeled probe to nuclear extract protein. The 
protein-DNA complexes were resolved by native PAGE (6% gel) in 
0.5xTris/borate/EDTA and visualized by autoradiography.
For supershift analysis, assay were performed as described above with the 
exception that antibody (2 ug) was normally added 4 h prior to addition of 
labelled oligonucleotide probe to NE. 
3.12 ImmunoFRET.
HEK 293 cells were plated on a slide and transfected with pCDNA3.1-V5-
CBX7. After 24 h from transfection the slides were incubated with RNase 10 
g/ml in 1xPBS for 45 min at room temperature.  For fixation, the slides were 
submerged in 4% paraformaldehyde solution for 20 min at room temperature 
and  then washed twice for 5 min with NH4Cl 50 mM in 1xPBS and then in 
0,2% Triton X-100 in 1xPBS. After a wash in 1xPBS, 200 l/slide of Blocking 
solution (1% BSA in 1xPBS) was added for 30 min. The slides were washed 
again in 1xPBS and were incubated with DNAsi 1 g/ml for 15 min. The slides 
were washed again and were incubated with primary antibodies (anti-HDAC2, 
Upstate; anti-CBX7, Neosystem) diluited in blocking solution, (0,5% BSA in 
1xPBS) for 45min-1hr at 37°C in the dark. Then the slides were incubated with 
the secondary antibody (Cy3-antiRabbit to CBX7 and Cy5-antimouse to 
HDAC2) diluted in blocking solution (0,5% BSA in 1xPBS) for 20 min at 
room temperature in the dark. After that, 30 l of 0.1 g/ml DAPI in 1X PBS, 
0,01% Tween20, were added and the slides were incubated at room 
temperature for 15 min. At the end the slides were washed in H2O and shake 
off excess liquid from the slides and fixed upon cover glass with 2 l of 50 % 
glycerol/PBS solution and seal with a nail polish. 
Imaging was performed by a Zeiss LSM510 meta confocal microscope 
equipped with a plan-apochromat 63x/1.4 oil immersion objective. Excitation 
lasers HeNe 543nm and 633nm, respectively for Cy3 and Cy5, were used to 
performe the FRET assay by acceptor photobleaching (Kenworthy 2001; 
Piston 2007). Upon Cy5 photobleaching, Cy3 fluorescence was releved to 
measure FRET efficiency. HDAC2, indirectly immunostained by Cy3 and Cy5 
was used as positive control while EGFP, indirectly immunostained by Cy3, 
was used as negative control.
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3.13 Transactivation assay.
In the luciferase transactivation assay, HEK 293 and HeLa cells were 
transiently transfected with the reporter construct (kindly provided by Dr ER 
Fearon, University of Michigan Medical School) in which the luciferase gene 
was driven by a fragment extending from -1359 bp 5’ to +125 bp 3’ of the 
human E-cadherin transcription start site (Hajra et al. 1999, Ji et al.1997). 
Reporter constructs containing 211 or 601 bp of E-cadherin promoter were 
generated by PCR and subcloning into pGL2-basic vector (Promega). All 
transfections experiments were performed in duplicate and normalized with the 
use of a co-transfected -galactosidase construct. Cell extracts were prepared 
48h post-transfection using reporter lysis buffer (Promega), followed by 
determination of luciferase and galactosidase activities Luciferase activity 
was analysed by Dual-Light System (Applied Biosystems, Massachusetts, 
USA).
3.14 DNA extraction and methylation analysis. 
DNA was prepared using QIAamp DNA Mini Kit (Qiagen) following the 
instruction manual. PCR primers to analyse E-cadherin promoter were 
designed by using Methprimer (Li and Dahiya 2002). The MassCLEAVE 
biochemistry was done as described previously (Ehrich et al. 2005). Mass 
spectra were acquired by using a MassARRAY Compact matrix-assisted laser 
desorption/ionization-time-of-flight (Sequenom) and spectra methylation ratios 
were generated by the Epityper software version 1.0 (Sequenom).
SEQUENOM MassARRAY platform was used for DNA methylation 
quantitative analysis. This system utilizes MALDI-TOF mass spectrometry in 
combination with RNA base specific cleavage (MassCLEAVE). A detectable 
pattern was then analysed for methylation status. PCR primers to analyse 
CDH1 promoter designed by using Methprimer 
(www.urogene.org/methprimer), were cdh1-10F 5’-
AGGAAGAGAGGATTTTAGTAATTTTAGGTTAGAGGGTT-3’ (position 
from nucleotides -190 to nucleotides -163) and cdh1-T7R 5’-
CAGTAATACGACTCACTATAGGGAGAAGGCTAAATACCTACAACAA
CAACAACAAC-3’ (from nucleotides +154 to nucleotides +178). For reverse 
primer, an additional T7 promoter tag for in vivo transcription was added, as 
well as a 10-mer tag on the forward primer to adjust for melting-temperature 
differences. The MassCLEAVE biochemistry was performed as previously 
described (Ehrich et al. 2005). Mass spectra were acquired by using a 
MassARRAY Compact MALDI-TOF (Compact matrix-assisted laser 
desorption/ionization-time-of-flight, Sequenom) and spectra's methylation 
ratios were generated by the Epityper software v1.0 (Sequenom). The whole 
procedure was performed at Sequenom GmbH Laboratories (Hamburg, 
Germany). The amplicons contained 32 CpG sites of which 26 were 
successfully analysed by MassARRAY.
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3.15 Fresh human thyroid tissue samples. 
Neoplastic human thyroid tissues and normal adjacent tissue or the normal 
contralateral thyroid lobe were obtained from surgical specimens and 
immediately frozen in liquid nitrogen. Thyroid tumors were collected at the 
Service d’Anatomo-Pathologie, Centre Hospitalier Lyon Sud, Pierre Bénite, 
France. The tumor samples were stored frozen until required for RNA, DNA 
and protein extraction.
3.16 RNA extraction, reverse transcription, and PCR analysis. 
Total RNA isolation from human tissues was performed with Trizol 
(Invitrogen) according to the manufacturer’s instructions. RNA was extracted 
from fresh specimens after pulverizing the tumors with a stainless steel mortar 
and pestle was chilled on dry ice. The integrity of the RNA was assessed by 
denaturing agarose gel electrophoresis. 1 g of total RNA of each sample was 
reverse-transcribed with the QuantiTect Reverse Transcription (QIAGEN 
group) using an optimized blend of oligo-dT and random primers according to 
the manufacturer’s instructions. To ensure that RNA samples were not 
contaminated with DNA, negative controls were obtained by performing PCR 
on samples that were not reverse transcribed but identically processed. For 
semiquantitative PCR (Pallante et al. 2005) the reactions were optimized for 
the number of cycles to ensure product intensity within the linear phase of 
amplification. The PCR products were separated on a 2% agarose gel, stained 
with ethidium bromide, and scanned using a Typhoon 9200 scanner (GE 
Healthcare, Piscataway, NJ). Digitized data were analysed using Imagequant 
(Molecular Dynamics). 
Primers used to semiquantitative analysis in ChIP and Re-Chip analysis are 
described in paragraph 3.10.
Primers used for siRNA experiments are:
Rat-Cbx7-F, 5’-GTCATGGCCTACGAGGAGAA-3’,
Rat-Cbx7-R, 5’-CTTGGGTTTCGGACCTCTCT-3’;
Rat-GAPDH-F, 5’-TGATTCTACCCACGGCAAGTT-3’
Rat-GAPDH-R, 5’-TGATGGGTTTCCCATTGATGA-3’
Rat-E-cadherin-F, 5’-CAAACACATCCCCCTTCACT-3’
Rat-E-cadherin-R, 5’-GTTGACGGTCCCTTCACAGT-3’
3.17 Selection of primers, probes and qRT-PCR. 
Briefly, using locked nucleic acid (LNATM) technology (Obika et al. 1997, 
Koshkin et al. 1998), Exiqon (Exiqon, Vedbaek, Denmark) provides 90 human 
prevalidated TaqMan probes of only 8-9 nucleotides that recognize 99% of 
human transcripts in the RefSeq database at NCBI (Mouritzen et al. 2004, 
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2005). Using the ProbeFinder assay design software (freely accessed on the 
web site www.probelibrary.com) we chose the best probe and primers pair for 
each gene of interest. Real-Time Quantitative TaqMan PCR was carried out 
with the Chromo4 Detector (MJ Research, Waltham, MA) in 96-well plates 
using a final volume of 20 ml. For PCR we used 8 ml of 2.5x 
RealMasterMixTM Probe ROX (Eppendorf AG, Hamburg, Germany) 200 nM 
of each primer, 100 nM probe and cDNA generated from 50 ng of total RNA. 
The conditions used for PCR were 2 min at 95°C and then 45 cycles of 20 sec 
at 95°C and 1 min at 60°C.
We also carried out qRT-PCR reactions with chromatin of ChIP in a final 
volume of 20 l using 10 l of 2x Power SYBR Green PCR Master Mix 
(Applied Biosystems), 200 nM of each primer and cDNA generated from 50 ng 
of total RNA. The conditions used for PCR were 10 min at 95°C and then 45 
cycles of 30 sec at 95°C and 1 min at 60°C. Each reaction was carried out in 
duplicate, and at the end of the PCR run, a dissociation curve was constructed 
using a ramping temperature of 0.2°C per sec from 65°C to 95°C. Each 
reaction was carried out in duplicate. We used the 2-CT method to calculate 
relative expression levels (Livak 2001). 
Primers used for quantitative analysis of ChIP and Re-Chip samples are 
described in paragraph 3.10. 
Primers used for quantitative analysis of gene expression are:
CBX7-F, 5’-CGTCATGGCCTACGAGGA-3’
CBX7-R, 5’-TGGGTTTCGGACCTCTCTT-3’
G6PD-F, 5’-ACAGAGTGAGCCCTTCTTCAA-3’
G6PD-R, 5’-GGAGGCTGCATCATCGTACT-3’
E- cadherin- F, 5’-CCACCAAAGTCACGCTGAA-3’
E- cadherin- R, 5’-TGCTTGGATTCCAGAAACG-3’
N-cadherin-F, 5-AGGGGACCTTTTCCTCAAGA-3’
N-cadherin-R, 5’-GGGGTTGAGAATGAAGATACCA-3’
3.18 Immunohistochemistry. 
The cell distribution of the CBX7 protein was assessed by immunostaining of 
formalin-fixed, paraffin-embedded thyroid tumor blocks retrieved from the 
files of the Dipartimento di Scienze Biomorfologiche e Funzionali at the 
University of Naples Federico II and selected to represent a wide range of 
thyroid neoplastic diseases. Tissue sections were processed as reported 
elsewhere (Pallante et al. 2005). We scored paraffin-embedded stained slides 
from 20 cases of FTA, 30 cases of classical PTC, 6 cases of TCV PTC, 32 
cases of FTC, 12 cases of PDC, and 12 cases of ATC. As controls, we selected 
areas of normal thyroid parenchyma from the lobe contralateral to the tumor in 
20 surgical specimens of PTC. Individual cells were scored for the expression 
of CBX7 by quantitative analysis performed with a computerized analyser 
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system (Ibas 2000, Kontron, Zeiss, Munich, Germany), as described previously 
(Pallante et al. 2005).
3.19 Statistical analysis. 
For the comparison between two groups of experiments, Student's t test was 
used. The statistical significant difference was considered when P < 0.05. A 
Pearson correlation coefficient (R2) close to 1 was considered indicative of a 
significant direct correlation. All experiments were done in triplicate and the 
data are mean ± SD of three independent experiments.
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4. RISULTS AND DISCUSSION
4.1 Proteomic analysis of CBX7 interacting proteins.
To investigate the mechanisms by which the loss of CBX7 expression 
correlates with the highly malignant phenotype, we searched for CBX7 
interacting proteins by performing a functional proteomic analysis. Therefore, 
we transiently transfected the HEK 293 cells with a V5-tagged CBX7 
expression vector and empty vector. About 1 mg of nucleas extract (NE) was 
used for the proteomic analysis. 
Preliminary SDS-PAGE experiments of immunoprecipitation (IP) showed a 
large number of protein bands, therefore, to avoid having many aspecific 
proteins in the loading buffer we eluted the IP by competition with peptide V5. 
Before performing the preparative assay we have confirmed the expression of 
the CBX7-V5 construct in transfected HEK 293 cells and the efficiency of the 
IP by Western blotting, using anti-V5 antiboby (figure 7A). Then, the 
preparative immunoprecipitated material was fractionated on a 12% one-
dimensional (1D) gel. Preparative gel was stained with Blue Coomassie as 
shown in figure 7B.
Figure 7. Proteomic analysis. A) A part of IP of empty vector and CBX7-V5 vector 
transfected HEK 293 cells were used to verify the expression of CBX7 in transfected 
cells and the efficiency of IP for proteomic assay. B) The preparative gel was stained 
with Blue coomassie (M:marker). 
The comparison between the “empty-vector” lane, corresponding to the 
immunoprecipitated lysate from empty-vector transfected cells, and the 
“CBX7-V5” lane, which corresponds to that of CBX7 overexpressing cells, 
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allowed us to identify several bands that were present only in the “CBX7-V5” 
lane and absent in the control. Both gel lanes were sequentially cut in several 
fragments as shown in figure 8. Each protein band was digested in situ with 
trypsin (Shevchenko et al. 1997) and the peptide mixture obtained was directly 
analysed by Liquid chromatography tandem mass spectrometry (LCMSMS).
The peak list of the peptides was introduced in the MASCOT MS/MS ion 
search software for protein identification. The final results are summarized in 
Table 1 (after the REFERENCES), where the names, accession numbers and 
function of the identified proteins are reported. It was not surprising that each 
excised band from 1-D gel separation contained more than one protein. We 
have also clustered CBX7 interacting proteins observing that there are many 
proteins involved in DNA regulation, export and metabolism.
Generally, two peptide sequences are sufficient to identify a single protein, 
together with information about the score of peptides.
In our proteomic experiment we identified the bait CBX7 on the basis of a 
single peptide sequence, because the protein was not abundant; for this reason 
after MASCOT we decided to take in consideration proteins present 
exclusively in the CBX7 IP even if identified by just a single peptide 
recognition. 
Figure 8. Proteomic analysis. IP of NE from cells transfected with empty and CBX7-
V5 vectors were fractionated on one-dimensional gel. Preparative gel was stained with 
Blue coomassie and the gel was sequentially cut in several fragments covering all 
lane as shown in the figure (M:marker; number indicates a putative unique band).
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4.2 In vitro characterization of CBX7 and HDAC2 interaction.
All CBX7 putative partners identified by the proteomic approach still needed 
to be confirmed by independent experiments, such as GST pull-down or co-IP. 
Among putative interactin protein we focused our attention on HDAC2 
because of its relevance in tumor biology (Glozak and Seto 2007). HDACs 
catalyze the removal of acetyl groups from core histones and, because of their 
ability to induce local condensation of chromatin, are generally considered
repressors of transcription. 
To examine the specificity of this interactions and to map the regions of CBX7 
proteins required for the binding to its molecular interactors, pull-down assays 
were performed incubating a total lysate deriving from HEK 293 cells with the 
CBX7 recombinant protein fused to GST (GST-CBX7), with two deletion 
mutants of CBX7: GST-CBX7-CHROMO (1-100 aminoacids) and GST-
CBX7-NOCHROMO (55-251 aminoacids), and as negative control with GST 
protein (figure 9A).
First, we analysed the interaction between CBX7 and HDAC2. No associated 
proteins were detectable in the complexes obtained incubating TCE with the 
GST protein alone or with the GST-CBX7-CHROMO fusion protein. Instead 
there was interaction between GST-CBX7 and the GST-CBX7-NOCHROMO 
mutant with HDCA2. These results clearly show that the interaction between 
CBX7 and HDCA2 involves the region of CBX7 outside the Chromodomain. 
Gels were stained with Blue coomassie to show that equal amount of GST-
fusion proteins were used for the pull-down assay (data not shown).
4.3 CBX7 physically interacts with HDAC2 protein.
To verify the CBX7/HDAC2 interaction in vivo, HEK 293 cells were 
transiently transfected with the V5-tagged CBX7 expression vector. Protein 
lysates were immunoprecipitated with either anti-V5 antibodies and 
immunoblotted with both anti-V5 and anti-HDAC2 antibodies (figure 9B). As 
shown in figure 9B, we detected the association between CBX7 and the 
endogenous HDAC2 protein, confirming that CBX7 and HDAC2 form 
complexes in vivo. The reciprocal experiment was performed 
immunoprecipitating with anti-HDAC2 and revealing with anti-V5 antibodies: 
it confirmed the interaction between the HDAC2 and CBX7 proteins (data not 
shown).
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Figure 9. CBX7 interacts with HDAC2. A) GST pull-down assay with GST or 
recombinant GST-CBX7 proteins (wild-type and mutants as schematically reported 
below). The filter was incubated with an anti-HDAC2 antibody. B) Co-
immunoprecipitation analysis. HEK 293 cells were transiently transfected with V5-
tagged-CBX7 or empty vectors. After 48 h, TCE were prepared and equal amounts of 
proteins were immunoprecipitated with anti-HDAC2 antibodies. The
immunocomplexes were analysed by Western blot analysis using anti-V5 and anti-
HDAC2 antibodies. IgG antibodies indicate the negative control of 
immunoprecipitation using an unrelated antibody.The relative inputs deriving from 
empty vector or V5-tagged-CBX7 overexpressing cells were tested for tubulin 
expression. 
4.4 CBX7 inhibits HDAC activity. 
In order to evaluate the effects of the CBX7/HDAC2 interaction on the 
HDAC2 activity, we performed an HDAC activity assay on HEK 293 cells 
overexpressing CBX7. As shown in figure 10A, CBX7 inhibited HDAC 
activity, almost as strongly as 250 mmol/L sodium butyrate (NaB), a strong 
HDAC inhibitory compound (Kruh 1982, Rada-Iglesias et al. 2007), used as 
positive control. In figure 10B are shown the CBX7 expression levels in 
transfected cells.
A
BA
ChromodomainChro odo ain
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Figure 10. HDAC activity assay. A) HEK 293 cells were transfected with empty 
vector (-) and CBX7 expression vector (+). NE were assayed for HDAC activity after 
48 h. Samples treated with sodium butyrate (NaB) were used as positive control. 
Values represent the average of three experiments +/- SD. B) Aliquots of the same 
lysates were resolved by SDS-PAGE, transferred to nitrocellulose membrane, and 
immunoblotted with the indicated antibodies.
To further confirm the effects of the CBX7/HDAC2 interaction on the HDAC2 
activity, we transfected HeLa and NPA cells with increasing amount of 
transfected CBX7. These nuclear extracts were used to perform a HDAC 
activity assay. CBX7 expression significantly inhibited HDAC activity in a 
dose-dependent manner. The percentage of inhibition was 65.15% and 42.55% 
in HeLa and NPA cells, respectively, after the transfection of 10 µg CBX7
expression vector (figure 11A and B). As positive control for HDAC inhibition, 
we used 250 mmol/L NaB. NE from NPA transfected with CBX7 were
immunoprecipitated with anti-HDAC2 antibodies. Then, immunoprecipitated
material was tested using a HDAC activity assay. Thus we confirmed that the 
decreased HDAC activity detected in previously assays depends by specific 
HDAC2 inhibition induced by CBX7 expression. As shown in fugure 10C, 
CBX7 specifically inhibited HDAC2 activity.
A B
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Figure 11. CBX7 inhibits HDAC activity. HeLa and NPA cells (A and B, 
respectively), transiently transfected with increasing amounts of CBX7 expression 
vector, were assayed for HDAC activity. Samples treated with NaB were used as 
positive control of HDAC activity inhibition. Aliquots of the same lysates were 
immunoblotted with the indicated antibodies. C) NPA cells were transiently transfected 
with the CBX7 expression vector or the empty vector. Nuclear extracts were 
immunoprecipitated using anti-HDAC2 antibodies and assayed for HDAC activity. 
Mean ± SD of three independent experiments.
4.5 CBX7 and HDAC activity in tumors.
As previously shown by RT-PCR and immunohistochemistry (Pallante et al. 
2008), CBX7 was strongly down-regulated in tumors. Therefore, we 
investigated HDAC activity in normal thyroid in comparison to ATC. As 
expected, in absence of CBX7 there was an increase in HDAC activity (figure 
12).
Figure 12. HDAC activity assay in anaplastic tumors (ATC). Normal thyroid and
ATC sample were assayed for HDAC activity. Values represent the average of three 
experiments +/- SD.
0
2000
4000
6000
8000
10000
12000
Normal ATC91 ATC25 ATC90
H
D
A
C
 a
c
ti
v
it
y
H
D
A
C 
a
ct
iv
it
y
Normal ATC9 ATC2 ATC9
H
D
A
C
 a
c
ti
v
it
y
H
D
A
C
 a
c
ti
v
it
y
H
D
A
C
 a
c
ti
v
it
y
H
D
A
C
 a
c
ti
v
it
y
H
D
A
C
 a
c
ti
v
it
y
H
D
A
C
 a
c
ti
v
it
y
H
D
A
C
 a
c
ti
v
it
y
H
D
A
C
 a
ct
iv
ity
42
4.6 CBX7 binds to the E-cadherin gene promoter.
HDACs catalyze the removal of acetyl groups from core histones (Marks et al. 
2001). Because of their capacity to induce local condensation of chromatin, 
HDACs are generally considered repressors of transcription (Marks et al. 2001) 
and it is already known that HDAC2 is able to repress E-cadherin gene 
expression (Ou et al. 2007) during tumor progression. E-cadherin is one of the 
caretakers of the epithelial phenotype and the loss of its expression has been 
shown to be a critical event of Epithelial-to-Mesenchymal Transition (Thiery 
2002, Thiery and Sleeman 2006). Given that CBX7 is a protein that probably 
binds chromatin, we asked whether the physical interaction between CBX7 and 
HDAC2 takes place on the human E-cadherin promoter. Therefore, to evaluate 
whether CBX7 protein was able to bind the E-cadherin promoter in vivo we 
performed ChIP assays. HEK 293 and HeLa cells were transfected with HA-
tagged-CBX7 expression vector, tested by Western blotting for protein 
expression, crosslinked, and immunoprecipitated with anti-HA or anti-IgG 
antibodies. Immunoprecipitation of chromatin was subsequently analysed by 
semiquantitative PCR, using primers spanning the region of the E-cadherin
promoter (-300 bp upstream to +40 bp downstream to the transcription start 
site). Anti-HA antibodies precipitated this E-cadherin promoter region from 
HEK 293 and HeLa cells transfected with HA-tagged-CBX7 protein (figure 
13). No immunoprecipitation was observed with IgG antibodies and with 
primers for the GAPDH control promoter (figure 13A) indicating that the 
binding is specific for the E-cadherin promoter. We performed also PCR 
amplification of the immunoprecipitated DNA using primers for p16, E2F1
and S100A4 gene promoter to validate the presence of the CBX7 on the 
promoters of other genes. Similar results were obtained when the NPA cells 
were used (data not shown). These results indicate that CBX7 protein binds the 
E-cadherin promoter region in vivo.
We also evaluated whether CBX7 protein binds the E-cadherin promoter in 
vitro, by performing an electrophoretic mobility shift assay (EMSA).
 Nuclear extracts from HEK 293 cells, transiently transfected with either V5-
tagged CBX7 or empty vectors, were incubated with a radiolabeled 
oligonucleotide corresponding to the E-cadherin promoter. In this way we 
identified a fragment of E-cadherin promoter containing an E-box. As shown 
in figure 13B, the E-cadherin oligonucleotide forms a specific complex 
(indicated in the figure as A) with nuclear proteins of cells transfected with V5-
tagged CBX7, which was not present in mock-transfected cells (compare lanes 
1 and 2). Binding specificity was shown by incubating the nuclear extract with 
a 100-fold molar excess of unlabeled E-cadherin oligonucleotide (lanes 3 and 
4).
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Figure 13. CBX7 binds the E-cadherin promoter region. A) Chromatin 
immunoprecipitation (ChIP) assay using anti-HA antibodies in HEK 293 and HeLa 
cells transiently transfected with HA-tagged CBX7 or the empty vector. The associated 
DNA was amplified by PCR using primers specific for the human gene promoters 
(left). For the E-cadherin promoter, a region spanning from nucleotide –300 to +40 of 
the gene with respect to the TSS was used. IgG antibodies were used as an 
immunoprecipitation control. B) Electrophoretic mobility shift assay with nuclear 
extracts from HEK 293 cells transiently transfected with the V5-tagged CBX7 
expression vector or the empty vector using the oligonucleotide spanning from 
nucleotide –70 to +54 of the human E-cadherin promoter as a probe. To assess the 
specificity of the binding, nuclear extracts were incubated in the presence of a 100-fold 
excess of unlabeled oligonucleotide used as competitor. 
A
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4.7 CBX7 occupies the E-cadherin promoter with HDAC2.
Then, to investigate whether the physical interaction between CBX7 and 
HDAC2 takes place on the human E-cadherin promoter, we performed re-
chromatin immunoprecipitation analysis (Re-ChIP). HEK 293 cells transiently 
transfected with HA-tagged CBX7 and empty vectors were crosslinked and 
immunoprecipitated with anti-HDCA2 antibodies. The anti-HDAC2 complexes 
were released, re-immunoprecipitated with anti-HA antibodies, and then 
analysed by PCR. The results shown in figure 14A reveal that the antibodies 
against HA precipitate the E-cadherin promoter after their release from anti-
HDAC2, indicating that CBX7 occupies this promoter region together with 
HDAC2. The reciprocal experiment provided comparable results (figure 14B).
Taken together, these results indicate that CBX7 binds the human E-cadherin
promoter in vivo and participates in the same DNA-bound complexes that 
contain HDAC2.
Figure 14. CBX7 binds E-cadherin promoter together to HDAC2. A) Re-ChIP 
experiments in which soluble chromatin immunoprecipitated with anti-HDAC2 was re-
immunoprecipitated with anti-HA. IgG antibodies control refers to Re-ChIP with anti-
HA. B) Re-ChIP experiments in which soluble chromatin immunoprecipitated with anti-
V5 was re-immunoprecipitated with anti-HDAC2. IgG antibodies control refers to re-
chromatin immunoprecipitation with anti-HDAC2.
4.8 CBX7 colocalize with HDAC2.
Indirect immunoFRET assay was used to further confirm the interaction 
between CBX7 and HDAC2 in HEK 293 cells. HEK 293 cells were transfected 
with pCDNA3.1-V5-CBX7. Upon fixation, cells were immunostained with 
anti-Cy3, that recognize anti-CBX7, and anti-Cy5, that recognize anti-HDAC2. 
As shown in figure 15A, CBX7 and HDAC2 perfectly colocalized in the 
A
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nucleus. Subsequently, we performed the FRET assay by acceptor 
photobleaching (Kenworthy 2001, Piston 2007). Upon Cy5 photobleaching, 
Cy3 fluorescence increased by 15% of its final value (figure 15B), which 
corresponds to 15% Cy3-Cy5 FRET efficiency. EGFP, the negative control, 
indirectly immunostained by Cy3, showed a negligible increase in Cy3 
fluorescence upon Cy5 bleaching. On the contrary, HDAC2 indirectly 
immunostained by Cy3 and Cy5 was the positive control and showed a 
remarkable increase in Cy3 fluorescence upon Cy5 bleaching. Therefore, the 
FRET assay succeeded in distinguishing CBX7/HDAC2 colocalization and in 
confirming CBX7/HDCA2 interaction.
      
Figure 15. CBX7/HDAC2 colocalization. A) (a-c) Immunostaining of a CBX7-
transfected HEK 293 cell with anti-CBX7 (green), anti-HDAC2(red) and DAPI (blue); 
(d) merging image of a, b and c; (e–g) immunostaining of a EGFP-transfected HEK 
293 cell with anti-EGFP (green), anti-HDAC2 (red) and DAPI (blue); (h) merging 
image of e, f and g. B) Summary of FRET acceptor photobleaching.
4.9 CBX7 positively regulates the E-cadherin promoter. 
To evaluate the effect of CBX7 expression on E-cadherin transcription, HEK
293 cells were transiently cotransfected with an expression vector encoding 
CBX7 and with a reporter vector carrying the luciferase gene under the control 
of the E-cadherin promoter. As shown in figure 16A, CBX7 increases the 
transcriptional activity of the E-cadherin promoter in a dose-dependent 
manner. The same results were obtained on the NPA and TPC1 cell lines (data 
not show). The treatment of cells with trichostatin A (TSA), a potent inhibitor 
of HDAC activity (Ou et al. 2007), cooperates with CBX7 to induce E-
cadherin gene transcription (figure 16B). These results strongly suggest that 
CBX7 protein is involved in the E-cadherin gene transcription likely 
counteracting with the already known inhibitory effect of HDAC2 on this gene 
promoter.
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Figure 16. CBX7 enhances E-cadherin promoter activity. A) Dose-response 
analysis of increasing amounts of CBX7 on the E-cadherin luciferase-reporter vector 
transiently transfected into HEK 293 cells. Western blot analysis confirmed the 
increasing amounts of CBX7 expression. -Tubulin expression served as a control of 
equal protein loading. B) Dose-response analysis of increasing amounts of CBX7 on 
the E-cadherin luciferase-reporter vector transiently transfected into HEK 293 cells 
treated or not with 300 nmol/L of HDAC inhibitor TSA.
To identify the region of CBX7 required for E-cadherin promoter activation, 
we constructed two CBX7 deletion mutants in the expression vector pCefl-HA: 
pCefl-HA-CBX7-CHROMO (1-100 amino acids) and pCefl-HA-CBX7-
NOCHROMO (55-251 amino acids). Transfection of the mutant pCefl-HA-
CBX7-CHROMO, containing only the chromodomain, did not induce 
transcriptional activation of the E-cadherin promoter. Conversely, the mutant 
lacking the chromodomain, pCefl-HA-CBX7-NOCHROMO, induced a 
moderate activation of the E-cadherin promoter. Thus, these data indicate that 
chromodomain is not essential for the CBX7 transcriptional activity on the E-
cadherin promoter (figure 17A).
To identify the regulatory elements essential for the activity of CBX7 on the E-
cadherin promoter, we also tested some deletion mutants of the E-cadherin
promoter: E-cadherin 601 and E-cadherin 211. Activation of E-cadherin
promoter by CBX7 protein was maintained on full-length and 601 mutants of 
E-cadherin promoter. Conversely, the 211 mutant, which lacks a portion of –
70/+54 sequence (able to bind CBX7), was not activated by CBX7 protein 
(figure 17B). In fact sequence elements within the proximal 108 bp of E-
cadherin promoter include the CCAAT-box, two E-box elements that may bind 
basic helix-loop-helix protein, and a consensus sequence for binding zinc-
finger proteins such as Sp1 and WT1 (Ji et al. 1997, Hajra et al. 1999). 
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Figure 17. Identification of essential elements for the activity of CBX7 on E-
cadherin promoter. A) Dose-response analysis of increasing amounts of CBX7 and 
the two CBX7-deletion mutants (schematically illustrated in figure 9A) on the E-
cadherin luciferase-reporter vector transiently transfected into HEK 293 cells. B) Dose 
response analisys of increasing amounts of CBX7 on the two deletion mutant of E-
cadherin promoter cloned in luciferase-reporter vector.
Moreover, to show that the expression of E-cadherin is directly regulated by 
CBX7, we generated some clones of NPA cells (NPA 4-11 and NPA 5-11) in 
which CBX7 cDNA was under the control of a tetracycline-regulated promoter. 
Western blot analysis (figure 18A, top) and quantitative RT-PCR experiment 
(figure 18A bottom) show that the expression of CBX7 increases the levels of 
E-cadherin only after treatment with tetracycline.
To further confirm the role of CBX7 in the modulation of the E-cadherin gene, 
we evaluated the expression of the E-cadherin gene in the normal rat thyroid 
cell line PC Cl3 in which the synthesis of Cbx7 was suppressed by RNA 
interference. The knockdown of the Cbx7 mRNA levels, observed at 48 h after 
treatment, resulted in the reduction of E-cadherin mRNA levels in comparison 
with the untreated cells or those treated with the nonsilencing control small 
interfering RNA (figure 18B).
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Figure 18. CBX7 modulates E-cadherin expression. A) top, Western blot analysis 
of CBX7 and E- cadherin expression in the NPA cell clones 4-11 and 5-11 treated or 
not with tetracycline. The treatment with tetracycline (+tet) was indicated on the top. -
Tubulin expression served as a control of equal protein loading. Bottom, quantitative 
RT-PCR (qRT-PCR) analysis of E-cadherin expression in the same NPA cell clones. 
The relative expression indicates the relative change in E-cadherin expression levels 
between treated cells versus the untreated ones, assuming that the value of E-
cadherin expression in the untreated cells is equal to 1. B) Cbx7 and E-cadherin gene 
expression was evaluated by RT-PCR in rat PC Cl3 cells after treatment with small 
interfering RNA against rat Cbx7. The expression of GAPDH was used to normalize 
the amounts of RNAs used in the experiment.
4.10 CBX7 expression results in increased histone acetylation of the E-
cadherin promoter. 
During the last years, chromatin remodeling and histone modifications have 
emerged as the main mechanisms in the control of gene expression and the 
connection between DNA methylation and histone deacetylation in the 
silencing of genes has been established (Marks et al. 2001, van Leeuwen and 
van Steensel 2005). Because we have shown previously that CBX7 (a) interacts 
with HDAC2 on the human E-cadherin promoter, (b) reduces the activity of 
HDACs, (c) increases the transcriptional activity of the E-cadherin promoter in 
A B
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a dose-dependent manner, we hypothesized that the positive effect on E-
cadherin activation by CBX7 may be due to its ability to reduce the HDAC 
activity on the E-cadherin promoter. Therefore, we have evaluated the lysine 
acetylation of histone tails at the E-cadherin promoter.
HEK 293 cells were transiently transfected with V5-tagged CBX7 expression 
vector or empty vector. Then, the cells were crosslinked and DNA-chromatin 
was immunoprecipitated with anti-H3 or anti-H4 acetylated or IgG antibodies. 
The immunoprecipitated chromatin was subsequently analysed by quantitative 
PCR using primers spanning the region of the E-cadherin promoter (–70 bp
upstream to +54 bp downstream to the TSS; ref. Li et al. 2007). As shown in 
figure 19, higher amounts of H3 and H4 acetylated tails were detected in the E-
cadherin promoter in the cells transfected with CBX7, with respect to those 
detected in mock-transfected cells, indicating an increased histone acetylation 
in CBX7-transfected cells, likely due to the ability of CBX7 to reduce HDAC 
activity. We also treated the cells, transfected or not with CBX7, with TSA to 
verify the HDAC activity on H3 and H4 tails. As shown in the same figure, 
there were higher amounts of H3 and H4 acetylated tails in CBX7-transfected 
samples treated with TSA than in untreated cells. These results indicate that 
CBX7 protein regulates the E-cadherin expression by modifying histone 
acetylation at its promoter, likely reducing HDAC activity.
Figure 19. Analysis of the histone acetylation of the human E-cadherin
promoter. HEK 293 cells transiently transfected with V5-tagged CBX7 expression or 
empty vectors, and treated or not with TSA for 24 h, were subjected to chromatin 
immunoprecipitation using anti-acetyl histone H3 (H3ac; left) and anti-acetyl histone 
H4 (H4ac; right) and analysed by quantitative RT-PCR for the E-cadherin promoter. 
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4.11 Increased methylation of H3K4 and decreased methylation of H3K9 
and H4K20 in CBX7-transfected cells. 
Lysine methylation can have different effects depending on which residue is 
modified: methylation of H3K4 and H3K36 is generally associated with 
transcribed chromatin; in contrast, methylation of H3K9, H3K27, and H4K20
generally correlates with gene repression (Li et al. 2007). Therefore, we have 
evaluated the lysine methylation status of histone tails of E-cadherin promoter 
in presence or absence of CBX7.
HEK 293 cells were transiently transfected with V5-tagged CBX7 or empty 
vectors and crosslinked, and DNA-chromatin was immunoprecipitated with 
anti-H3K4m2, anti-H3K4m3, anti-H3K9m2, anti-H3K9m3, and anti-H4K20m3 
or IgG antibodies. The immunoprecipitated chromatin was subjected to PCR 
with specific primers for the E-cadherin promoter region (–70/+54).
Higher amounts of chromatin immunoprecipitated for H3K4m2 and H3K4m3 
were observed in the CBX7-transfected cells compared with the control ones, 
indicating that this lysine is methylated in a higher proportion in CBX7-
transfected cells with respect to that observed in control cells. Conversely, in 
the case of chromatin immunoprecipitated for the H3K9m2, H3K9m3, and 
H4K20m3, higher amounts of chromatin were detected in control cells,
indicating that these sites were methylated at a higher level in the control cells 
versus CBX7-transfected cells (figure 20). These data indicate that CBX7 is 
able to alter the methylation status of specific lysines of E-cadherin promoter, 
promoting the transcriptional activity of E-cadherin promoter.
Figure 20. Analysis of the histone methylation of the human E-cadherin
promoter. HEK 293 cells transiently transfected with V5-tagged CBX7 expression or 
empty vectors were subjected to chromatin immunoprecipitation using anti-H3K4m2 
and anti-H3K4m3 (left), anti-H3K9m2 and anti-H3K9m3 (middle), and anti-H4K20m3 
(right) and analysed by quantitative RT-PCR for the E-cadherin promoter.
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4.12 CBX7 and E-cadherin expression levels are correlated in human 
thyroid carcinomas. 
E-cadherin down-regulation, due to epigenetic mechanisms, including 
transcriptional repression, also mediated by HDAC activity, and promoter 
hypermethylation is a frequent event during human cancer progression 
(Koizume et al. 2002, Peinado at al. 2004). Because previous experiments 
showed that CBX7 expression was lost in most advanced thyroid cancers, we 
hypothesized the down-regulation of E-cadherin as a possible mechanism by 
which loss of CBX7 is involved in advanced stages of thyroid carcinogenesis. 
This hypothesis was also supported by recent results showing a role of 
polycomb repressive complex 1/2 in the regulation of E-cadherin expression
(Cao et al. 2008).
Therefore, we analysed CBX7 and E-cadherin mRNA levels in human thyroid 
carcinomas of different histotypes (Figure 21A). CBX7 and E-cadherin mRNA 
levels were drastically reduced in anaplastic thyroid carcinoma, whereas just a 
weak decrease was observed for both genes in papillary thyroid carcinoma. The 
Epithelial-to-Mesenchymal Transition in our tumor samples was also 
confirmed by the increased N-cadherin expression (figure 21A).
We found a positive statistical correlation between CBX7 and E-cadherin 
expression in human thyroid carcinomas as shown in figure 21B. We also 
compared CBX7 and E-cadherin at protein level, by immunohistochemical 
analysis, confirming that E-cadherin protein expression parallels that of CBX7 
(figure 21C).
Because hypermethylation of the E-cadherin promoter has been postulated to 
play a critical role in the loss of E-cadherin expression and has been reported 
previously in other cancers, we decided to investigate the DNA methylation 
status of E-cadherin promoter (Hajra and Fearon 2002). We analysed DNA 
methylation status of 26 CpG sites located in a 368-bp region spanning the E-
cadherin gene TSS (figure 21D, inset) on 16 papillary thyroid carcinomas, 15
follicular variants of papillary thyroid carcinomas, 4 anaplastic thyroid 
carcinomas, and 4 normal thyroid tissue samples. A very low level of 
methylation was present in both normal and tumor samples, with the exception 
of only one anaplastic thyroid carcinoma sample in which a high degree of 
methylation was detected (figure 21D).
Therefore, epigenetic mechanisms, other than hypermethylation of the E-
cadherin promoter, have a critical role in the down-regulation of E-cadherin 
expression.
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Figure 21. CBX7 and E-cadherin gene expression levels are correlated in human 
thyroid carcinomas. A) CBX7, E-cadherin, and N-cadherin gene expression in 
thyroid tumor samples was analysed by quantitative RT-PCR. Relative expression 
indicates the change in expression levels between tumor and normal samples, 
assuming that the value of each normal sample is equal to 1. B) Positive statistical 
correlation between CBX7 and E-cadherin expression in human thyroid carcinomas 
analysed in A. R
2
, Pearson correlation coefficient. C) Immunohistochemical analysis of 
normal and tumor samples stained with anti-CBX7 and anti-E-cadherin antibodies. 
The percentage of positive cells for the staining/total number of cells was reported. D)
top, positions of the primers used for amplifications of the region spanning from 
nucleotide –200 to + 200 of E-cadherin with respect to the TSS; bottom, average 
methylation degree of 26 CpG sites at E-cadherin promoter in human thyroid 
carcinomas. PTC, papillary thyroid carcinoma; ATC, anaplastic thyroid carcinoma.
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5. CONCLUSIONS
In a previous study our group has reported that CBX7 gene expression was 
drastically down-regulated in thyroid carcinomas and progressively decreased 
with malignant grade and neoplastic stage (Pallante et al. 2008). 
Thus, to elucidate the mechanism by which the loss of CBX7 expression is 
involved in cancer progression, we investigated, by proteomic approach, 
proteins interacting with CBX7. Among the CBX7 interacting proteins, we 
selected the HDAC2 because of its relevance in tumor biology. HDACs
regulate the expression and activity of numerous proteins involved in both 
cancer initiation and cancer progression, inducing a nonpermissive chromatin 
conformation that prevents the transcription of genes involved in tumorigenesis 
such as E-cadherin (Glozak and Seto 2007). In addition to histone, HDACs 
bind to and deacetylate a variety of protein targets including transcription 
factors and other abundant cellular proteins implicated in the control of cell 
growth, differentiation and apoptosis (Smith 2008). Therefore HDAC can alter 
the expression and function of cancer associated proteins by both 
transcriptional and post-translational mechanisms. HDACs, in fact, are often 
overexpressed in many tumors: for example, prostate cancer cells overexpress 
HDAC1, whereas gastric carcinomas, colorectal carcinomas, cervical 
dysplasias and endometrial stromal sarcomas all overexpress HDAC2 (Glozak 
and Seto 2007). 
In this study, we show that CBX7 physically interacts with HDAC2 protein 
and is able to inhibit its activity. It is known that HDAC2 represses E-cadherin 
expression during tumor progression therefore we investigated whether the 
physical interaction between CBX7 and HDAC2 takes place on the human E-
cadherin promoter. This evidence aimed us to hypothesize a role for CBX7 as 
a trascriptional regulator of E-cadherin expression. Our data, in fact, suggested 
that the loss of CBX7 expression is strictly correlated with the acquisition of 
malignant phenotype, often, accompanied by the loss of the epithelial features 
and the gain of a mesenchymal phenotype, a process known as Ephitelial-to-
Mesenchymal Transition (EMT). One of the caretakers of the epithelial 
phenotype is E-cadherin, which loss leads to disruption of cell junctions and 
consequent gain of cell mobility. In fact, a direct correlation between lack of E-
cadherin expression and loss of the epithelial phenotype has been demonstrated 
(Thiery 2002). In most cancers, E-cadherin down-regulation during neoplastic 
progression occurs by epigenetic mechanisms, including transcriptional 
repression, in some cases mediated by HDAC activity (Peinado et al. 2004), 
and hypermethylation of the promoter (Hajra and Fearon 2002). Only in a few 
cases mutations have been found in the E-cadherin gene leading to the absence 
or the expression of a nonfunctional protein (Thiery 2002). For this reason, we 
evaluated E-cadherin expression in human thyroid carcinomas of different 
histotypes: an evident correlation was found between CBX7 and E-cadherin 
expression levels in human thyroid carcinomas, both being drastically down-
54
regulated in anaplastic thyroid carcinomas in comparison with the normal
thyroid tissue. Interestingly, no hypermethylation of E-cadherin promoter was 
observed in thyroid carcinomas. Our hypothesis about the role of CBX7 as a 
transcriptional regulator of E-cadherin seems also supported by recent results 
showing the involvement of PRC1/PRC2 complexes in the regulation of E-
cadherin expression (Cao et al. 2008). 
We confirmeded, by ChIP, that both HDAC2 and CBX7 bind the E-cadherin
promoter. We also showed the ability of CBX7 to positively regulate E-
cadherin expression by interacting with HDAC2 and inhibiting its activity on 
the E-cadherin promoter. Further, we demonstrated that, in the presence of the 
CBX7 protein, there is an increased histone acetylation of the E-cadherin
promoter, validating our hypothesis that CBX7 recruits HDCA2 on the E-
cadherin promoter. Moreover, we show modifications in the histone 
methylation state on the E-cadherin promoter in the cells transfected with 
CBX7 confirming a relationship between acetylation and DNA methylation 
(Kouzarides 2007).
Finally, here we propose a novel pathway regulating the progression step of 
carcinogenesis in which the CBX7 protein, whose loss of expression correlates 
with a highly malignant phenotype, is a key molecule. Indeed, our results 
indicate that the loss of CBX7 expression contributes to cancer progression
allowing the down-regulation of E-cadherin expression because of the lack of 
its inhibitory effect on HDAC activity on the E-cadherin promoter.
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TABLE  CBX7 interacting proteins
BAND PROTEIN ID score
N° 
peptidi
MW Function Process
T1
(P62826) GTP-binding nuclear protein 
Ran (GTPase Ran) (Ras-like protein 
TC4)
27 2 25
GTP-binding protein involved in nucleocytoplasmic transport. Required for the 
import of protein into the nucleus and also for RNA export. Involved in chromatin 
condensation and control of cell cycle.Nuclear; becomes dispersed throughout the 
cytoplasm during mitosis. Interact with RANGAP1
 GTPase activity/ Signal 
transduction ; Cell communication  
T4
(P61981) 14-3-3 protein gamma (Protein 
kinase C inhibitor protein 1)
88 1 28
Adapter protein implicated in the regulation of a large spectrum of both general and 
specialized signaling pathway. Binds to a large number of partners, usually by 
recognition of a phosphoserine or phosphothreonine motif. Binding generally results 
in the modulation of the activity of the binding partner.Interacts with RAF1 and 
SSH1.Cytoplasm. 
Receptor signaling complex 
scaffold activity/ Signal 
transduction; cell communication
T5 (O95931) Chromobox protein homolog 7 40 1 28 BAIT
(P04083) Annexin A1 (Annexin I) 
(Lipocortin I) (Calpactin II) 
(Chromobindin-9)
785 19 39
Calcium/phospholipid-binding protein which promotes membrane fusion and is 
involved in exocytosis. This protein regulates phospholipase A2 activity. It seems to 
bind from two to four calcium ions with high affinity.Phosphorylated by protein 
kinase C, epidermal growth factor receptor/kinase and TRPM7. Phosphorylation 
results in loss of the inhibitory activity. 
   Calcium ion binding/Signal 
transduction ; Cell communication 
(P07355) Annexin A2 (Annexin II) 
(Lipocortin II) (Calpactin I heavy chain) 
(Chromobindin-8)  
284 5 39
 Calcium-regulated membrane-binding protein whose affinity for calcium is greatly 
enhanced by anionic phospholipids. It binds two calcium ions with high affinity
   Calcium ion binding/Signal 
transduction ; Cell communication 
T7
(Q08188) Protein-glutamine gamma-
glutamyltransferase E precursor
231 6 77
Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins. 
It is responsible for the later stages of cell envelope formation in the epidermis and 
the hair follicle
Transaminase activity/ 
Metabolism; Cell growth and/or 
maintenance
gi|37183160 HRPE773 [Homo sapiens] 215 7 20 Q96DA0 HUMAN Similar to common salivary protein 1 Unknown
 gi|662841 heat shock protein 27 147 5 22
Involved in stress resistance and actin organization. Associates with alpha- and beta-
tubulin and microtubules. Interacts with HSPB8.Cytoplasm. Nucleus. Cytoplasmic in 
interphase cells. Colocalizes with mitotic spindles in mitotic cells. Translocates to the 
nucleus during heat shock. 
Chaperone activity/Cell 
proliferation
gi|20334354 S100 calcium binding 
protein A14
144 2 12 Cytoplasm.
   Calcium ion binding/Biological 
Process Unknown
gi|4885607 small proline-rich protein 3 
[Homo sapiens]
132 3 19 Cross-linked envelope protein of keratinocytes. Cytoplasm. 
Structural molecule activity/ Cell 
growth and/or maintenance
gi|31645 glyceraldehyde-3-phosphate 
dehydrogenase [Homo sapiens]
110 4 36
It has been suggested that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
play a role in nuclear tRNA export
Catalytic activity/ Nuclear export
gi|187302 epithelial cell marker protein 1               
(14-3-3 sigma)
90 2 28
 Adapter protein implicated in the regulation of a large spectrum of both general and 
specialized signaling pathway. Binds to a large number of partners, usually by 
recognition of a phosphoserine or phosphothreonine motif. Binding generally results 
in the modulation of the activity of the binding partner. p53-regulated inhibitor of 
G2/M progression. Cytoplasm. Or: Secreted protein. May be secreted by a non-
classical secretory pathway. Belongs to the 14-3-3 family. 
  Receptor signaling complex 
scaffold activity /Signal 
transduction ; Cell communication 
gi|45592961 chromosome 20 open 
reading frame 70 [Homo sapiens]
76 2 27
containing a lipid binding domain - similar to short palate, lung and nasal epithelium 
carcinoma-associated protein 2
Unknown/Biological Process 
Unknown
gi|18204442  Ribosomal protein L18 64 1 22 Ribosomal protein
Ribosomal subunit/ Protein 
metabolism
 gi|895845 p64 CLCP 62 1 24
Seems to act as a chloride ion channel.. Mostly in the nucleus including in the 
nuclear membrane. Cytoplasm. Cell membrane. Small amount in the cytoplasm and 
the plasma membrane.SIMILARITY: Belongs to the chloride channel CLIC family. 
SUBCELLULAR LOCATION: Nucleus; nuclear membrane
Transmembrane receptor activity/ 
receptor
(P09651) Heterogeneous nuclear 
ribonucleoprotein A1 (Helix-destabilizing 
protein)
58 1 39
Involved in the packaging of pre-mRNA into hnRNP particles, transport of poly(A) 
mRNA from the nucleus to the cytoplasm and may modulate splice site selection. 
Nucleus. Cytoplasm. Shuttles continuously between the nucleus and the cytoplasm 
along with mRNA. Component of ribonucleosomes. 
  Ribonucleoprotein/ Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism/ 
Nucleus export  
T8
gi|627650 transcription factor BTF2 chain 
p34 - human
56 1 35
FUNCTION: Component of the core-TFIIH basal transcription factor involved in 
nucleotide excision repair (NER) of DNA and, when complexed to CAK, in RNA 
transcription by RNA polymerase II. Anchors XPB.SUBUNIT: One of the six 
subunits forming the core-TFIIH basal transcription factor.SUBCELLULAR 
LOCATION: Nucleus.SIMILARITY: Belongs to the TFB4 family. 
 nucleotide-excision repair/ 
regulation of transcription, DNA-
dependent 
(P29692) Elongation factor 1-delta (EF-1-
delta)
171 3 31
EF-1-beta and EF-1-delta stimulate the exchange of GDP bound to EF-1-alpha to 
GTP
 Guanyl-nucleotide exchange 
factor activity/ Translation 
regulator activity
(Q15024) Exosome complex exonuclease 
RRP42  (Ribosomal RNA-processing
protein 42)
73 1 32
Component of the exosome 3'->5' exoribonuclease complex. Required for the 3' 
processing of the 7S pre-RNA to the mature 5.8S rRNA. associated with the GTPase 
Ran. Interacts directly with CSL4. Nucleus; nucleolus
DNA binding/ Cell growth and/or 
maintenance
T9
gi|34335134 SEC13-like 1 isoform b 45 1 36 Molecular function unknown ( Putative nucleoporin interacting protein) unknown
T10 gi|12654583 Ribosomal protein P0 236 5 34 Localization:  Citoplasm, nucleus, nucleolus
Ribosomal subunit/ Protein 
metabolism
T14
(O43684) Mitotic checkpoint protein 
BUB3
137 4 38  Required for kinetochore localization of BUB1. Nucleus.                                                                   
protein serine/threonine kinae 
activity/Signal transduction; Cell 
communication   
(P68400) Casein kinase II subunit alpha 124 5 45
Casein kinases are operationally defined by their preferential utilization of acidic 
proteins such as caseins as substrates. The alpha and alpha' chains contain the 
catalytic site. Participates in Wnt signaling.Subunit alpha 1 e 2  interact with 
HISTONE DEACETILASE 2 (HDAC2) 
 Protein serine/threonine kinase 
activity/ Signal transduction ; Cell 
communication  
(Q01085) Nucleolysin TIAR 118 3 42
RNA-binding protein. Possesses nucleolytic activity against cytotoxic lymphocyte 
target cells. May be involved in apoptosis. Nuclear localization
RNA binding/Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism 
(Q15366) Poly(rC)-binding protein 2 84 2 39
Major cellular poly(rC)-binding protein. Binds also poly(rU). Nucleus. Cytoplasm. 
Loosely bound in the nucleus. May shuttle between the nucleus and the cytoplasm
RNA binding/Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism 
(Q14103) Heterogeneous nuclear 
ribonucleoprotein D0 (hnRNP D0) 
76 3 38
Binds with high affinity to RNA molecules that contain AU-rich elements (AREs) 
found within the 3-prime untranslated regions of many protooncogenes and cytokine 
mRNAs. Also binds to double- and single-stranded DNA sequences in a specific 
manner and functions a transcription factor. Binding of RRM1 to DNA inhibits the 
formation of DNA quadruplex structure which may play a role in telomere 
elongation. May be involved in translationally coupled mRNA turnover. Implicated 
with other RNA-binding proteins in the cytoplasmic deadenylation/translational and 
decay interplay of the FOS mRNA mediated by the major coding-region determinant 
of instability (mCRD) domain. Nuclear; component of ribonucleosomes. 
  Ribonucleoprotein/Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism  
T15
gi|1808644 arginine methyltransferase 64 2 40
Protein arginine methyltransferase that functions as a histone methyltransferase 
specific for H4 
Methyltransferase activity/ 
Histone modifing protein
T17
gi|4758158 Septin 2 50 1 42
Septins may form a mitotic scaffold for CENP-E and other effectors to coordinate 
cytokinesis with chromosome congression and segregation
Interact with S100 calcium-binding protein A4 . Nucleus.
Receptor signaling complex 
scaffold activity/  Signal 
transduction ; Cell communication  
(O00303) Eukaryotic translation initiation 
factor 3 subunit 5 (eIF-3 epsilon)
108 2 38
Binds to the 40S ribosome and promotes the binding of methionyl-tRNAi and 
mRNA. Associates with the complex p170-eIF3. 
 Translation regulator activity/ 
Protein metabolism  
T16
(Q12905) Interleukin enhancer-binding 
factor 2 
80 3 43
Appears to function predominantly as a heterodimeric complex with ILF3. This 
complex may regulate transcription of the IL2 gene during T-cell activation. It can 
also promote the formation of stable DNA-dependent protein kinase holoenzyme 
complexes on DNA. Nucleus; nucleolus.
  Transcription factor activity/ 
Regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism  
(Q86U42) Polyadenylate-binding protein 
2 (Poly(A)-binding protein 2)
57 1 33
Involved in the 3'end formation of mRNA precursors (pre-mRNA) by the addition of 
a poly(A) tail of 200-250 nt to the upstream cleavage product. Stimulates poly(A) 
polymerase (PAPOLA) conferring processivity on the poly(A) tail elongation 
reaction and controls also the poly(A) tail length. Increases the affinity of poly(A) 
polymerase for RNA. Is also present at various stages of mRNA metabolism 
including nucleocytoplasmic trafficking and nonsense-mediated decay (NMD) of 
mRNA. Cooperates with SKIP to synergistically activate E-box-mediated 
transcription through MYOD1 and may regulate the expression of muscle-specific 
genes. Binds to poly(A) and to poly(G) with high affinity. May protect the poly(A) 
tail from degradation.Shuttles between the nucleus and the cytoplasm but 
predominantly found in the nucleus. Its nuclear import may involve the 
nucleocytoplasmic transport receptor transportin and a RAN-GTP-sensitive import 
mechanism. Is exported to the cytoplasm by a carrier-mediated pathway that is 
independent of mRNA traffic. Nucleus; nucleoplasm; nuclear speckle. 
 RNA binding/Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism/ 
Nuclear export/import
(Q8NFW8) N-acylneuraminate 
cytidylyltransferase
53 2 49
Catalyzes the activation of N-acetylneuraminic acid (NeuNAc) to cytidine 5'-
monophosphate N-acetylneuraminic acid (CMP-NeuNAc), a substrate required for 
the addition of sialic acid. Has some activity toward NeuNAc, N-glycolylneuraminic 
acid (Neu5Gc) or 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN). 
Nucleus. The BC2 (basic cluster 2) motif is necessary and sufficient for the nuclear 
localization and contains the catalytic active site. The localization in the nucleus is 
however not required for the enzyme activity 
 Ligase activity /Metabolism ; 
Energy pathways 
(P60842) Eukaryotic initiation factor 4A-
I
47 1 46
ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in 
cap recognition and is required for mRNA binding to ribosome.  Belongs to the 
DEAD box helicase family. eIF4A subfamily. 
 Translation regulator activity/ 
Protein metabolism  
T18
(P68104) Elongation factor 1-alpha 1 
(EF-1-alpha-1)
245 7 50
 This protein promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site 
of ribosomes during protein biosynthesis. 
Found in a nuclear export complex with XPO5, EEF1A1, Ran and aminoacylated 
tRNA. Interacts with XPO5. 
 Translation regulator activity/ 
Protein metabolism 
gi|33327055 DERPC [Homo sapiens] 71 2 51
nuclear, strong basic protein; decreased expression in renal and prostate tumors; has 
cell growth inhibiting function
 DNA binding/ Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism/ Cell 
proliferation  T20
gi|8922679 smu-1 suppressor of mec-8 
and unc-52 homolog
47 1 58 unknown unknown
T21
gi|48146467  HSPC117 [Homo sapiens] 108 3 56 unknown unknown
gi|5901990 katanin p60 subunit A 1 
[Homo sapiens]
51 2 56
 Microtubules, polymers of alpha and beta tubulin subunits, form the mitotic spindle 
of a dividing cell and help to organize membranous organelles during interphase. 
Katanin is a heterodimer that consists of a 60 kDa ATPase (p60 subunit A 1) and an 
80 kDa accessory protein (p80 subunit B 1). The p60 subunit acts to sever and 
disassemble microtubules, while the p80 subunit targets the enzyme to the 
centrosome. This gene encodes the p80 subunit. This protein is a member of the 
AAA family of ATPases.
ATPase activity/Metabolism; Cell 
maintenance
gi|47940653   Chaperonin containing 
TCP1, subunit 8 (theta)
68 2 60
 Chaperone activity/ Cell 
maintenance
gi|56789228 Chaperonin containing 
TCP1, subunit 7 (eta) [Homo sapiens]
53 1 60
 Chaperone activity/ Cell 
maintenanceT22
gi|71051977 HDAC2 protein [Homo 
sapiens]
65 2 45
Histone deacetylase family. Deacetylase activity. Interact with  casein kinase 2, alpha 
1 polypeptide   
Histone modifing protein
T23
 (P14866) Heterogeneous nuclear 
ribonucleoprotein L (hnRNP L)
267 11 61
This protein is a component of the heterogenous nuclear ribonucleoprotein (hnRNP) 
complexes which provide the substrate for the processing events that pre-mRNAs 
undergo before becoming functional, translatable mRNAs in the cytoplasm. L is 
associated with most nascent transcripts including those of the landmark giant loops 
of amphibian lampbrush chromosomes. Nucleus; nucleoplasm
 Ribonucleoprotein/ Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism 
T24
 (Q13283) Ras-GTPase-activating 
protein-binding protein 1 (ATP-
dependent DNA helicase V)
180 4 52
May be a regulated effector of stress granule assembly. Phosphorylation-dependent 
sequence-specific endoribonuclease in vitro. Binds to the SH3 domain of Ras-
GTPase-activating protein (RASA1) in proliferating cells. No interaction in quiescent 
cells.Interacts with USP10, and may regulate it. Forms homodimers and oligomers. 
Cytoplasm. Cytoplasm; cytosol. Cell membrane. Nucleus. Cytoplasmic in 
proliferating cells, can be recruited to the plasma membrane in exponentially 
growing cells. Cytosolic and partially nuclear in resting cells. Recruited to stress 
granules (SGs) upon either arsenite or high temperature treatment. Recruitment to 
SGs is influenced by HRAS.
Ribonuclease activity/ Regulation 
of nucleobase, nucleoside, 
nucleotide and nucleic acid 
metabolism  
 (Q12800) Alpha-globin transcription 
factor CP2 (Transcription factor LSF)
166 3 58
 Binds a variety of cellular and viral promoters including fibrinogen, alpha-globin, 
SV40 and HIV-1 promoters. Activation of the alpha-globin promoter in erythroid 
cells is via synergistic interaction with UBP1. Functions as part of the SSP (stage 
selector protein) complex. Facilitates the interaction of the gamma-globin genes with 
enhancer elements contained in the locus control region in fetal erythroid cells. 
Interacts by binding to the stage selector element (SSE) in the proximal gamma-
globin promoter. 
 Transcription factor activity/ 
Regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism 
gi|1809248  siah binding protein 1 [Homo 
sapiens]
107 2 58 Hypotetical Ribonucleoprotei/ RNA binding protein
 RNA binding/ Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism 
gi|14124984 Chaperonin containing 
TCP1, subunit 3 (gamma) [Homo 
sapiens]
61 1 60
 Chaperone activity/ Cell 
maintenance
(P33240) Cleavage stimulation factor, 64 
kDa subunit (CSTF 64 kDa subunit)
324 8 61
 One of the multiple factors required for polyadenylation and 3'-end cleavage of 
mammalian pre-mRNAs. This subunit is directly involved in the binding to pre-
mRNAs.Nucleus. 
 RNA binding/ Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism 
gi|57209129 paraspeckle component 1 199 5 59 Putative RNA binding protein
 RNA binding/ Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism 
gi|23398584 Interferon regulatory factor 
2 binding protein 1
80 1 62
 Transcription regulator activity/ 
Regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism  
gi|8923040 collaborates/cooperates with 
ARF (alternate reading frame) protein
74 1 61
  RNA binding/ Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism  
T25
 (Q8WXI9) Transcriptional repressor p66 
beta (p66/p68) (GATA zinc finger 
domain-containing protein 2)
47 1 66
Has transcriptional repressor activity. Targets MBD3 to discrete loci in the nucleus. 
Nucleus. Nuclear, in discrete foci. 
 Transcription regulator activity/ 
Regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism  
gi|178027 alpha-actin 258 9 42 Cell maintenanceT26c
(P11940) Polyadenylate-binding protein 1 
(Poly(A)-binding protein 1) (PABP 1)
48 1 71
 Binds the poly(A) tail of mRNA. May be involved in cytoplasmic regulatory 
processes of mRNA metabolism. Its function in translational initiation regulation can 
either be enhanced by PAIP1 or repressed by PAIP2. Can probably bind to 
cytoplasmic RNA sequences other than poly(A) in vivo. May be involved in 
translationally coupled mRNA turnover. Implicated with other RNA-binding proteins 
in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA 
mediated by the major coding-region determinant of instability (mCRD) domain. 
Cytoplasm. Nucleus. Shuttles between the cytoplasm and the nucleus. 
 RNA binding/Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism  
T28
(Q9BTC8) Metastasis-associated protein 
MTA3
58 2 68
Plays a role in maintenance of the normal epithelial architecture through the 
repression of SNAI1 transcription in a histone deacetylase-dependent manner, and 
thus the regulation of E-cadherin levels.Nucleus. Interact with histone deacetilase 2 
non directly
 Transcription regulator activity/ 
Regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism  
 (Q9UBU9) Nuclear RNA export factor 1 
(Tip-associating protein)
56 1 71
Involved in the nuclear export of mRNA species bearing retroviral constitutive 
transport elements (CTE) and in the export of mRNA from the nucleus to the 
cytoplasm. Nuclear; localized predominantly in the nucleoplasm and at both the 
nucleoplasmic and cytoplasmic faces of the nuclear pore complex. Shuttles between 
the nucleus and the cytoplasm.
 RNA binding/Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism 
gi|57165052 Thyroid autoantigen 70kDa 53 1 70
Single stranded DNA-dependent ATP-dependent helicase. Has a role in chromosome 
translocation. The DNA helicase II complex binds preferentially to fork-like ends of 
double-stranded DNA in a cell cycle-dependent manner. It works in the 3'-5' 
direction. Binding to DNA may be mediated by p70. Involved in DNA 
nonhomologous end joining (NHEJ) required for double-strand break repair and 
V(D)J recombination. The Ku p70/p86 dimer acts as regulatory subunit of the DNA-
dependent protein kinase complex DNA-PK by increasing the affinity of the catalytic 
subunit PRKDC to DNA by 100-fold. The Ku p70/p86 dimer is probably involved in 
stabilizing broken DNA ends and bringing them together. The assembly of the DNA-
PK complex to DNA ends is required for the NHEJ ligation step. Required for 
osteocalcin gene expression 
 DNA repair protein/Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism  
T27
 gi|15530265 Eukaryotic translation 
elongation factor 1 gamma
320 8 50
 Translation regulator activity/ 
Protein metabolism 
gi|34783356 RANGAP1 protein 99 2 64
GTPase activator for the nuclear Ras-related regulatory protein Ran, converting it to 
the putatively inactive GDP-bound state. 
 GTPase activator activity/ Signal 
transduction ; Cell communication  
gi|14250668 Cortactin, isoform b 106 3 58
 Cytoskeletal protein binding/Cell 
growth and/or maintenance  
gi|82546879 GTP binding protein 1 106 2 73
FUNCTION: Not known, the C-terminus can act as an allosteric activator of the 
cholera toxin catalytic subunit. 
 GTPase activity/ Signal 
transduction ; Cell communication  
 (Q14157) Ubiquitin-associated protein 2-
like
97 3 104 Unclassified  
 Unknown/Biological_process 
unknown 
 (P19447) TFIIH basal transcription 
factor complex helicase XPB subunit
97 2 90
ATP-dependent 3'-5' DNA helicase, component of the core-TFIIH basal transcription 
factor, involved in nucleotide excision repair (NER) of DNA and, when complexed 
to CAK, in RNA transcription by RNA polymerase II. Acts by opening DNA either 
around the RNA transcription start site or the DNA damage. 
  DNA repair protein/ Regulation 
of nucleobase, nucleoside, 
nucleotide and nucleic acid 
metabolism 
(Q9BSJ2) Gamma-tubulin complex 
component 2
69 1 104
 Gamma-tubulin complex is necessary for microtublule nucleation at the centrosome. 
Centrosome. 
 Cytoskeletal protein binding/ Cell 
growth and/or maintenance  
T30
 (Q12906) Interleukin enhancer-binding 
factor 3 (Nuclear factor of activated T-
cells 90 kDa)
64 1 96
 May facilitate double-stranded RNA-regulated gene expression at the level of post-
transcription. Can act as a translation inhibitory protein which binds to coding 
sequences of acid beta-glucosidase (GCase) and other mRNAs and functions at the 
initiation phase of GCase mRNA translation, probably by inhibiting its binding to 
polysomes. Can regulate protein arginine N-methyltransferase 1 activity. May 
regulate transcription of the IL2 gene during T-cell activation. Can promote the 
formation of stable DNA-dependent protein kinase holoenzyme complexes on DNA. 
Nucleus; nucleolus. 
  Transcription factor 
activity/Regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism  
(Q01826) DNA-binding protein SATB1 
(Special AT-rich sequence-binding 
protein 1)
60 1 86
 Binds to DNA at special AT-rich sequences at nuclear matrix- or scaffold-associated 
regions. Thought to recognize the sugar-phosphate structure of double-stranded 
DNA. Nucleus. 
 Transcription factor activity/ 
Regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism  
 (P33992) DNA replication licensing 
factor MCM5 (CDC46 homolog) (P1-
CDC46)
46 2 83
 DNA binding  /Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism  
gi|2494898 Periodic tryptophan protein 2 
homolog
68 2 103
Nucleus; nucleolus. PWP2 is essential for viability and may play a role in the early 
G1 phase of the cell cycle.( La prot. Possiede diversi domini WD40)
  Regulation of cell cycle/ Signal 
transduction ; Cell communication  
T31
(Q02779) Mitogen-activated protein 
kinase kinase kinase 10 
40 2 104 Activates the JUN N-terminal pathway 
Protein serine-threonine kinase 
activity/ Signal transduction ; Cell 
communication  
  (P43243) Matrin-3 160 6 95
May play a role in transcription or may interact with other nuclear matrix proteins to 
form the internal fibrogranular network. In association with the SFPQ-NONO 
heteromer may play a role in nuclear retention of defective RNAs. Nucleus; 
nucleoplasm; nuclear matrix. 
 RNA binding/Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism 
T32
(P11586) C-1-tetrahydrofolate synthase, 
cytoplasmic (C1-THF synthase)
110 2 102 Cytoplasm
Catalytic activity/ Metabolism; 
Energy pathways
(P55884) Eukaryotic translation initiation 
factor 3 subunit 9
62 2 93 Binds to the 40S ribosome and promotes the binding of methionyl-tRNAi and mRNA
 Translation regulator activity/ 
Protein metabolism 
(Q9H0D6) 5'-3' exoribonuclease 2 (EC 
3.1.11.-) (DHM1-like protein)
61 1 109
Possesses 5'->3' exoribonuclease activity and may be involved in homologous 
recombination and RNA metabolism, such as RNA synthesis and RNA trafficking 
.Nucleus; nucleolus. 
Ribonuclease activity/ Regulation 
of nucleobase, nucleoside, 
nucleotide and nucleic acid 
metabolism  
(Q99613) Eukaryotic translation initiation 
factor 3 subunit 8 (eIF3 p110)
57 1 106 Binds to the 40S ribosome and promotes the binding of methionyl-tRNAi and mRNA
 Translation regulator activity/ 
Protein metabolism 
 (Q9ULK4) CRSP complex subunit 3 
(Cofactor required for Sp1 transcriptional 
activation subunit 3)
102 2 158 Plays a role in transcriptional coactivation. 
 Transcription regulator activity/ 
Regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism  
T33
(P26640) Valyl-tRNA synthetase (EC 
6.1.1.9) (Valine--tRNA ligase)
88 2 142
 Translation regulator activity/ 
Protein metabolism 
 (Q92900) Regulator of nonsense 
transcripts 1 (EC 3.6.1.-) (ATP-dependent 
helicase RENT1)
70 2 126
Part of a post-splicing multiprotein complex. Involved in nonsense-mediated decay 
(NMD) of mRNAs containing premature stop codons. Essential for embryonic 
viability. 
  RNA binding/ Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism  
 (O00267) Transcription elongation factor 
SPT5 (hSPT5)
56 2 121
Component of the DRB sensitivity-inducing factor complex (DSIF complex), which 
regulates mRNA processing and transcription elongation by RNA polymerase II. 
DSIF positively regulates mRNA capping by stimulating the mRNA 
guanylyltransferase activity of RNGTT/CAP1A. DSIF also acts cooperatively with 
the negative elongation factor complex (NELF complex) to enhance transcriptional 
pausing at sites proximal to the promoter. NUCLEO
transcription
 (Q13435) Splicing factor 3B subunit 2 
(Spliceosome-associated protein 145)
56 1 98
Subunit of the splicing factor SF3B required for 'A' complex assembly formed by the 
stable binding of U2 snRNP to the branchpoint sequence (BPS) in pre-mRNA. 
Sequence independent binding of SF3A/SF3B complex upstream of the branch site is 
essential, it may anchor U2 snRNP to the pre-mRNA. May also be involved in the 
assembly of the 'E' complex. Belongs also to the minor U12-dependent spliceosome, 
which is involved in the splicing of rare class of nuclear pre-mRNA intron. Nucleus.
  RNA binding/ Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism  
 (O75533) Splicing factor 3B subunit 1 
(Spliceosome-associated protein 155
52 2 146
Subunit of the splicing factor SF3B required for 'A' complex assembly formed by the 
stable binding of U2 snRNP to the branchpoint sequence (BPS) in pre-mRNA. 
Sequence independent binding of SF3A/SF3B complex upstream of the branch site is 
essential, it may anchor U2 snRNP to the pre-mRNA. May also be involved in the 
assembly of the 'E' complex. Belongs also to the minor U12-dependent spliceosome, 
which is involved in the splicing of rare class of nuclear pre-mRNA intron.
  RNA binding/ Regulation of 
nucleobase, nucleoside, nucleotide 
and nucleic acid metabolism  
gi|89047296 similar to SMC hinge 
domain containing 1
136 3 221 Unknown
T34
gi|33946327 nucleoporin 214kDa [Homo 
sapiens]
54 3 214 integral to membrane.Interact with  con Nuclear RNA export factor 1 
porin activity/ protein import/ 
export
gi|71044479  death inducer-obliterator 1 
isoform c
358 12 245
Apoptosis, a major form of cell death, is an efficient mechanism for eliminating 
unwanted cells and is of central importance for development and homeostasis in 
metazoan animals. In mice, the death inducer-obliterator-1 gene is upregulated by 
apoptotic signals and encodes a cytoplasmic protein that translocates to the nucleus 
upon apoptotic signal activation. When overexpressed, the mouse protein induced 
apoptosis in cell lines growing in vitro. This gene is similar to the mouse gene and 
therefore is thought to be involved in apoptosis. Alternatively spliced transcripts have 
been found for this gene, encoding multiple isoforms.          
 Putative DNA binding protein/ 
Cell proliferation/ Apoptosis/ 
Regulation of nucleobase, 
nucleoside, nucleotide and nucleic 
acid metabolism  
T35
gi|13606056 DNA dependent protein 
kinase catalytic subunit [Homo sapiens]
106 4 470
Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. 
Involved in DNA nonhomologous end joining (NHEJ) required for double-strand 
break (DSB) repair and V(D)J recombination. Must be bound to DNA to express its 
catalytic properties. Promotes processing of hairpin DNA structures in V(D)J 
recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The 
assembly of the DNA-PK complex at DNA ends is also required for the NHEJ 
ligation step. Required to protect and align broken ends of DNA. May also act as a 
scaffold protein to aid the localization of DNA repair proteins to the site of damage. 
Found at the ends of chromosomes, suggesting a further role in the maintenance of 
telomeric stability and the prevention of chromosomal end fusion. Also involved in 
modulation of transcription. Recognizes the substrate consensus sequence [S/T-Q]. 
Phosphorylates Ser-139 of histone variant H2AX/H2AFX, thereby regulating DNA 
damage response mechanism.
protein kinase  activity/DNA 
REPAIR
UbcH10 overexpression may represent a marker of anaplastic
thyroid carcinomas
P Pallante1, MT Berlingieri1, G Troncone2, M Kruhoffer3, TF Orntoft3, G Viglietto1, A Caleo2, I Migliaccio2,
M Decaussin-Petrucci4, M Santoro1, L Palombini2 and A Fusco*,1,5
1Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facolta` di Medicina e
Chirurgia di Napoli, Universita` degli Studi di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy; 2Dipartimento di Anatomia Patologica e Citopatologia,
Facolta` di Medicina e Chirurgia di Napoli, Universita` di Napoli ‘Federico II’, via Pansini, 5, 80131 Naples, Italy; 3Department of Clinical Biochemistry,
Aarhus University Hospital, Skejby DK 8200 Aarhus N, Denmark; 4Service d’Anatomo-Pathologie, Centre Hospitalier Lyon Sud, Pierre Be´nite, France;
5NOGEC (Naples Oncogenomic Center)-CEINGE, Biotecnologie Avanzate, via Comunale Margherita, 80131 Naples, Italy
The hybridisation of an Affymetrix HG_U95Av2 oligonucleotide array with RNAs extracted from six human thyroid carcinoma cell
lines and a normal human thyroid primary cell culture led us to the identification of the UbcH10 gene that was upregulated by 150-
fold in all of the carcinoma cell lines in comparison to the primary culture cells of human normal thyroid origin. Immunohistochemical
studies performed on paraffin-embedded tissue sections showed abundant UbcH10 levels in thyroid anaplastic carcinoma samples,
whereas no detectable UbcH10 expression was observed in normal thyroid tissues, in adenomas and goiters. Papillary and follicular
carcinomas were only weakly positive. These results were further confirmed by RT–PCR and Western blot analyses. The block of
UbcH10 protein synthesis induced by RNA interference significantly reduced the growth rate of thyroid carcinoma cell lines. Taken
together, these results would indicate that UbcH10 overexpression is involved in thyroid cell proliferation, and may represent a
marker of thyroid anaplastic carcinomas.
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Tumours are the result of the accumulation of different modifica-
tions in critical genes involved in the control of cell proliferation.
In a large number of carcinomas with worst prognosis, lesions are
not diagnosed until the disease is at an advanced stage. Although
various therapeutic approaches are followed in clinical practice,
most of them are not life saving. Hence, the discovery of ways to
diagnose cancer at an early stage and to establish more effective
therapies is a critical and urgent issue. To achieve this goal,
identification and characterisation of key molecules that partici-
pate in carcinogenesis are essential steps. Thyroid neoplasms
represent a good model for studying the events involved in
epithelial cell multistep carcinogenesis, because they comprise a
broad spectrum of lesions with different degrees of malignancy
from benign adenomas, which are not invasive and very well
differentiated, to the undifferentiated anaplastic thyroid carcino-
mas, which are very aggressive and always fatal; papillary and
follicular carcinomas, the most common forms of thyroid cancer,
represent intermediate forms of neoplasia being differentiated and
having a good prognosis (Hedinger et al, 1989; Wynford-Thomas,
1997).
The involvement of several oncogenes has been demonstrated in
papillary thyroid carcinomas. Activation of the RET/PTC onco-
gene, caused by rearrangements of the RET protooncogene, is
detectable in about 30% of the cases (Grieco et al, 1990; Tallini
et al, 1998). Mutations of the B-RAF gene have been demonstrated
in almost 40% of papillary carcinomas (Fukushima et al, 2003).
TRK gene rearrangements (Pierotti et al, 1995) and MET gene
overexpression are often found in papillary carcinomas (Di Renzo
et al, 1992). RAS gene mutations (Suarez et al, 1990) and PAX8-
PPAR-g rearrangements (Kroll et al, 2000) are frequently detected
in tumours of the follicular type. Impairment of the p53 tumour
suppressor gene function represents a typical feature of the
anaplastic carcinomas (Ito et al, 1992; Dobashi et al, 1993; Donghi
et al, 1993; Fagin et al, 1993; Matias-Guiu et al, 1994). Even though
critical molecular mechanisms of thyroid carcinogenesis have been
clarified, other molecular steps of neoplastic progression need to
be investigated.
Therefore, to identify the genes regulated in the process of
thyroid carcinogenesis, we analysed a microarray with RNAs
extracted from normal human thyroid primary cell culture
(NTPC), and six human thyroid carcinoma cell lines of different
histotype (one from a follicular carcinoma, three derived from
papillary carcinomas and two from anaplastic carcinomas). Our
attention was focused on the UbcH10 gene that was upregulated
Received 2 March 2005; revised 16 June 2005; accepted 22 June 2005;
published online 2 August 2005
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about 150-fold in all of the cell lines tested by the cDNA
microarray. The UbcH10 gene belongs to the E2 gene family and
codes for a protein of 19.6 kDa that is involved in the ubiquitin-
dependent proteolysis. In this pathway, ubiquitin-conjugating
enzyme (E2), together with ubiquitin ligase (E3), transfers
ubiquitin to specific substrate proteins (Hershko and Ciechanover,
1998; Joazeiro and Weissman, 2000).
The expression level of UbcH10 was extremely low in the normal
thyroid primary culture cells, but strong in all the cancerous cell
lines. Immunohistochemical and RT–PCR analyses on a large
panel of thyroid neoplasms of different histotypes revealed an
increased UbcH10 expression in anaplastic thyroid carcinomas,
whereas follicular and papillary carcinomas were just weakly
positive. The block of UbcH10 protein synthesis by RNA
interference inhibited the growth of two thyroid carcinoma cell
lines.
MATERIALS AND METHODS
Cell culture and transfections
The human thyroid carcinoma cell lines used in this study are:
TPC-1 (Tanaka et al, 1987), WRO (Estour et al, 1989), NPA and
ARO (Pang et al, 1989), FRO (Fagin et al, 1993), NIM 1 (Zeki et al,
1993), B-CPAP (Fabien et al, 1994), FB-1 (Fiore et al, 1997), FB-2
(Basolo et al, 2002), Kat-4 and Kat-18 (Ain et al, 1997). They were
grown in DMEM (Gibco Laboratories, Carlsbad, CA, USA)
containing 10% fetal calf serum (Gibco Laboratories), glutamine
(Gibco Laboratories) and ampicillin/streptomycin (Gibco Labora-
tories) in a 5% CO2 atmosphere. Normal human thyroid primary
culture cells have been established and grown as already described
(Curcio et al, 1994). PC Cl 3 cell line derived from Fischer rat
thyroid (Fusco et al, 1987) was cultured in modified F12 medium
supplemented with 5% calf serum (Gibco Laboratories) and six
growth factors (thyrotropic hormone, hydrocortisone, insulin,
transferrin, somatostatin and glycyl-histidyl-lysine; Sigma, St
Louis, MO, USA). Thyroid cells were transfected using Lipofecta-
mine reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. The transfected cells were selected in
a medium containing geneticin (G418) (Life Technologies, Italy).
For each transfection, several G418-resistant clones and the mass
cell population were isolated and expanded for further analysis.
Human thyroid tissue samples
Neoplastic human thyroid tissues and normal adjacent tissue or
the controlateral normal thyroid lobe were obtained from surgical
specimens and immediately frozen in liquid nitrogen. Thyroid
tumours were collected at the Service d’Anatomo-Pathologie,
Centre Hospitalier Lyon Sud, Pierre Be´nite, France. The tumour
samples were stored frozen until RNA or protein extractions were
performed.
RNA isolation
Total RNA was extracted from tissues and cell cultures using the
RNAeasy mini kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s instructions. The integrity of the RNA was assessed
by denaturing agarose gel electrophoresis.
Reverse transcriptase – PCR analysis
In total, 5mg of total RNA from each sample, digested with DNAseI
(Invitrogen), were reverse transcribed using random hexanucleo-
tides and MuLV reverse transcriptase (Applied Biosystems, Foster
City, CA, USA). PCR was carried out on cDNA using the GeneAmp
PCR System 9600 (Applied Biosystems). RNA PCR Core Kit
(Applied Biosystems) was used to perform RT–PCR reactions.
For the UbcH10 gene, after a first denaturing step (941C for 3 min),
PCR amplification was performed for 25 cycles (941C for 30 s, 571C
for 30 s, 721C for 30 s). The sequences of forward and reverse
primers, amplifying a fragment of 115 bp in the UbcH10 cDNA,
were: forward 50-GCCCGTAAAGGAGCTGAG-30 and reverse 50-
GGGAAGGCAGAAATCCCT-30. The human b-actin gene primers,
amplifying a 109 bp cDNA fragment, were used as control;
amplification was performed for 25 cycles (941C for 30 s, 551C for
30 s, 721C for 30 s). b-Actin-forward, 50-TCGTGCGTGACATTAAG
GAG-30; b-actin-reverse, 50-GTCAGGCAGCTCGTAGCTCT-30. To
ensure that RNA samples were not contaminated with DNA,
negative controls were obtained by performing the PCR on samples
that were not reverse-transcribed, but otherwise identically
processed. The PCR products were separated on a 2% agarose gel,
stained with ethidium bromide and scanned using a Typhoon 9200
scanner. Quantitative PCR was performed in triplicate using iCycler
(Bio-Rad, Hercules, CA, USA) with SYBRs Green PCR Master Mix
(Applied Biosystems) as follows: 951C 10 min and 40 cycles (951C
15 s and 601C 1 min). Fold mRNA overexpression was calculated
according to the formula 2(RtEt)/2(RnEn) as described previously
(El-Rifai et al, 2001), where Rt is the threshold cycle number for the
reference gene in the tumour, Et for the experimental gene in the
tumor, Rn for the reference gene in the normal sample and En for
the experimental gene in the normal sample.
Protein extraction, Western blotting and antibodies
Cells were washed once in cold PBS and lysed in a lysis buffer
containing 50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
10% glycerol, 1% Triton-X-100, 1 mM phenylmethylsulphonyl
fluoride, 1 mg aprotinin, 0.5 mM sodium orthovanadate, 20 mM
sodium pyrophosphate. The lysates were clarified by centrifuga-
tion at 14 000 r.p.m. 10 min. Protein concentrations were esti-
mated by a Bio-Rad assay (Bio-Rad), and boiled in Laemmli buffer
(Tris-HCl pH 6.8, 0.125 M, SDS 4%, glycerol 20%, 2-mercaptoetha-
nol 10%, bromophenol blue 0.002%) for 5 min before electrophor-
esis. Proteins were subjected to SDS–PAGE (15% polyacrylamide)
under reducing condition. After electrophoresis, proteins were
transferred to nitrocellulose membranes (Immobilon-P Millipore
Corp., Bedford, MA, USA); complete transfer was assessed using
prestained protein standards (Bio-Rad). After blocking with TBS-
BSA (25 mM Tris, pH 7.4, 200 mM NaCl, 5% bovine serum
albumin), the membrane was incubated with the primary antibody
against UbcH10 (Boston Biochem Inc., Cambridge, MA, USA) for
60 min (at room temperature). Primary antibody against c-Fos
protein (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was
used to confirm the specificity of siRNAs against UbcH10 protein.
To ascertain that equal amounts of protein were loaded, the
Western blots were incubated with antibodies against the g-tubulin
protein (Sigma). Membranes were then incubated with the
horseradish peroxidase-conjugated secondary antibody (1 : 3000)
for 60 min (at room temperature) and the reaction was detected
with a Western blotting detection system (ECL; Amersham
Biosciences, UK).
Immunohistochemistry: tissue samples
UbcH10 protein cellular distribution was assessed by immunohis-
tochemical analysis and compared to that of the standard cell
proliferation marker Ki-67/MIB1. A series of surgical specimens
from patients with thyroid diseases comprised of Hashimoto’s
thyroiditis-HT (six cases), nodular goiter (12 cases), follicular
carcinoma (13 cases), papillary carcinoma (33 cases), poorly
differentiated carcinoma (five cases) and anaplastic carcinoma (15
cases) was chosen to represent a wide range of thyroid pathology.
As control, 10 areas of normal thyroid parenchyma were selected
from the lobe controlateral to the tumour in surgical specimens of
papillary carcinoma.
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Immunostaining: technique, evaluation and statistical
analysis
Xylene dewaxed and alcohol-rehydrated paraffin sections were
placed in Coplin jars filled with a 0.01 M tri-sodium citrate solution,
and heated for 3 min in a conventional pressure cooker (Troncone
et al, 2003). After heating, slides were thoroughly rinsed in cool
running water for 5 min. They were then washed in Tris-Buffered
Saline (TBS) pH 7.4 before incubating overnight with the specific
antibody, diluted as follows: rabbit polyclonal a-UbcH10 (Boston
Biochem) 1 : 1000; a-MIB-1 (Novocastra, Newcastle upon Tyne,
UK) 1 : 50. After incubation with the primary antibody, tissue
sections were stained with biotinylated anti-rabbit or anti-mouse
immunoglobulins, followed by peroxidase-labelled streptavidine
(Dako, Carpinteria, CA, USA); the signal was developed by using
diaminobenzidine (DAB) chromogen as substrate. Incubations
both omitting the specific antibody, and including unrelated
antibodies, were used as negative controls.
Individual cells were scored for expression of UbcH10 and Ki-67
in similar areas of adjacent sections by quantitative analysis
performed with a computerised analyser system (Ibas 2000,
Kontron, Zeiss), as already described (Troncone et al, 2003). In
each case, the distribution of these proteins was evaluated in at
least 500 epithelial follicular cells and expressed as a percentage of
the total cell population. The statistical analysis was performed
using SPSS ‘Ver. 9.0.1 for Windows’. Data are expressed as median
value and range. The nonparametric Mann–Whitney U-test was
used to compare differences in labelling indexes for UbcH10 and
Ki-67 in thyroid carcinomas. The Spearman rank order correlation
was used to verify the association between UbcH10 and Ki-67. A
P-value less than 0.05 was considered statistically significant.
RNA interference
For small interfering RNA (siRNA) experiments, the following
double-strand RNA oligo specific for UbcH10 coding region was
used: 50-AACCTGCAAGAAACCTACTCA-30 as previously de-
scribed (Wagner et al, 2004). As negative control, we used a
corresponding scrambled sequence as follows: 50-AACTAACAC
TAGCTCAAGACC-30. All of the siRNA duplexes were purchased
from Qiagen and were transfected using Oligofectamine (Invitro-
gen) according to the manufacturer’s recommendations. Small
interfering RNAs were used at a final concentration of 100 nM and
12 105 cells well1 were plated in a six-well format plates.
Proteins were extracted 48 h after siRNA treatment and the levels
of the UbcH10 protein were evaluated by Western blot.
Assay of the transformed state
Tumorigenicity of the cell lines was tested by injecting 2 106 cells
subcutaneously into athymic mice. Soft agar colony assay was
performed as previously described (Macpherson and Montagnier,
1964).
RESULTS
Expression of UbcH10 gene in normal human thyroid cells
and thyroid carcinoma cell lines
To search for candidate genes involved in the neoplastic
transformation of thyroid gland, RNAs extracted from normal
human thyroid primary cells and six human thyroid carcinoma
cell lines of different origin (WRO cell line from a follicular
carcinoma, TPC-1 and FB-2 cell lines, both deriving from papillary
thyroid cancers, NPA cell line, which derives from a poorly
differentiated papillary carcinoma, ARO and FRO cell lines
originating from anaplastic carcinomas) were hybridised to
U95Av2 Affymetrix oligonucleotide arrays (data not shown). We
concentrated our attention on the UbcH10 gene that was
upregulated about 150-fold in all of the cell lines tested by the
cDNA microarray. This result was confirmed by RT– PCR in a
larger panel of thyroid carcinoma cell lines using as control normal
thyroid primary culture (Figure 1A). Western blot analysis of
UbcH10 expression, shown in Figure 1B, confirmed the RT–PCR
data. In fact, the UbcH10 protein was abundantly expressed in all
of the carcinoma cell lines, whereas it was barely detectable in
normal thyroid cells.
Analysis of UbcH10 expression in normal and neoplastic
thyroid tissues by immunohistochemistry, Western blot
and RT– PCR
In order to evaluate whether the overexpression of UbcH10 is a
feature of the thyroid tumours and not only of cultured thyroid
carcinoma cell lines, we performed immunohistochemical analysis
using a commercial antibody against UbcH10 protein. This
methodology allows a rapid and sensitive screening of thyroid
pathological tissues and is amenable to regular use as a routine
diagnostic test. To find the best experimental conditions, ARO cell
line and tumours, induced by injecting the ARO cell line into
athymic mice, were used as positive controls (Cerutti et al, 1996).
No staining was observed with normal human thyroid primary cell
culture, whereas a positive staining was obtained with ARO cell
line and ARO-induced tumours (data not shown). We found that
normal thyroid, nodular goiter and Hashimoto’s thyroiditis (HT)
were almost always completely negative for UbcH10 expression.
Only occasionally, single UbcH10-labelled thyroid epithelial cells
showing mitotic figures could be observed by meticulous scrutiny
(Figure 2A). In HT, there was a sharp contrast between the
negative epithelial oxyphilic cells and the positive lymphoid
germinal centers (Figure 2B). While a weak staining is detectable
in follicular adenomas (Figure 2C), higher levels of UbcH10 were
recorded in papillary (median value 2.2% of positive cells; range
0.9–4.1%), follicular (median value 2.8% of positive cells; range 1–
6.1%) and poorly differentiated (median value 10.4% of positive
cells; range 8 –14.9%) carcinomas, signal being always easily
detectable in the nuclei of scattered neoplastic cells (Figure 2D, E
and F). UbcH10 staining pattern was somewhat different in
NT
PC
WR
O
N-
PA
P
TP
C-1
BC
-PA
P
NIM FR
O
AR
O
KA
T-4
KA
T-1
8
FB
-1
FB
-2
NT
PC
WR
O
N-
PA
P
TP
C-1
BC
-PA
P
NIM FR
O
AR
O
KA
T-4
KA
T-1
8
FB
-1
FB
-2
UbcH10
UbcH10
 -Actin
 -Tubulin
A
B
Figure 1 UbcH10 expression in human thyroid carcinoma cell lines. (A)
UbcH10 gene expression analysis by RT–PCR in human thyroid carcinoma
cell lines vs the normal human thyroid primary culture cells (NTPC). b-
Actin gene expression was evaluated as control to normalise the amount of
the used RNAs. (B) UbcH10 protein expression analysis by Western Blot
in human thyroid carcinoma cell lines. Blot against g-tubulin has been
performed as control for equal protein loading.
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anaplastic carcinomas, the percentage (median value 45.8% of
positive cells; range 38.8–56.2%) of stained cells being large and
the intensity of the neoplastic cells being strong (Figure 2G and H).
No staining was observed when the same anaplastic carcinoma
samples were stained with antibodies preincubated with UbcH10
recombinant protein (Figure 2I) or in the absence of the primary
antibodies (data not shown). Therefore, as a general rule, UbcH10
expression is negligible in non-neoplastic thyroid, noticeable in
well-differentiated carcinomas and conspicuous in less-differen-
tiated tumours (Figure 3A).
To determine the relationship between UbcH10 expression and
tissue proliferation, we correlated its expression in carcinomas
with the proliferation rate of thyrocytes, as measured by Ki-67
staining; this latter showed the same tissue distribution of UbcH10,
which was evident when adjacent (mirror) sections were stained.
By using the Spearman rank order correlation, we determined that
the association between UbcH10 and Ki-67 expression in thyroid
cancer was statistically significant. In fact, the value of the
Spearman R was 0.4 (Po0.001) (Figure 3B).
Western blot analysis, performed on 30 surgically removed
thyroid tumours, confirmed the immunohistochemical data. A
representative Western blot is shown in Figure 4A. A strong band
of 19.6 kDa corresponding to the UbcH10 protein was detected in
anaplastic thyroid carcinomas and a weak one in poorly
differentiated carcinomas, but not in papillary carcinomas and
normal thyroids. These data strongly indicate that the expression
of UbcH10 is more abundant in thyroid carcinomas characterised
by a highly malignant and aggressive phenotype. Equal amounts of
total proteins were used for each sample as demonstrated by the
same gel analysed with an antibody against g-tubulin.
UbcH10 expression was also evaluated by RT–PCR analysis on a
panel of matched tumour/normal tissues. This analysis confirmed
the protein data. In fact, as shown in Figure 4B, an amplified band
of 115 bp was clearly detected in the anaplastic and poorly
differentiated carcinoma samples, but not in the papillary ones and
in all the corresponding normal thyroid tissues. Finally, quanti-
tative RT– PCR analysis confirmed a great increase of UbcH10
expression in thyroid anaplastic samples, whereas a light increase
was observed in papillary carcinoma samples (Figure 4C).
UbcH10 expression in experimental models of thyroid
carcinogenesis
Thyroid neoplasias developing in transgenic animal lines expres-
sing TRK (Tg-TRK) (Russell et al, 2000), RET/PTC3 (Tg-RET/
PTC3) (Powell et al, 1998) and large T SV40 (Tg-SV40) (Ledent
et al, 1991) oncogenes under the transcriptional control of the
thyroglobulin promoter have been analysed for UbcH10 expres-
sion by Western blot analysis. Transgenic mice carrying TRK and
RET/PTC3 oncogenes develop thyroid papillary carcinomas
(Powell et al, 1998; Russell et al, 2000); thyroid anaplastic
carcinomas were, conversely, obtained in the Tg-SV40 mice
A B C
F
IH
ED
G
Figure 2 UbcH10 staining pattern in normal, inflammatory and neoplastic thyroid tissues. Follicular epithelial cells of normal thyroid (A) and oxyphilic cells
of Hashimoto’s thyroiditis (HT) (B) do not stain for UbcH10, with occasional mitotic figures (A, arrow) and lymphoid centroblasts of HT (B, arrow)
providing the appropriate internal positive control. In neoplastic thyroid, UbcH10 staining pattern is strongly related to tumour grade, being weak in follicular
adenoma (C), slightly more evident in well-differentiated papillary (D) and follicular (E) carcinomas, whereas stronger in poorly differentiated (F) and in
anaplastic (G) carcinomas. In the latter, most of neoplastic cells show a very intense labelling, with intense nuclear staining (H), whereas signal disappeared by
antigen incubation (I).
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(Ledent et al, 1991). As shown in Figure 5, elevated UbcH10
protein levels were observed in the thyroid anaplastic carcinomas
derived from large TSV40 transgenic mice. Conversely, UbcH10
protein was absent in normal mouse thyroid tissue and in the
papillary carcinomas originating from TRK and RET/PTC3 mice.
Therefore, the analysis of the experimental models of thyroid
carcinogenesis seems to confirm that the UbcH10 overexpression
is essentially restricted to the undifferentiated histotype.
Suppression of the UbcH10 synthesis inhibits thyroid
carcinoma cell growth
We asked whether UbcH10 overexpression had a role in the
process of thyroid carcinogenesis by evaluating the growth rate of
two thyroid carcinoma cell lines, in which UbcH10 protein was
suppressed by RNA interference. The NPA and TPC-1 cell lines
were treated with siRNA duplexes targeting to the UbcH10 mRNA.
After transfection, we observed an efficient knockdown of the
UbcH10 protein levels at 48 h after treatment (Figure 6A). The
analysis of cell growth of these cell lines in the presence or absence
of the UbcH10 siRNA duplexes revealed that the block of the
UbcH10 protein synthesis significantly inhibits thyroid carcinoma
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Figure 3 Statistical analysis of the immunohistochemical data. (A)
Protein expression of UbcH10 (% positive cells) progressively increases in
the several diagnostic categories from thyroid goiter to the thyroid
anaplastic carcinomas. The analysis has been carried out using the Kruskal–
Wallis test. HT, Hashimoto’s thyroiditis; PTC, papillary thyroid carcinoma;
FTC, follicular thyroid carcinoma; PDC, poorly differentiated thyroid
carcinoma; ATC, anaplastic thyroid carcinoma. (B) Protein expression of
UbcH10 (% positive cells) is correlated to that of Ki-67 (% positive cells) in
the several diagnostic categories. The analysis has been carried out
calculating the Spearman rank correlation coefficient.
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Figure 4 UbcH10 expression in human thyroid fresh tumour samples.
(A) Western blot analysis of UbcH10 protein expression in a panel of
thyroid neoplasias. The level of g-tubulin has been used as loading control.
NT, normal thyroid tissue; PTC1 and PTC2, papillary thyroid carcinomas
from two different patients; PDC1, poorly differentiated carcinoma; ATC1,
anaplastic thyroid carcinoma. (B) RT–PCR analysis of UbcH10 expression
in human thyroid tumour samples vs their normal thyroid counterparts. b-
Actin expression shows the same amount of RNAs used. NT, normal
thyroid tissue; PTC1 and PTC2, papillary thyroid carcinomas from two
different patients; PDC1, poorly differentiated carcinoma; ATC1 and ATC2,
anaplastic thyroid carcinomas from two different patients. (C) Quantitative
RT–PCR analysis was performed on human thyroid tumour samples of
different histotype. The Fold Change values indicate the relative change in
the expression levels between tumour samples and normal samples,
assuming that the value of each normal sample is equal to 1.
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Figure 5 UbcH10 expression in experimental mouse thyroid tumours.
Western blot analysis of experimental thyroid carcinomas developed in
transgenic mice expressing TRK, RET-PTC-3 and large T SV40 oncogenes.
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amount of protein level.
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cell growth. In fact, as shown in Figure 6B, a significant reduction
in cell growth rate was observed in NPA and TPC-1 cell lines
treated with UbcH10 siRNA in comparison to the untreated cells or
those treated with the control scrambled siRNA.
These results indicate a role of UbcH10 in neoplastic thyroid cell
proliferation.
UbcH10 overexpression is not sufficient to transform rat
thyroid cells
To further characterise the role of UbcH10 in thyroid carcinogen-
esis, we transfected normal rat thyroid cells with an expression
vector carrying the UbcH10 gene under the transcriptional control
of the cytomegalovirus promoter. The selected clones were shown
to express high UbcH10 protein levels (data not shown). We
evaluated the growth rate of the UbcH10-transfected PC Cl 3 cells
and the same cells transfected with a backbone vector: no
differences were observed. Equally, the neoplastic phenotype of
the UbcH10-transfected PC Cl 3 cells was evaluated by a soft agar
colony assay and by injection into athymic mice. As reported in
Table 1, the PC Cl 3 cells transfected with the UbcH10 expression
vector were not able to give rise to colonies in soft agar and induce
tumours in athymic mice. As a positive control, we used the PC Cl
3 cells transformed with the Myeloproliferative sarcoma virus (PC
MPSV): these cells have a very highly malignant phenotype (Fusco
et al, 1987).
These results indicate that UbcH10 overexpression is not able to
transform rat thyroid cells in vitro.
DISCUSSION
Thyroid neoplasms represent an excellent model for studying the
process of cell transformation since they include a broad spectrum
of histotypes showing different degree of malignancy (Hedinger
et al, 1989; Wynford-Thomas, 1997). From the Affymetrix
microarray analysis, we found the UbcH10 gene that appeared
greatly increased in all of the thyroid carcinoma cell lines. UbcH10
was previously identified as a human homologue of the cyclin-
selective E2 (E2-c), which is required for the destruction of mitotic
cyclins by the ubiquitination pathway. The UbcH10 gene belongs
to the E2 gene family and codes for a protein of 19.6 kDa that is
involved in the ubiquitin-dependent proteolysis. In this system,
three distinct enzymes cooperate to process target proteins for
degradation. More precisely, the ubiquitin-conjugating enzyme
(E2) transfers activated ubiquitin by ubiquitin-activating enzyme
(E1) to a lysine residue of the target proteins in cooperation with
the ubiquitin-ligase (E3). Polyubiquitinated proteins are then
recognised by the 26S proteasome and rapidly degraded (Hershko
and Ciechanover, 1998; Joazeiro and Weissman, 2000).
In our study, we have evaluated the expression of UbcH10 in
human thyroid neoplasias and in mouse experimental tumours. No
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Figure 6 The block of UbcH10 protein synthesis by RNA interference
inhibits the proliferation of thyroid carcinoma cells. (A) Inhibition of
UbcH10 protein expression by RNAi in NPA and TPC-1 cell lines
evaluated by Western blot analysis. At 48 h after siRNA transfection, total
cell lysates were prepared and normalised for protein concentration. The
expression of g-tubulin was used to control equal protein loading (30 mg).
In this figure, we also show the expression of a fast turning-over gene like c-
Fos to confirm the specific effect of siRNAs against UbcH10. (B) Growth
curves of NPA and TPC-1 cell lines after siUbcH10 treatment. NPA and
TPC-1 cells were transfected with siUbcH10 duplexes (siUbcH10) and the
relative number of viable cells was determined by MTT assay. Cells
transfected with a scrambled duplex (siScrambled) and untransfected cells
(Untransfected) were used as negative controls. Absorbance was read at
570 nm and the data are the mean of triplicates.
Table 1 Analysis of the neoplastic phenotype of the UbcH10-
transfected rat thyroid cell lines
Cell line
Doubling time
(h)
Colony-
forminga
efficiency (%)
Tumourb
incidence
PC CL 3 24 0 0/4
PC UbcH10 CL1 24 0 0/4
PC UbcH10 CL2 23 0 0/4
PC MPSV 18 70 4/4
aColony-forming efficiency was calculated by the formula (number of colonies
formed/number of plated cells) 100. bTumorigenicity was assayed by injecting
2 106 cells into athymic mice (4–6 weeks old).
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significant UbcH10 expression was observed in normal thyroids,
goiters and adenomas, whereas a great induction of UbcH10
expression was observed in anaplastic human thyroid carcinomas
and in experimental undifferentiated thyroid tumours. Just a weak
expression of UbcH10 was observed in follicular and papillary
human thyroid carcinomas. Therefore, these data strongly indicate
that UbcH10 overexpression could be associated with the thyroid
tumour progression since there is a good correlation with the late
stage of thyroid neoplastic transformation. The low UbcH10 levels
detected in the differentiated thyroid malignancies would appear
in contrast with the data showing an abundant UbcH10 expression
in the cell lines deriving from differentiated carcinomas. We retain
this discrepancy only apparent since thyroid carcinoma cell lines,
even deriving from differentiated tumours, cannot be completely
compared to surgically removed tumours. In fact, these cell lines
harbour p53 mutations that are rare in thyroid differentiated
neoplasias (Tanaka et al, 1987; Estour et al, 1989; Pang et al, 1989;
Ito et al, 1992; Dobashi et al, 1993; Donghi et al, 1993; Fagin et al,
1993; Zeki et al, 1993; Fabien et al, 1994; Matias-Guiu et al, 1994;
Ain et al, 1997; Fiore et al, 1997; Basolo et al, 2002) and they have a
high proliferation rate. However, this consideration does not
exclude the validity of the use of the thyroid carcinoma cell lines as
experimental model to draw new information that, however, need
to be subsequently validated on fresh tumours.
Our results also indicate a correlation between UbcH10 over-
expression and the proliferation status since there is a good
association with the proliferation marker Ki-67/MIB1.
An aim of our work was to evaluate the possible causal role of
UbcH10 overexpression in thyroid carcinogenesis. Indeed, the
block of protein synthesis significantly inhibited the growth of
several thyroid carcinoma cell lines, suggesting an important role
of UbcH10 in thyroid cell proliferation, and then in the
progression step of thyroid carcinogenesis.
Therefore, even though the mechanisms by which UbcH10
overproduction contributes to the neoplastic phenotype remains
unclear, we can assume that it leads to a deregulation of cell
growth. These results are quite consistent with previous published
data showing that UbcH10 was expressed at high levels in primary
tumours derived from the lung, stomach, uterus, and bladder as
compared with their corresponding normal tissues, suggesting that
UbcH10 is involved in tumorigenesis or cancer progression
(Okamoto et al, 2003; Wagner et al, 2004). It has also been shown
that UbcH10 is upregulated in NIH3T3 cell line transformed by
EWS/FLI1, but not in untransformed NIH3T3 cell clone expressing
EWS/FLI1 (Arvand et al, 1998). Moreover, it has been shown that
UbcH10 is required for override metaphase, likely degrading
growth suppressor, and for destruction of mitotic cyclins,
indicating a role of UbcH10 in cell cycle progression (Arvand
et al, 1998).
However, overexpression of UbcH10 in normal rat thyroid cells
did not affect cell growth neither induced a malignant phenotype,
indicating that UbcH10 overexpression is not sufficient for
malignant thyroid cell transformation. This result might appear
in contrast with those showing that NIH3T3 stable transfectants
overexpressing UbcH10 exhibited a malignant phenotype as
compared with parental NIH3T3 cells (Okamoto et al, 2003). This
discrepancy is, in our opinion, just apparent since we have to
consider that NIH 3T3 cells are preneoplastic cells, whereas PC Cl 3
cells are much more resistant to express the neoplastic phenotype,
since even the expression of several oncogenes (v-ras-Ki, v-ras-Ha,
etc.) are not able to lead these cells to the fully malignant
phenotype that is achieved only when there is a synergy of two
different oncogenes (Fusco et al, 1987). In conclusion, our data
propose the UbcH10 overexpression as a feature of the anaplastic
carcinoma histotype. The block of UbcH10 expression significantly
reduced the growth of thyroid carcinoma cell lines indicating an
involvement of UbcH10 in the increased proliferation of these
carcinoma cell lines. Therefore, these results open the perspective
of a therapy of the anaplastic thyroid carcinoma, one of the most
aggressive tumours in mankind, based on the suppression of the
UbcH10 synthesis and/or function.
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Abstract
Using gene expression profiling, we found that the CBX7 gene
was drastically down-regulated in six thyroid carcinoma cell
lines versus control cells. The aims of this study were to
determine whether CBX7 is related to the thyroid cancer
phenotype and to try to identify new tools for the diagnosis
and prognosis of thyroid cancer. We thus evaluated CBX7
expression in various snap-frozen and paraffin-embedded
thyroid carcinoma tissues of different degrees of malignancy
by quantitative reverse transcription-PCR and immunohisto-
chemistry, respectively. CBX7 expression progressively de-
creased with malignancy grade and neoplasia stage. Indeed, it
decreased in an increasing percentage of cases going from
benign adenomas to papillary (PTC), follicular, and anaplastic
(ATC) thyroid carcinomas. This finding coincides with results
obtained in rat and mouse models of thyroid carcinogenesis.
CBX7 loss of heterozygosity occurred in 36.8% of PTC and in
68.7% of ATC. Restoration of CBX7 expression in thyroid
cancer cells reduced growth rate, with a retention in the G1
phase of the cell cycle, suggesting that CBX7 can contribute to
the proliferation of the transformed thyroid cells. In conclu-
sion, loss of CBX7 expression correlates with a highly
malignant phenotype in thyroid cancer patients. [Cancer Res
2008;68(16):6770–8]
Introduction
Thyroid tumors originating from follicular cells are a good
model with which to investigate the events involved in carcino-
genesis because they differ in malignant potential from differen-
tiated to undifferentiated phenotypes (1, 2). Papillary thyroid
carcinoma (PTC), which is differentiated and has a good prognosis,
is the most frequent malignancy of the thyroid gland (2). The tall-
cell variant (TCV) of PTC has a worse prognosis than conventional
PTC (3). Poorly differentiated carcinomas (PDC) have a less
differentiated phenotype and a poor 5-year survival rate (2). Finally,
anaplastic carcinomas (ATC) are completely undifferentiated, very
aggressive, and always fatal (2). In PTC, activation of the RET/PTC
oncogene, caused by rearrangements of the RET proto-oncogene,
occurs in about 20% of cases (2), whereas the B-RAF gene is
mutated in about 40% of cases (4). These tumors have also been
associated with TRK gene rearrangements (5) and MET gene
overexpression (6). RAS gene mutations (7) and PAX8-PPAR-g
rearrangements (8) are frequent in follicular thyroid carcinomas
(FTC), whereas impaired function of the p53 tumor suppressor
gene is a feature of ATC (9). Although critical molecular
mechanisms of thyroid carcinogenesis have been clarified, other
molecular steps of thyroid neoplastic progression need to be
investigated.
Therefore, within the context of a microarray study, we found
that the CBX7 gene was down-regulated in thyroid carcinoma–
derived cell lines and in surgically removed tumors. CBX7 , which is
located on chromosome 22q13.1, encodes a novel Polycomb
protein (Pc) of 28.4 kDa and 251 amino acids that contains a
‘‘chromodomain’’ between amino acids 10 and 46. The chromodo-
main was originally defined as a 37-amino-acid region of homology
shared by heterochromatin protein 1 (HP1) and Pc proteins from
Drosophila melanogaster (10, 11). The CBX7 protein seems to be
involved in the control of normal cell growth (11, 12). Moreover,
mouse CBX7 associates with facultative heterochromatin and with
the inactive X chromosome, which indicates that CBX7 is involved
in the repression of gene transcription (13).
Thyroid cancer is the most prevalent endocrine neoplasia. About
20,000 new cases are diagnosed in the United States each year, and
>1,500 patients die of thyroid cancer annually. Given the poor
prognosis associated with the less differentiated histologic types,
namely TCV-PTC and Hurthle variants, and the undifferentiated
ATC, there is a need for molecular markers that can help to predict
prognosis, so that patients with a dismal prognosis can be offered a
different, perhaps, innovative therapy.
In an attempt to determine whether CBX7 is related to thyroid
cancer phenotype, and to find new tools for the diagnosis and
prognosis of thyroid cancer, we have evaluated its expression in a
large number of thyroid carcinoma tissues and in rat and mouse
models of thyroid carcinogenesis. This analysis revealed a
decreased CBX7 expression in an increasing percentage of cases
going through from benign adenomas (FTA) to PTC, FTC, and
ATC. Taken together, these results indicate a correlation of the
loss of CBX7 expression with a highly malignant phenotype in
thyroid cancer patients. Because restoration of CBX7 expression
in thyroid cancer cells reduced growth rate, a role of the loss of
CBX7 gene expression in thyroid carcinogenesis may be
envisaged.
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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Materials and Methods
Cell culture and transfections. We used the following human thyroid
carcinoma cell lines in this study: TPC-1, WRO, NPA, ARO, FRO, NIM 1, B-
CPAP, FB-1, FB-2, Kat-4, and Kat-18, which are described elsewhere (14).
They were grown in DMEM (Gibco Laboratories) containing 10% FCS
(Gibco Laboratories), glutamine (Gibco Laboratories), and ampicillin/
streptomycin (Gibco Laboratories) in a 5% CO2 atmosphere. Normal human
thyroid primary culture cells have been established and grown as already
described (15). PC Cl 3 (16) and FRTL-5 (17) cell lines were cultured in
modified F12 medium supplemented with 5% calf serum (Gibco
Laboratories) and six growth factors (thyrotropic hormone, hydrocortisone,
insulin, transferrin, somatostatin, and glycyl-histidyl-lysine; Sigma). PC CL 3
and FRTL-5 infected with several oncogenes PC KiMSV, PC HaMSV, PC v-
raf , PC MPSV (16), PC PyMLV (18), PC E1A, PC E1A+v-raf (19), PC RET/
PTC, PC HaMSV+RET/PTC1 (20), PC MPSV-HMGA2 (21), FRTL-5 KiMSV
(22), and FRTL-5 KiMSV-HMGA1 (23) cells were cultured in the same
medium as PC CL 3 and FRTL-5 cells but without the six growth factors.
Thyroid cells were transfected using Lipofectamine reagent (Invitrogen)
according to the manufacturer’s instructions. The transfected cells were
selected in a medium containing geneticin (G418; Life Technologies). For
each transfection, several G418-resistant clones and the mass cell
population were isolated and expanded for further analysis.
Human thyroid tissue samples. Neoplastic human thyroid tissues and
normal adjacent tissue or the contralateral normal thyroid lobe were
obtained from surgical specimens and immediately frozen in liquid
nitrogen. Thyroid tumors were collected at the Service d’Anatomo-
Pathologie, Centre Hospitalier Lyon Sud, Pierre Be´nite, France. The tumor
samples were stored frozen until required for RNA or protein extraction.
This study has been approved by the institutional review board of the
Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita` degli
Studi di Napoli ‘‘Federico II’’.
RNA isolation. Total RNA was extracted from tissues and cell cultures
using the RNAeasy Mini Kit (Qiagen) according to the manufacturer’s
instructions. The integrity of the RNA was assessed by denaturing agarose
gel electrophoresis.
Reverse transcription and PCR analysis. One microgram of total RNA
from each sample was reverse-transcribed with QuantiTect Reverse
Transcription Kit (Qiagen) using an optimized blend of oligo-dT and
random primers according to the manufacturer’s instructions. PCR was
carried out on cDNA as previously described (14). Primer sequences are
available as Supplementary Materials and Methods. To design a quantitative
reverse transcription-PCR (qRT-PCR) assay, we used the Human ProbeLi-
brary system (Exiqon). Detailed procedure and primer sequences, as well as
qRT-PCR experiments, are available as Supplementary Materials and
Methods.
Protein extraction, Western blotting, and antibodies. Protein
extraction and Western blotting procedure were carried out as reported
elsewhere (14). Membranes were incubated with a primary antibody raised
against the COOH terminus of the human CBX7 protein (Neosystem) for
60 min (at room temperature). To ascertain that equal amounts of protein
were loaded, the Western blots were incubated with antibodies against the
a-tubulin protein (Sigma). Membranes were then incubated with the
horseradish peroxidase–conjugated secondary antibody (1:3,000) for 60 min
(at room temperature) and the reaction was detected with a Western
blotting detection system (enhanced chemiluminescence; GE Healthcare).
Histologic analyses. The cell distribution of the CBX7 protein was
assessed by immunostaining formalin-fixed, paraffin-embedded thyroid
tumor blocks retrieved from the files of the Dipartimento di Scienze
Biomorfologiche e Funzionali at the Universita` di Napoli ‘‘Federico II’’ and
selected to represent a wide range of thyroid neoplastic diseases. Briefly,
xylene-dewaxed and alcohol-rehydrated paraffin sections were placed in
Coplin jars filled with a 0.01 mol/L trisodium citrate solution and heated for
3 min in a conventional pressure cooker (14). After heating, slides were
thoroughly rinsed in cool running water for 5 min. They were washed in
TBS (pH 7.4) and then incubated overnight with the specific rabbit
polyclonal primary antibody. Subsequently, tissue sections were stained
with biotinylated anti-rabbit immunoglobulins and then with peroxidase-
labeled streptavidin (Dako). The signal was developed by using diamino-
benzidine chromogen as substrate. Incubations both omitting and
preadsorbing the specific antibody were used as negative controls.
To ensure that we evaluated CBX7 expression only on technically
adequate slides, we discarded slides that lacked a convincing internal
control, namely labeling of stromal, endothelial, or lymphoid cell, shown to
be positive in a preliminary normal tissue microarray analysis (data not
shown). Based on these criteria, we scored paraffin-embedded stained slides
from 20 cases of FTA, 30 cases of classic PTC, 6 cases of TCV PTC, 32 cases
of FTC, 12 cases of PDC, and 12 cases of ATC. As controls, we selected areas
of normal thyroid parenchyma from the lobe contralateral to the tumor in
20 surgical specimens of PTC. Individual cells were scored for the
expression of CBX7 by quantitative analysis performed with a computerized
analyzer system (Ibas 2000, Kontron, Zeiss), as described previously (14),
and tumors were subdivided into low expressors (<50% of positive cells) and
high expressors (>50% of positive cells).
Thyroid fine-needle aspiration biopsies. The fine-needle aspiration
biopsies (FNAB) were carried out at the Cytopathology Section of the
Dipartimento di Scienze Biomorfologiche e Funzionali (Universita` di Napoli
‘‘Federico II’’) as described elsewhere (24, 25). To evaluate whether CBX7
gene expression analysis is also feasible on cytologic samples, we selected
cell-block specimens obtained from 15 FNAB diagnosed as PTC and
histologically confirmed. Five-micrometer paraffin-embedded sections were
cut from each cell block and were examined for the presence of neoplastic
cells by H&E staining, before CBX7 immunocytochemistry and qRT-PCR
had been carried out. Nonneoplastic cytologic specimens, used as controls,
were obtained from the cell block corresponding to FNAB taken from goiter
nodules. FNAB samples were processed for RNA extraction using the
procedure described in a previous section.
Loss of heterozygosity analysis. We used several single nucleotide
polymorphism (SNP) markers to evaluate the loss of heterozygosity (LOH)
at the CBX7 locus on chromosome 22q13.1. We selected the SNP markers4
that showed high average heterozygosity levels to obtain the highest
number of informative cases. Briefly, genomic DNA was PCR amplified in a
region spanning about 200 bp around the SNP analyzed, then the purified
PCR product was sequenced. We measured the height of the two peaks on
the chromatogram and calculated the ratio of the two alleles in the matched
tumor/normal samples: LOH was defined if the ratio in the carcinoma
sample was <50%. SNPs and relative primer sequences are available as
Supplementary Materials and Methods.
Plasmid constructs and cell colony-forming assay. CBX7 expression
plasmid was constructed by cloning the human cDNA sequence in a pCRII
TA Cloning vector (Invitrogen). The primers used were as follows: CBX7
forward 5¶-ATGGAGCTGTCAGCCATC-3¶ and CBX7 reverse 5¶-TCA-
GAACTTCCCACTGCG-3¶. The inserted cDNA was then subcloned into
the BamHI/XhoI sites of the mammalian expression vector pcDNA 3.1
(Invitrogen). The expression of CBX7 was assessed by Western blotting.
Cells, plated at a density of 90% in 100-mm dishes, were transfected with
5 Ag pcDNA3.1 or pCBX7 and supplemented with geneticin (G418) 24 h later.
Two weeks after the onset of drug selection, the cells were fixed and stained
with crystal violet (0.1% crystal violet in 20% methanol).
Cell cycle analysis. Cells were harvested in PBS containing 2 mmol/L
EDTA, washed once with PBS, and treated for 30 min in cold ethanol (70%).
Cells were washed once in PBS and permeabilized with 0.2% Tween 20 and
1 mg/mL RNase A for 30 min, and washed and stained with 50 Ag/mL
propidium iodide. Stained cells were analyzed with a FACSCalibur (Becton
Dickinson), and the data were analyzed using a Mod-Fit cell cycle analysis
program.
Preparation of recombinant adenovirus and infection protocol. The
recombinant adenovirus was constructed using the AdEasy Vector System
(Quantum Biotechnologies). The cDNA fragment was inserted in the sense
orientation into the NotI and HindIII sites of the pShuttle-CMV vector to
4 http://www.ncbi.nih.gov/SNP/
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generate the recombinant pShuttle-CBX7-CMV construct. It was linearized
and cotransformed through electroporation with pAdEasy-1, which carries
the adenovirus genome, in BJ5183 electrocompetent cells. After homologous
recombination, a recombinant AdEasy-CMV-CBX7 plasmid was generated
(Ad-CBX7), which was then extracted and linearized. QBI-293A cells were
transfected with different clones to produce different viral particles, and the
infectivity of each clone was tested. Viral stocks were expanded in QBI-293A
cells, which were harvested 36 to 40 h after infection and lysed. The virus
titer of the 293 cells was determined. The adenovirus AdCMV-GFP
(Quantum Biotechnologies) was used as control. Cells (5  104) were
Figure 1. CBX7 expression in human thyroid carcinoma cell lines and neoplastic thyroid tissues. A, CBX7 gene expression by microarray analysis in human thyroid
carcinoma cell lines versus human normal thyroid primary culture cells (NTPC ). The average difference (Avg. Diff ) is a quantitative relative indicator of a transcript
expression level [f(PM-MM) / pairs on average]. B, CBX7 gene expression analysis by RT-PCR in human thyroid carcinoma cell lines versus normal thyroid
primary culture cells. b-Actin gene expression served as loading control. C, normal and neoplastic thyroid tissues analyzed for CBX7 protein expression by
immunohistochemistry. D, CBX7 nuclear staining was intense in benign follicular epithelial cells of normal thyroid (1) and follicular adenoma (2 ), whereas it was
weaker in malignant lesions (3), where normal thyroid and papillary carcinoma are adjacent. The decrease of CBX7 in neoplastic lesions was progressive going from
well-differentiated cancer, such as minimally invasive follicular carcinoma (4) and ‘‘classic variant’’ papillary carcinomas (PTC; 5) to the ‘‘tall cell variant’’ of PTC (6),
whose nuclei are magnified to better show lack of signal, to poorly differentiated (7) and anaplastic (8) carcinomas. The signal disappeared after incubation of the
sample with antigen (9). Arrows with letters indicate the following sample features: P!, nuclei showing cytologic features of PTC negative for CBX7 expression;
N!, normal thyroid adjacent to papillary cancer; L!, lymphocyte showing CBX7 expression and providing positive internal control.
Cancer Research
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seeded in a six-well plate. After 24 h, cells were infected at a multiplicity of
infection (MOI) of 100 with Ad-CBX7 or Ad-GFP for 90 min using 500 AL of
infection medium (DMEM supplemented with 2% fetal bovine serum) at
37jC in a 5% CO2 incubator. Pilot experiments with Ad-GFP were carried
out to determine the optimal MOI for each cell line. At MOI 100, the cell
lines became GFP positive without manifesting toxicity. Infected cells were
harvested and counted daily in a hematocytometric chamber.
Results
CBX7 gene expression is down-regulated in human thyroid
carcinoma cell lines. To look for genes potentially involved in the
neoplastic transformation of the thyroid gland, we extracted RNAs
from normal human thyroid primary cells and six human thyroid
carcinoma cell lines (WRO cell line from FTC, TPC-1 and FB-2 cell
lines from PTC, NPA cell line from a poorly differentiated PTC, and
ARO and FRO cell lines from ATC) and hybridized them to U95Av2
Affymetrix oligonucleotide arrays (Affymetrix) containing 12,625
transcripts (14). We looked for genes whose expression was
drastically (at least 10-fold) up- or down-regulated in all the six
thyroid carcinoma cell lines versus normal thyroid primary cell
culture, on the assumption that genes whose expression was
altered in all carcinoma cell lines could be involved in thyroid cell
transformation. Thus, genes that were decreased in all the
carcinoma cell lines were considered candidate tumor suppressor
Figure 2. CBX7 expression in fresh thyroid tumor
samples from patients. A, RT-PCR analysis of CBX7
expression in human thyroid tumor samples versus their
normal thyroid counterparts. h-Actin expression served
as loading control. NT, normal thyroid tissue; PTC1 to
PTC6, papillary thyroid carcinomas from different
patients; ATC1 to ATC5, anaplastic thyroid carcinomas
from different patients. B, qRT-PCR analysis of human
thyroid tumor samples of different histotypes. The fold
change indicates the relative change in expression levels
between tumor samples and normal samples, assuming
that the value of each normal sample is equal to 1. C,
qRT-PCR and immunocytochemical analyses of FNAB,
whose PTC preoperative cytologic diagnosis was
histologically proven. FNAB goiter samples were used as
controls. The fold change indicates the relative change in
expression levels between tumor and goiter samples,
assuming that the value of the goiter sample was equal
to 1. NG, nodular goiter.
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genes. Among these genes, we decided to concentrate our studies
on CBX7. The reasons of this choice were that CBX7 was one of the
genes with the highest down-regulation in all the carcinoma cell
lines, according to the data of the cDNA microarray analysis
(Fig. 1A), and that previous studies suggested its involvement in the
repression of gene transcription (13), and then, a possible tumor
suppressor function. This result was confirmed by RT-PCR analysis
in a large panel of thyroid carcinoma cell lines with normal thyroid
primary culture cells as control (Fig. 1B).
The loss of CBX7 expression correlates with a more
aggressive phenotype of thyroid carcinomas. Because thyroid
carcinoma cell lines have a relative validity (26), we decided to
carry out an immunohistochemical analysis of paraffin-embedded
tissues using polyclonal antibodies raised against the carboxyl-
terminal region of the human CBX7 protein. As shown in
Fig. 1C , all 20 samples of normal thyroid parenchyma expressed
CBX7 at a high level, which coincides with the strong CBX7
staining in all follicles (Fig. 1D, subpanel 1). The intensity of
nuclear labeling of epithelial thyroid cells in FTA (Fig. 1D,
subpanel 2) and in goiters (not shown) was similar to that of
normal thyroids and of the internal control represented by
lymphoid cells. Conversely, CBX7 expression was reduced in
malignant lesions, as it was evident when neoplastic and normal
tissue areas were adjacent (Fig. 1D, subpanel 3). The percentage
of low expressors was high in well-differentiated tumors, namely
FTC (66%, 21 of 32 samples; Fig. 1C and D, subpanel 4) and PTC
(57%, 17 of 30 samples; Fig. 1C and D, subpanel 5). It was even
higher in the less differentiated tumors, namely PDC (83%, 10 of
12 samples; Fig. 1C and D, subpanel 7) and TCV PTC (83%, 5 of
6 samples; Fig. 1C and D, subpanel 6). In the latter, neoplastic
cells were almost devoid of CBX7 expression, which sharply
contrasted with the intense staining of the infiltrating lympho-
cytes and stromal cells. Similarly, CBX7 expression was
completely lost in the neoplastic cells in all cases of ATC
(100%, 12 of 12; Fig. 1C and D, subpanel 8). No staining was
observed when normal thyroid gland samples were stained with
antibodies preincubated with the peptide against which the
antibodies were raised (Fig. 1D, subpanel 9) or in the absence of
the primary antibodies (data not shown). Therefore, CBX7 was
expressed in normal thyroid and in benign neoplastic lesions,
decreased in well-differentiated carcinomas, and drastically
reduced in aggressive thyroid tumors.
Analysis of CBX7 expression in normal and neoplastic
thyroid tissues by RT-PCR and quantitative real-time PCR.
We also evaluated CBX7 expression by RT-PCR in a panel of
matched normal/tumor tissues. The results confirmed the
immunohistochemical data. In fact, there was an amplified band
corresponding to CBX7 in normal thyroid tissues (Fig. 2A). The
amplified band decreased in PTC samples (Fig. 2A, top) and
almost disappeared in ATC (Fig. 2A, bottom). Quantitative qRT-
PCR analysis of a large number of human thyroid carcinoma
samples of different histotypes confirmed a correlation between
the reduction of CBX7 expression and a more malignant
phenotype of thyroid neoplasias. In fact, as reported in Fig. 2B ,
there was a negative fold change in CBX7 expression from 2.1 to
13 (average 4.8) in the PTC samples versus the normal
counterpart tissues. The reduction was even more pronounced in
the ATC samples, with a fold change ranging from 10.8 to 24.5
(average 14.6). These data are well correlated with the
immunohistochemical data and suggest that CBX7 expression is
controlled at the transcriptional level.
Analysis of human thyroid FNAB. FNAB has become an integral
part of the preoperative evaluation of thyroid nodules. To evaluate
whether CBX7 gene expression analysis is also feasible preopera-
tively, immunocytochemistry and qRT-PCR were carried out on cell
block specimens obtained from 15 FNAB diagnosed as PTC and
histologically confirmed. In 8 cases of 15, CBX7 expression was
lower in PTC cell blocks than in specimen from thyroid goiter as
evaluated by immunocytochemistry and qRT-PCR (Fig. 2C). This
percentage was quite similar to that obtained by analyzing paraffin-
embedded tissues diagnosed as PTC by immunohistochemistry.
LOH at CBX7 locus. In some types of cancers, LOH of tumor
suppressor genes at region 22q is believed to be a key step in
carcinogenesis (27, 28). We therefore used several SNP markers to
evaluate LOH at the CBX7 locus on chromosome 22q13.1 in 77
cases of thyroid carcinomas of different histotypes. As shown in
Table 1, LOH at the CBX7 locus occurred in 36.8% of the
informative PTC (7 of 19 cases) and in 68.7% (11 of 16 cases) of
informative ATC. No LOH was observed in FTA (0 of 6 cases).
CBX7 expression in rat thyroid cells transformed by viral
oncogenes and in experimental mouse models of thyroid
carcinogenesis. The infection of two rat thyroid differentiated cell
lines, PC Cl 3 and FRTL-5, with several murine retroviruses, induces
different effects on the differentiated and transformed phenotype
(16–23). PC MPSV cells are dedifferentiated and tumorigenic,
whereas PC v-raf , PC KiMSV, and PC E1A cells are dedifferentiated
but not tumorigenic when injected into nude mice. PC E1A cells
are transformed to an irrefutable neoplastic phenotype after
introducing a second oncogene such as the polyoma middle-T
antigen or v-raf genes. Conversely, FRTL-5 cells become tumori-
genic after infection with the Kirsten murine sarcoma virus
carrying the v-ras-Ki oncogene. We evaluated the CBX7 expression
in these cell lines. As shown Fig. 3A , the gene was abundantly
expressed in normal thyroid cells and in all cells that did not show
the malignant phenotype, whereas its expression was abolished in
the malignantly transformed cells FRTL-5 KiMSV and PC MPSV,
and in PC E1A v-raf oncogene. This result was also confirmed by
Western blot analysis on representative cell lines (Supplementary
Fig. S2). Interestingly, CBX7 expression was retained in FRTL-5
KiMSV-HMGA1 and in PC MPSV-HMGA2, cells previously trans-
fected with a vector carrying the HMGA1 and HMGA2 genes,
respectively, in an antisense orientation, able to prevent the
malignant transformation of FRTL-5 and PC Cl 3 cells (21, 23), and
then with the relative oncogene. In fact, although these cells
Table 1. LOH frequency statistics at the CBX7 locus
(22q13.1) by SNP sequencing method
Histotype Cases (Inf)* LOH
c
Follicular adenoma 10 (6) 0% (0/6)
Follicular carcinoma 5 (3) 66.6% (2/3)
Papillary carcinoma—classic variant 36 (19) 36.8% (7/19)
Papillary carcinoma—tall cell variant 6 (4) 75% (3/4)
Anaplastic carcinoma 20 (16) 68.7% (11/16)
*Informative cases (Inf) are samples showing SNP heterozygosity
corresponding to two peaks (two alleles) on the sequencing
chromatogram.
cThe LOH frequency is equal to the ratio between allelic loss and
informative cases.
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undergo morphologic changes and lose the thyroid differentiation
markers, they are unable to grow in soft agar and to induce tumors
after injection into athymic mice (21, 23). Therefore, the analysis of
rat thyroid cells transformed in vitro also confirms that the loss of
CBX7 expression is associated with the expression of a highly
malignant phenotype.
In addition, we used qRT-PCR analysis to evaluate CBX7
expression in thyroid neoplasias developing in transgenic animal
lines expressing some oncogenes under the transcriptional control
of the thyroglobulin promoter. Transgenic mice carrying TRK and
RET/PTC3 oncogenes develop PTC (29, 30), whereas N-ras mice
develop thyroid follicular neoplasms that undergo dedifferentia-
tion, predominantly FTC (31). ATCs were obtained from mice
carrying SV40 large T antigen (32). As shown in Fig. 3B , CBX7
expression was much lower in ATC from large T SV40 transgenic
mice compared with mouse normal thyroid tissue. CBX7 mRNA
expression was significantly, albeit not greatly, reduced in PTC
from TRK and RET/PTC3 mice. CBX7 expression was also reduced
in the FTC from N-ras mice.
Restoration of CBX7 gene expression inhibits the growth of
thyroid carcinoma cell lines. To determine whether the loss of
CBX7 gene expression affects thyroid carcinogenesis, we evaluated
the growth rate of three thyroid carcinoma cell lines in which CBX7
expression had been restored. To this aim, we carried out a colony-
forming assay with three human thyroid carcinoma cell lines (ARO,
NPA, TPC-1) after transfection with the vector carrying the CBX7
gene or the backbone vector. As shown in Fig. 4A , cells transfected
with the CBX7 gene generated a lower number of colonies than
cells transfected with the backbone vector did.
Moreover, we have analyzed the growth potential of CBX7
stably expressing ARO cells by a 2,3-bis[2-methoxy-4-nitro-5-
sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT) as-
say at different times after plating. As shown in Fig. 4B , the ARO
cells expressing the CBX7 gene grew at a significantly slower rate
Figure 3. CBX7 expression in experimental models of
thyroid carcinogenesis. A, CBX7 expression by RT-PCR in
rat thyroid cells transformed by several oncogenes.
GAPDH gene expression was evaluated as control to
normalize the amount of the used RNAs. B, CBX7
expression by qRT-PCR in thyroid carcinomas developing
in transgenic mice expressing RET-PTC-3, TRK, N-ras,
and large T SV40 oncogenes. The fold change indicates
the relative change in expression levels between tumor
samples and normal samples, assuming that the value of
normal sample is equal to 1.
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compared with the untransfected and backbone vector-transfected
ARO cells.
We then investigated the cell cycle phase distribution of these
CBX7 stably transfected ARO cells through flow cytometric
analysis. As shown in Fig. 4C , ARO cells expressing CBX7 had a
significant increase in the G1-phase population (ARO CBX7-1, 66%;
ARO CBX7-8, 64%), compared with empty vector–transfected cells
(ARO HA-3, 49%; ARO HA-4, 51%) and parental cells (ARO, 48%).
Therefore, these results suggest that CBX7 negatively regulates
thyroid carcinoma cell proliferation.
Generation of an adenovirus carrying the CBX7 gene. We
generated a replication-defective adenovirus carrying the CBX7
gene in the sense (Ad-CBX7) orientation. We then infected thyroid
carcinoma cell lines with the Ad-CBX7 virus and measured protein
levels in cell lysates collected at different time points after
adenovirus infection. No CBX7 protein was detected in carcinoma
cells infected with the control virus (Ad-GFP). We then constructed
growth curves of cells infected with Ad-CBX7 and control
adenovirus (Ad-GFP). As shown in Fig. 4D , cell growth rate was
significantly lower in ARO and NPA cell lines infected with Ad-
CBX7 than in the same cells infected with the control virus. The
percentage of growth inhibition 5 days after infection was 38.5% in
ARO cells and 54% in NPA cells.
Expression of CDKN2A/p16 in human thyroid tumor
samples. It has been reported that a target of CBX7 would be
the CDKN2A/p16 tumor suppressor gene (11, 12, 33), suggesting
that overexpression of CBX7 could enable cells to evade oncogene-
induced senescence; we then evaluated CDKN2A/p16 expression in
Figure 4. Effect of CBX7 restoration on thyroid carcinoma cell lines. A, colony-forming assay with CBX7 transfection in several thyroid carcinoma cell lines (ARO, NPA,
and TPC-1). B, growth curve of ARO cells and ARO cells stably carrying a vector expressing CBX7 (ARO CBX7-1 and ARO CBX7-8) or the backbone vector (ARO
HA-3 and ARO HA-4). The relative number of viable cells was determined by the XTTassay. Absorbance was read at 450 nm and the data are the mean of triplicates.
C, CBX7 expression affects the cell cycle distribution of ARO cells as assessed by flow cytometric analysis. The expression of the CBX7 protein in ARO CBX7-1 and
ARO CBX7-8 was confirmed by Western blot. D, top, inhibitory effects of Ad-CBX7 infection on the growth of human thyroid carcinoma cell lines. Representative
curves of three independent experiments are reported. Bottom, CBX7 expression by Western blot analysis. Blot against a-tubulin is to show an equal protein loading.
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a panel of thyroid tumors. Consistent with already published
results (34, 35), we show that CDKN2A/p16 is moderately
overexpressed in PTCs and highly overexpressed in ATCs
compared with normal thyroid tissues (Fig. 5). These results seem
to confirm that CDKN2A/p16 is negatively regulated by CBX7.
However, they also suggest that CDKN2A/p16 is not effective in
thyroid carcinoma cells because ATCs are fast-growing highly
malignant tumors (2). Because recent evidence shows that
senescence acts as a barrier to tumorigenesis in response to
oncogene activation (36), it is reasonable to retain that this result
may represent an effect of the activated oncogenes. However,
further studies are required to elucidate this paradoxical result.
Therefore, other molecular mechanisms must be envisaged to
explain the negative role exerted by CBX7 restoration in thyroid
carcinoma cells.
Discussion
Microarray studies are widely used to define diagnostic and
prognostic signatures in cancers and they have led to the
identification of a large list of carcinoma-regulated genes also in
thyroid cancers (37). Just within the context of a microarray study,
we found that the CBX7 gene was drastically down-regulated in all
the thyroid carcinoma–derived cell lines analyzed.
The results of this study show that CBX7 expression decreased
with malignancy grade and neoplasia stage. In fact, CBX7
expression was comparable with normal thyroid tissue in FTA,
which is benign; slightly reduced in PTC displaying the classic
histotype; and drastically reduced, and in most cases absent, in
FTC, TCV PTC, PDC, and ATC. Our finding of a decrease in CBX7
levels in relation to malignancy was supported by our model of rat
thyroid cells transformed by several oncogenes and in transgenic
mice carrying thyroglobulin promoter-driven oncogenes. CBX7
expression was absent in rat thyroid cells that show a highly
malignant phenotype and in ATC that develop in large T SV40
transgenic mice. Differently, CBX7 expression was retained, albeit
at a low level, in transformed rat thyroid cells that are not yet
tumorigenic and in PTC developing in RET/PTC and TRK mice.
Therefore, our data indicate that loss of CBX7 expression correlates
with a more aggressive phenotype of thyroid carcinomas and,
likely, with a worse prognosis. Interestingly, a recent article
concerning the cytogenetics of Chernobyl thyroid tumors identified
a correlation between the deletion of the chromosomal region
22q13.1, where the CBX7 gene is located, and a worse prognosis
(38). Our preliminary finding shows a correlation between low
CBX7 expression and reduced survival in colon carcinoma.5
Moreover, the association between lack of CBX7 expression and a
more aggressive histotype seems to apply also to breast, ovary, and
lung carcinomas.6
To determine whether CBX7 may contribute to thyroid
carcinogenesis, we restored the CBX7 function in human thyroid
cancer cell lines and examined cell growth rate. Restoration of
CBX7 expression reduced cell growth rate, indicating that the loss
of CBX7 expression may play a role in thyroid carcinogenesis.
In the attempt to unravel the mechanism underlying the loss of
CBX7 gene expression in malignant thyroid neoplasias, we
analyzed LOH at the CBX7 locus (22q13.1). We detected LOH in
36.8% and 68.7% of the PTC and ATC, respectively, but not in FTA.
However, no mutations were found in thyroid carcinomas;
moreover, no hypermethylation status was observed in ATC (data
not shown), which are practically devoid of CBX7 expression.
Therefore, we suggest that other epigenetic mechanisms associated
with an allelic loss might account for the reduced CBX7 expression
in thyroid carcinomas. Consistent with this hypothesis, our
preliminary data indicate that the HMGA1 proteins, also overex-
pressed in highly malignant neoplasias (39), are able to directly
down-regulate the CBX7 expression.
The data reported here seem to propose CBX7 as a tumor
suppressor gene. However, recent publications (11, 12, 33) seem to
attribute oncogenic functions to CBX7. In fact, it has been shown,
by the generation of transgenic mice overexpressing CBX7, that
CBX7 can initiate T-cell lymphomagenesis and cooperate with c-
Myc to produce highly aggressive B-cell lymphomas (33). Moreover,
it has been also shown that CBX7 expression facilitates the survival
of the mouse embryonic fibroblasts (11), consistently with a CBX7
oncogenic role. These contrasting results are, in our opinion, not
mutually exclusive at all. The cellular context can account for the
opposite functions attributed to CBX7. We retain that this can
occur with a certain frequency with chromatin proteins: the
cellular partners, which may vary from cell to cell, can modify the
action exerted by them. This hypothesis is supported by the studies
on the HMGA1 proteins that are overexpressed in most of the
malignant tumors, and in vitro and in vivo studies showed the
oncogenic activity of overexpressed HMGA proteins (40–42).
However, the phenotype of the null mice revealed that the HMGA1
gene plays a hitherto unsuspected tumor suppressor role because
they developed, even at the heterozygous state, B-cell lymphomas
and myeloid malignancies (43). There are also evidence that some
E2F family members are able to act as both oncogene and tumor
suppressor gene depending on the context (44). In fact, E2F1
expression can either promote or inhibit tumorigenesis depending
on the nature of the other oncogenic mutations that are present
(44). The dual role of the CBX7 gene as an oncogene or a tumor
suppressor is also suggested by the loss of CBX7 expression in
pediatric ependymomas (45), and also by our recent data showing a
correlation between CBX7 overexpression and a high malignant
Figure 5. qRT-PCR analysis of CDKN2A/p16 expression in human thyroid
tumor samples of different histotypes. The fold change indicates the relative
change in expression levels between tumor samples and normal samples,
assuming that the value of each normal sample is equal to 1.
5 P. Pallante and L. Terracciano, in preparation.
6 P. Pallante and G. Troncone, in preparation.
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phenotype in head and neck tumors, although an inverse
correlation has been found in ovary, lung, and colon carcinomas.7
Moreover, mouse embryonic fibroblasts (MEF) null for CBX7
(generated in our laboratory) have a higher proliferation rate than
the wild-type MEFs, whereas the CBX7+/ MEFs show an
intermediate behavior, suggesting a negative role of the CBX7
protein in the growth of these cells (Supplementary Fig. S1).
In conclusion, our data indicate that a reduced CBX7 gene
expression is associated with a malignant phenotype of thyroid
neoplasias and suggest that the loss of CBX7 could contribute to
thyroid cancer progression.
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Abstract
Chromobox protein homologue 7 (CBX7) is a chromobox
family protein encoding a novel polycomb protein, the
expression of which shows a progressive reduction, well
related with the malignant grade of the thyroid neoplasias.
Indeed, CBX7 protein levels decreased in an increasing
percentage of cases going from benign adenomas to papillary,
follicular, and anaplastic thyroid carcinomas. To elucidate the
function of CBX7 in carcinogenesis, we searched for CBX7
interacting proteins by a proteomic analysis. By this
approach, we identified several proteins. Among these
proteins, we selected histone deacetylase 2 (HDAC2), which
is well known to play a key role in neoplastic cell
transformation and down-regulation of E-cadherin expres-
sion, the loss of which is a critical event in the epithelial-to-
mesenchymal transition. We confirmed by coimmunoprecipi-
tation that CBX7 physically interacts with the HDAC2 protein
and is able to inhibit its activity. Then, we showed that both
these proteins bind the E-cadherin promoter and that CBX7
up-regulates E-cadherin expression. Consistent with these
data, we found a positive statistical correlation between CBX7
and E-cadherin expression in human thyroid carcinomas.
Finally, we showed that the expression of CBX7 increases the
acetylation status of the histones H3 and H4 on the E-cadherin
promoter. Therefore, the ability of CBX7 to positively regulate
E-cadherin expression by interacting with HDAC2 and
inhibiting its activity on the E-cadherin promoter would
account for the correlation between the loss of CBX7
expression and a highly malignant phenotype. [Cancer Res
2009;69(17):7079–87]
Introduction
Chromobox protein homologue 7 (CBX7) gene encodes a novel
polycomb protein of 28.4 kDa and 251 amino acids, which contains
a ‘‘chromodomain’’ between amino acids 10 and 46 (1, 2). CBX7 is a
chromobox family protein and a member of the polycomb
repressive complex 1, which, together with the polycomb repressive
complex 2, maintains developmental regulatory genes in a silenced
state (3–5). Mouse Cbx7 associates with facultative heterochroma-
tin and with the inactive X chromosome, suggesting a role of the
Cbx7 protein in the repression of gene transcription (6, 7). We have
found previously that the CBX7 gene was drastically down-
regulated in six thyroid carcinoma cell lines versus normal thyroid
cells. Subsequently, the analysis of CBX7 expression in a large
number of thyroid carcinoma samples revealed a progressive
reduction of CBX7 levels that was well related with the malignant
grade of the thyroid neoplasias (8). Indeed, it decreased in an
increasing percentage of cases going from benign adenomas to
papillary, follicular, and anaplastic thyroid carcinomas (9, 10). The
analysis of rat and mouse models of thyroid carcinogenesis gave
rise to very similar results (8). More recent results confirmed a
correlation between low CBX7 expression and a reduced survival in
colon carcinoma patients.5 Moreover, the association between lack
of CBX7 expression and a more aggressive histotype has also been
shown by our group in breast, ovary, and prostate carcinomas.6
Restoration of CBX7 expression in thyroid cancer cells reduced
their growth rate, indicating that CBX7 plays a critical role in the
regulation of transformed thyroid cell proliferation (8).
The aim of the present work has been to elucidate the
mechanisms by which the loss of CBX7 is involved in carcinogen-
esis, attempting to identify the CBX7 protein partners by
performing a functional proteomic experiment. Here, we show
that CBX7 interacts with histone deacetylase 2 (HDAC2)
and inhibits its activity. Moreover, both HDAC2 and CBX7 bind
the E-cadherin (CDH1 ) promoter, and CBX7 contrasts the
inhibiting effect of HDAC2 on E-cadherin expression.
Therefore, the ability of CBX7 to positively regulate E-cadherin
expression might account for the correlation of the loss of CBX7
expression with a highly malignant phenotype in cancer patients.
Materials and Methods
Cell culture and transfections. TPC1 and NPA (derived from thyroid
papillary carcinomas) and PC Cl3, HEK 293, and HeLa cells were grown as
described previously (8, 11). PC Cl3 cells are differentiated thyroid cells of
18-month-old rat Fischer origin depending on thyrotropine for the growth
(12). For the inhibition of CBX7 expression, rat Cbx7 small interfering RNANote: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
Requests for reprints: Alfredo Fusco, Istituto di Endocrinologia ed Oncologia
Sperimentale del CNR, via Pansini 5, 80131 Napoli, Italy. Phone: 39-81-7463602; Fax: 39-
81-2296674; E-mail: afusco@napoli.com or alfusco@unina.it.
I2009 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-09-1542
5 Pallante et al., submitted for publication.
6 Pallante, Terracciano, and Troncone, manuscript in preparation.
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(SI01495795 and SI01495802; Qiagen) and nonsilencing control small
interfering RNA (1022076; Qiagen) were transfected using Oligofectamine
(Invitrogen) according to the manufacturer’s recommendations. CBX7 -
inducible NPA cells were generated by transfecting NPA cells with the
pcDNA6/TR regulatory vector (Invitrogen). Trichostatin A (Sigma) treat-
ments were done for 24 h after transfection.
Plasmids. V5-tagged CBX7 expression plasmid was generated by the
insertion of the PCR product CBX7 cDNA into pcDNA-DEST-40 Gateway
Vector (Invitrogen). HA-tagged CBX7 expression plasmid was obtained by
PCR amplification and subcloned into the pCefl-HA expression vector.
CBX7-deletion mutants were cloned in pCefl-HA as well.
Protein extraction, Western blotting, and immunoprecipitation
assays. Protein extraction, Western blotting, and coimmunoprecipitation
procedures were carried out as reported elsewhere (13). The antibodies
used for immunoprecipitation and Western blotting were anti-CBX7 (8),
anti-HA (Roche), anti-V5 (Sigma), anti-pan-cadherin (Sigma), and anti-
a-tubulin (Sigma).
GST pull-down experiments. GST fusion proteins were constructed by
cloning the human cDNA sequence in a pGEX4T-1 vector (Promega). GST
pull-down experiments were carried out as reported elsewhere (14).
HDAC activity assay. Cells were transfected with increasing amount of
CBX7 expression vector and were used to assay the HDAC activity according
to themanufacturer’s instructions of Histone Deacetylase AssayKit (Upstate).
Fresh human thyroid tissue samples. Neoplastic human thyroid
tissues and normal adjacent tissue or the normal contralateral thyroid lobe
were obtained as described previously (8).
RNA extraction, reverse transcription, and PCR analysis. Total RNA
isolation and reverse transcription-PCR (RT-PCR) from human tissues were
done as described previously (8, 15). Each reaction was carried out in
duplicate. We used the 2DDCTmethod to calculate relative expression levels
(16, 17). Detailed primer sequences are available as Supplementary
Materials and Methods.
Immunohistochemistry. Immunohistochemical analysis were done as
described previously (8).
Electrophoretic mobility shift assay. For gel shift analysis, nuclear
extracts were prepared as described elsewhere (18) and electrophoretic
mobility shift assay was done as described previously (19). The double-
strand oligonucleotides covered a region spanning from nucleotide 70 to
+54 of the human E-cadherin promoter with respect to the transcription
start site (TSS).
Chromatin immunoprecipitation and re-chromatin immunoprecip-
itation assays. After transfection, chromatin samples were processed for
chromatin immunoprecipitation and re-chromatin immunoprecipitation
experiments as reported elsewhere (19). Samples were subjected to
immunoprecipitation with the following specific antibodies: anti-HA
(Roche) and anti-HDAC2, anti-H3K4m2, anti-H3K4m3, anti-H3K9me, anti-
H3K9m3, and anti-H4K20 (Upstate). The sequences of the used primers are
available as Supplementary Materials and Methods.
Transactivation assay. Cells were transiently transfected with the
reporter construct in which the luciferase gene was driven by described
fragments of E-cadherin promoter (20, 21) and normalized with the use of a
cotransfected h-galactosidase construct. Luciferase activity was analyzed by
Dual-Light System (Applied Biosystems).
DNA extraction and methylation analysis. DNA was prepared using
QIAamp DNA Mini Kit (Qiagen) following the instruction manual. PCR
primers to analyze E-cadherin promoter were designed by using
Methprimer (22). The MassCLEAVE biochemistry was done as described
previously (23). Mass spectra were acquired by using a MassARRAY
Compact matrix-assisted laser desorption/ionization—time-of-flight
(Sequenom) and spectra methylation ratios were generated by the Epityper
software version 1.0 (Sequenom).
Statistical analysis. For the comparison between two groups of
experiments, Student’s t test was used. The statistical significant difference
was considered when P < 0.05. A Pearson correlation coefficient (R2) close
to 1 was considered indicative of a significant direct correlation. All
experiments were done in triplicate and the data are mean F SD of three
independent experiments.
Results
CBX7 physically interacts with HDAC2 protein. To investigate
the mechanisms by which the loss of CBX7 expression correlates
with the highly malignant phenotype, we searched for CBX7
interacting proteins by performing a functional proteomic analysis.
Therefore, we transiently transfected the HEK 293 cells with a V5-
tagged CBX7 expression vector, immunoprecipitated the nuclear
protein lysates with anti-V5 antibodies (Supplementary Fig. S1A),
and fractionated the immunoprecipitated material on a 12% one-
dimensional gel and stained with colloidal Coomassie (Supple-
mentary Fig. S1B). After SDS-PAGE, single components of the
immunoprecipitated complexes were analyzed by mass spectrom-
etry (24). In Supplementary Table S1, we report some representa-
tive CBX7 interacting proteins. Among them, we focused our
attention on HDAC2 because of its relevance in tumor biology (25).
HDACs catalyze the removal of acetyl groups from core histones
and, because of their ability to induce local condensation of
chromatin, are generally considered repressors of transcription.
To verify the CBX7/HDAC2 interaction in vivo , HEK 293 cells
were transiently transfected with the V5-tagged CBX7 expression
Figure 1. CBX7 interacts with HDAC2.
A, HEK 293 cells were transiently
transfected with V5-tagged CBX7 or empty
vector and total cell extracts (TCE ) were
coimmunoprecipitated using anti-V5
antibodies. Immunocomplexes were
analyzed by Western blot with either
anti-V5 or anti-HDAC2 antibodies. IgG
indicates the negative control of
immunoprecipitation using an unrelated
antibody. B, GST pull-down assay with
GST or recombinant GST-CBX7 proteins
(wild-type and mutants as schematically
reported below). The filter was incubated
with an anti-HDAC2 antibody.
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vector. Protein lysates were immunoprecipitated with either anti-
V5 or anti-HDAC2 antibodies and immunoblotted with both anti-
V5 and anti-HDAC2 antibodies (Fig. 1A ; Supplementary Fig. S1C).
As shown in Fig. 1A , we detected the association between CBX7
and the endogenous HDAC2 protein, confirming that CBX7 and
HDAC2 form complexes in vivo .
To further examine the specificity of this interaction, and to map
the regions of CBX7 protein required for the binding to HDAC2,
pull-down assays were done incubating total cell extracts deriving
from HEK 293 cells, with the CBX7 recombinant protein fused to
GST (GST-CBX7) and with two deletion mutants of CBX7: GST-
CBX7-CHROMO (1-100 amino acids) and GST-CBX7-NOCHROMO
(55-251 amino acids). As shown in Fig. 1B , HDAC2 interacts with
both GST-CBX7 and GST-CBX7-NOCHROMO mutants but not with
the GST alone or the GST-CBX7-CHROMO mutant. These results
clearly show that the CBX7 chromodomain is not required for the
interaction between CBX7 and HDCA2.
CBX7 inhibits HDAC activity. To evaluate the effects of the
CBX7/HDAC2 interaction on the HDAC2 activity, nuclear extracts
from HeLa and NPA cells were prepared and the ability of
increasing amount of transfected CBX7 to modulate HDAC activity
was tested using a HDAC activity assay. CBX7 expression
significantly inhibited HDAC activity in a dose-dependent manner
(the percentage of inhibition was 65.15% and 42.55% in HeLa and
NPA cells, respectively, after the transfection of 10 Ag CBX7
expression vector; Fig. 2A and B). As positive control for HDAC
inhibition, we used 250 mmol/L sodium butyrate, a strong HDAC
inhibitory compound (26, 27). Nuclear extracts from NPA trans-
fected with CBX7 were immunoprecipitated with anti-HDAC2
antibodies. Then, immunoprecipitated material was tested using a
HDAC activity assay. As shown in Fig. 2C , CBX7 specifically
inhibited HDAC2 activity.
CBX7 binds to the E-cadherin gene promoter. It has been
recently shown that HDAC2 is involved in the repressive complex
that silences the E-cadherin gene expression during tumor
progression (28). E-cadherin is emerging as one of the caretakers
of the epithelial phenotype because the loss of its expression has
been shown to be a critical event of epithelial-to-mesenchymal
transition (29, 30). Therefore, to evaluate whether CBX7 was able
to bind the E-cadherin promoter in vitro , we performed an
electrophoretic mobility shift assay. Nuclear extracts from HEK 293
cells transiently transfected with either V5-tagged CBX7 or empty
vectors were incubated with a radiolabeled oligonucleotide
corresponding to the E-cadherin promoter. As shown in Fig. 3A ,
the E-cadherin oligonucleotide forms a specific complex (indicated
in the figure as A) with nuclear proteins of cells transfected with
V5-tagged CBX7, which was not present in mock-transfected cells
(compare lanes 1 and 2). Binding specificity was shown by
incubating the nuclear extract with a 100-fold molar excess of
unlabeled E-cadherin oligonucleotide (lanes 3 and 4).
Then, HEK 293 and HeLa cells were transiently transfected with
HA-tagged CBX7 expression vector, tested by Western blotting for
protein expression (Fig. 3B), crosslinked, and immunoprecipitated
with anti-HA or IgG antibodies. Immunoprecipitation of chromatin
was subsequently analyzed by semiquantitative PCR using primers
spanning the region of the E-cadherin promoter (300 bp
upstream to +40 bp downstream to the TSS). Anti-HA antibodies
precipitated this E-cadherin promoter region from HEK 293 and
HeLa cells transfected with HA-tagged CBX7 protein. No immuno-
precipitation was observed with IgG precipitates, and when
primers for the control promoter GAPDH were used (Fig. 3B),
indicating that the binding is specific for the E-cadherin promoter.
Similar results were obtained when NPA cells were used (data not
shown). These results indicate that CBX7 binds the E-cadherin
promoter region in vivo .
Then, to investigate whether the physical interaction between
CBX7 and HDAC2 takes place on the human E-cadherin promoter,
we performed re-chromatin immunoprecipitation analysis. HEK
293 cells transiently transfected with HA-tagged CBX7 were
crosslinked and immunoprecipitated with anti-HDCA2 antibodies.
The anti-HDAC2 complexes were released, re-immunoprecipitated
with anti-HA antibodies, and then analyzed by PCR. The results
shown in Fig. 3C reveal that the antibodies against HA precipitate
the E-cadherin promoter after their release from anti-HDAC2,
indicating that CBX7 occupies this promoter region together with
HDAC2. The reciprocal experiment provided comparable results
(Fig. 3D). Taken together, these results indicate that CBX7 binds the
human E-cadherin promoter in vivo and participates in the same
DNA-bound complexes that contain HDAC2.
CBX7 positively regulates the E-cadherin promoter. To
evaluate the effect of CBX7 expression on E-cadherin transcription,
HEK 293 cells were transiently cotransfected with an expression
Figure 2. CBX7 inhibits HDAC activity. HeLa and NPA cells (A and B , respectively), transiently transfected with increasing amounts of CBX7 expression vector,
were assayed for HDAC activity. Samples treated with sodium butyrate (NaB ) were used as positive control of HDAC activity inhibition. Aliquots of the same
lysates were immunoblotted with the indicated antibodies (bottom ). C, NPA cells were transiently transfected with the CBX7 expression vector or the
empty vector. Nuclear extracts were immunoprecipitated using anti-HDAC2 antibodies and assayed for HDAC activity. Mean F SD of three independent
experiments.
CBX7 Up-regulates E-Cadherin Expression
www.aacrjournals.org 7081 Cancer Res 2009; 69: (17). September 1, 2009
vector encoding CBX7 and with a reporter vector carrying the
luciferase gene under the control of the E-cadherin promoter. As
shown in Fig. 4A (top), CBX7 increases the transcriptional activity
of the E-cadherin promoter in a dose-dependent manner. The same
results were obtained on the NPA and TPC1 cell lines (Supple-
mentary Fig. S2A). The treatment of cells with trichostatin A, a
potent inhibitor of HDAC activity (31), cooperates with CBX7 to
induce E-cadherin gene transcription (Fig. 4A, bottom). These
results strongly suggest that CBX7 protein is involved in the E-
cadherin gene transcription likely counteracting with the already
known inhibitory effect of HDAC2 on this gene promoter.
To identify the region of CBX7 required for E-cadherin promoter
activation, we constructed two CBX7 deletion mutants in the
expression vector pCefl-HA: pCefl-HA-CBX7-CHROMO (1-100
amino acids) and pCefl-HA-CBX7-NOCHROMO (55-251 amino
acids). Transfection of the mutant pCefl-HA-CBX7-CHROMO,
containing only the chromodomain, did not induce transcriptional
activation of the E-cadherin promoter. Conversely, the mutant
lacking the chromodomain, pCefl-HA-CBX7-NOCHROMO,
induced a moderate activation of the E-cadherin promoter. Thus,
these data indicate that chromodomain is not essential for the
CBX7 transcriptional activity on the E-cadherin promoter
(Fig. 4B).
Moreover, to show that the expression of E-cadherin is directly
regulated by CBX7, we generated some clones of NPA cells (NPA
4-11 and NPA 5-11) in which CBX7 cDNA was under the control of
a tetracycline-regulated promoter. Western blot analysis (Fig. 4C,
top) and quantitative RT-PCR experiment (Fig. 4C, bottom) show
that the expression of CBX7 increases the levels of E-cadherin only
after treatment with tetracycline.
Figure 3. CBX7 binds to the E-cadherin
gene promoter. A, electrophoretic mobility
shift assay with nuclear extracts from HEK
293 cells transiently transfected with the
V5-tagged CBX7 expression vector or the
empty vector using the oligonucleotide
spanning from nucleotide 70 to +54 of the
human E-cadherin promoter as a probe.
To assess the specificity of the binding,
nuclear extracts were incubated in the
presence of a 100-fold excess of unlabeled
oligonucleotide used as competitor.
B, chromatin immunoprecipitation (ChIP )
assay using anti-HA antibodies in HEK 293
and HeLa cells transiently transfected
with HA-tagged CBX7 or the empty vector.
The associated DNA was amplified by PCR
using primers specific for the human
gene promoters (left ). For the E-cadherin
promoter, a region spanning from
nucleotide 300 to +40 of the gene with
respect to the TSS was used. IgGs were
used as an immunoprecipitation control.
C, re-chromatin immunoprecipitation
experiments in which soluble chromatin
immunoprecipitated with anti-HDAC2 was
re-immunoprecipitated with anti-HA.
IgG control refers to re-chromatin
immunoprecipitation with anti-HA.
D, re-chromatin immunoprecipitation
experiments in which soluble chromatin
immunoprecipitated with anti-V5 was
re-immunoprecipitated with anti-HDAC2.
IgG control refers to re-chromatin
immunoprecipitation with anti-HDAC2.
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To further confirm the role of CBX7 in the modulation of the
E-cadherin gene, we evaluated the expression of the E-cadherin
gene in the normal rat thyroid cell line PC Cl3 in which the
synthesis of Cbx7 was suppressed by RNA interference. The
knockdown of the Cbx7 mRNA levels, observed at 48 h after
treatment, resulted in the reduction of E-cadherin mRNA levels in
comparison with the untreated cells or those treated with the
nonsilencing control small interfering RNA (Fig. 4D).
To identify the regulatory elements essential for the activity of
CBX7 on the E-cadherin promoter, we also tested some deletion
mutants of the E-cadherin promoter: E-cadherin 601 and
E-cadherin 211 (20, 21). Activation of E-cadherin promoter by
CBX7 protein was maintained on full-length and 601 mutants of
E-cadherin promoter. Conversely, the 211 mutant, which lacks a
portion of 70/+54 sequence (able to bind CBX7), was not
activated by CBX7 protein (Supplementary Fig. S2B).
CBX7 expression results in increased histone acetylation of
the E-cadherin promoter. During the last years, chromatin
remodeling and histone modifications have emerged as the main
mechanisms in the control of gene expression and the connection
between DNA methylation and histone deacetylation in the
silencing of genes has been established (32–37).
Because we have shown previously that CBX7 (a) interacts with
HDAC2 on the human E-cadherin promoter, (b) increases the
transcriptional activity of the E-cadherin promoter in a dose-
dependent manner, and (c) reduces the activity of HDACs, we
hypothesized that the positive effect on E-cadherin activation by
CBX7 may be due to its ability to reduce the HDAC activity on the
E-cadherin promoter. Therefore, we have evaluated the lysine
acetylation of histone tails at the E-cadherin promoter.
HEK 293 cells were transiently transfected with V5-tagged CBX7
expression vector or empty vector. Then, the cells were crosslinked
and DNA-chromatin was immunoprecipitated with anti-H3 or anti-
H4 acetylated or IgG antibodies. The immunoprecipitated
chromatin was subsequently analyzed by quantitative PCR
using primers spanning the region of the E-cadherin promoter
Figure 4. CBX7 enhances E-cadherin
promoter activity. A, top, dose-response
analysis of increasing amounts of CBX7 on
the E-cadherin luciferase-reporter vector
transiently transfected into HEK 293 cells.
Western blot analysis confirmed the
increasing amounts of CBX7 expression.
a-Tubulin expression served as a
control of equal protein loading. Bottom,
dose-response analysis of increasing
amounts of CBX7 on the E-cadherin
luciferase-reporter vector transiently
transfected into HEK 293 cells treated or
not with 300 nmol/L of HDAC inhibitor
trichostatin A (TSA ). B, dose-response
analysis of increasing amounts of CBX7
and the two CBX7 -deletion mutants
(schematically illustrated in Fig. 1B) on the
E-cadherin luciferase-reporter vector
transiently transfected into HEK 293 cells.
C, top, Western blot analysis of CBX7
and E-cadherin expression in the NPA cell
clones 4-11 and 5-11 treated or not
with tetracycline. The treatment
with tetracycline (+tet) was indicated on
the top. a-Tubulin expression served as a
control of equal protein loading. Bottom,
quantitative RT-PCR (qRT-PCR ) analysis
of E-cadherin expression in the same
NPA cell clones. The relative expression
indicates the relative change in E-cadherin
expression levels between treated cells
versus the untreated ones, assuming that
the value of E-cadherin expression in the
untreated cells is equal to 1. D, Cbx7 and
E-cadherin gene expression was evaluated
by RT-PCR in rat PC Cl3 cells after
treatment with small interfering
RNA against rat Cbx7 . The expression of
GAPDH was used to normalize the
amounts of RNAs used in the experiment.
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(70 bp upstream to +54 bp downstream to the TSS; ref. 38). As
shown in Fig. 5A , higher amounts of H3 and H4 acetylated tails
were detected in the E-cadherin promoter in the cells transfected
with CBX7, with respect to those detected in mock-transfected
cells, indicating an increased histone acetylation in CBX7-trans-
fected cells, likely due to the ability of CBX7 to reduce HDAC
activity. We also treated the cells, transfected or not with CBX7,
with trichostatin A to verify the HDAC activity on H3 and H4 tails.
As shown in the same figure, there were higher amounts of H3
and H4 acetylated tails in CBX7-transfected samples treated
with trichostatin A than in untreated cells. These results indicate
that CBX7 protein regulates the E-cadherin expression by
modifying histone acetylation at its promoter, likely reducing
HDAC activity.
Increasedmethylation of H3K4 and decreasedmethylation of
H3K9 and H4K20 in CBX7-transfected cells. Lysine methylation
can have different effects depending on which residue is modified:
methylation of H3K4 and H3K36 is generally associated with
transcribed chromatin; in contrast, methylation of H3K9, H3K27,
and H4K20 generally correlates with gene repression (38). Therefore,
we have evaluated the lysine methylation status of histone tails of
E-cadherin promoter in presence or absence of CBX7.
HEK 293 cells were transiently transfected with V5-tagged CBX7
or empty vectors and crosslinked, and DNA-chromatin was
immunoprecipitated with anti-H3K4m2, anti-H3K4m3, anti-
H3K9m2, anti-H3K9m3, and anti-H4K20m3 or IgG antibodies.
The immunoprecipitated chromatin was subjected to PCR with
specific primers for the E-cadherin promoter region (70/+54).
Higher amounts of chromatin immunoprecipitated for H3K4m2
and H3K4m3 were observed in the CBX7-transfected cells
compared with the control ones, indicating that this lysine is
methylated in a higher proportion in CBX7-transfected cells with
respect to that observed in control cells. Conversely, in the case of
chromatin immunoprecipitated for the H3K9m2, H3K9m3, and
H4K20m3, higher amounts of chromatin were detected in control
cells, indicating that these sites were methylated at a higher level in
the control cells versus CBX7-transfected cells (Fig. 5B). These data
indicate that CBX7 is able to alter the methylation status of specific
lysines of E-cadherin promoter, promoting the transcriptional
activity of E-cadherin promoter.
CBX7 and E-cadherin expression levels are correlated in
human thyroid carcinomas. E-cadherin down-regulation, due to
epigenetic mechanisms, including transcriptional repression, also
mediated by HDAC activity, and promoter hypermethylation is a
frequent event during human cancer progression (39, 40). Because
previous experiments showed that CBX7 expression was lost in
most advanced thyroid cancers, we hypothesized the down-
regulation of E-cadherin as a possible mechanism by which loss
of CBX7 is involved in advanced stages of thyroid carcinogenesis.
This hypothesis was also supported by recent results showing a
role of polycomb repressive complex 1/2 in the regulation of E-
cadherin expression (41).
Therefore, we analyzed CBX7 and E-cadherin mRNA levels in
human thyroid carcinomas of different histotypes (Fig. 6A).
CBX7 and E-cadherin mRNA levels were drastically reduced in
anaplastic thyroid carcinoma, whereas just a weak decrease
was observed for both genes in papillary thyroid carcinoma.
The epithelial-to-mesenchymal transition in our tumor samples
was also confirmed by the increased N-cadherin expression
(Fig. 6A).
Figure 5. Analysis of the histone code modifications of the human E-cadherin promoter. A, HEK 293 cells transiently transfected with V5-tagged CBX7 expression
or empty vectors, and treated or not with trichostatin A for 24 h, were subjected to chromatin immunoprecipitation using anti-acetyl histone H3 (H3ac ; left ) and
anti-acetyl histone H4 (H4ac ; right ) and analyzed by quantitative RT-PCR for the E-cadherin promoter. B, HEK 293 cells transiently transfected with V5-tagged CBX7
expression or empty vectors were subjected to chromatin immunoprecipitation using anti-H3K4m2 and anti-H3K4m3 (left ), anti-H3K9m2 and anti-H3K9m3
(middle ), and anti-H4K20m3 (right ) and analyzed by quantitative RT-PCR for the E-cadherin promoter.
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We found a positive statistical correlation between CBX7
and E-cadherin expression in human thyroid carcinomas as
shown in Fig. 6B . We also compared CBX7 and E-cadherin
at protein level, by immunohistochemical analysis, confirming
that E-cadherin protein expression parallels that of CBX7
(Fig. 6C).
Because hypermethylation of the E-cadherin promoter has
been postulated to play a critical role in the loss of E-cadherin
expression and has been reported previously in other cancers,
we decided to investigate the DNA methylation status of
E-cadherin promoter (42). We analyzed DNA methylation status
of 26 CpG sites located in a 368-bp region spanning the E-
cadherin gene TSS (Fig. 6D, inset) on 16 papillary thyroid
carcinomas, 15 follicular variants of papillary thyroid carcinomas,
4 anaplastic thyroid carcinomas, and 4 normal thyroid tissue
samples. A very low level of methylation was present in both
normal and tumor samples, with the exception of only one
anaplastic thyroid carcinoma sample in which a high degree of
methylation was detected (Fig. 6D).
Therefore, epigenetic mechanisms, other than hypermethylation
of the E-cadherin promoter, have a critical role in the down-
regulation of E-cadherin expression.
Figure 6. CBX7 and E-cadherin gene expression levels are correlated in human thyroid carcinomas. A, CBX7, E-cadherin , and N-cadherin gene expression in thyroid
tumor samples was analyzed by quantitative RT-PCR. Relative expression indicates the change in expression levels between tumor and normal samples,
assuming that the value of each normal sample is equal to 1. B, positive statistical correlation between CBX7 and E-cadherin expression in human thyroid carcinomas
analyzed in A. R2, Pearson correlation coefficient. C, immunohistochemical analysis of normal and tumor samples stained with anti-CBX7 and anti-E-cadherin
antibodies. The percentage of positive cells for the staining/total number of cells was reported. D, top, positions of the primers used for amplifications of the region
spanning from nucleotide 200 to + 200 of E-cadherin with respect to the TSS; bottom, average methylation degree of 26 CpG sites at E-cadherin promoter in
human thyroid carcinomas. PTC, papillary thyroid carcinoma; ATC, anaplastic thyroid carcinoma.
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Discussion
Our group has reported previously that CBX7 gene is drastically
down-regulated in thyroid carcinomas and its expression progres-
sively decreases with malignant grade and neoplastic stage (8).
These data suggest that the loss of CBX7 expression may be strictly
correlated with the acquisition of invasiveness accompanied by the
loss of the epithelial features and the gain of a mesenchymal
phenotype, a process known as epithelial-to-mesenchymal transi-
tion. E-cadherin is a main component of the cell-cell adhesion
junctions that plays a principal role in maintaining normal
epithelial cell morphology, therefore emerging as one of the
caretakers of the epithelial phenotype. In most cancers, E-cadherin
down-regulation during neoplastic progression occurs by epige-
netic mechanisms, including transcriptional repression, in some
cases mediated by HDAC activity (40), and hypermethylation of the
promoter (42). Only in a few cases mutations have been found in
the E-cadherin gene leading to the absence or the expression of
a nonfunctional protein (29). For this reason, we evaluated
E-cadherin expression in human thyroid carcinomas of different
histotypes: an evident correlation was found between CBX7 and
E-cadherin expression levels in human thyroid carcinomas, both
being drastically down-regulated in anaplastic thyroid carcinomas
in comparison with the normal thyroid tissue. Interestingly, no
hypermethylation of E-cadherin promoter was observed in thyroid
carcinomas. Therefore, we have hypothesized a role for CBX7 as a
transcriptional repressor of E-cadherin. We have shown that CBX7
binds to E-cadherin gene promoter in vitro by electrophoretic
mobility shift assay and in vivo by chromatin immunoprecipitation
and is able to positively regulate the activity of E-cadherin
promoter. At the same time, a proteomic approach, aimed to
unravel the mechanism by which the loss of CBX7 expression is
involved in cancer progression, has identified HDAC2 among the
CBX7 interacting proteins. HDACs regulate the expression and
activity of numerous proteins involved in both cancer initiation
and cancer progression, inducing a nonpermissive chromatin
conformation that prevents the transcription of genes encoding
proteins involved in tumorigenesis. HDACs are often overexpressed
in many tumors (25).
Here, we show that CBX7 physically interacts with HDAC2
protein inhibiting its activity. Chromatin immunoprecipitation
shows that both HDAC2 and CBX7 bind the E-cadherin promoter.
We also show the ability of CBX7 to positively regulate E-cadherin
expression by interacting with HDAC2 and inhibiting its activity on
the E-cadherin promoter. Further, we show that, in the presence of
the CBX7 protein, there is an increased histone acetylation of the
E-cadherin promoter, validating our hypothesis that CBX7 recruits
HDCA2 on the E-cadherin promoter. Moreover, we showed modi-
fications in the histone methylation state on the E-cadherin
promoter in the cells transfected with CBX7 confirming a
relationship between acetylation and DNA methylation (36).
It is noteworthy that, among CBX7 interacting proteins, we have
also identified an arginine methylation protein that can have a
regulator effect on HDACs activity, because a cross-talk between
histone acetylation and arginine methylation has also been
observed (43). In fact, histone deacetylation is a prerequisite for
PRMT5-mediated H3 and H4 arginine methylation, whereas histone
acetylation enhances H3R17 methylation by PRMT4 (44–46).
In conclusion, here we propose a novel pathway regulating the
progression step of carcinogenesis in which the CBX7 protein, the
loss of expression of which correlates with a highly malignant
phenotype, is a key molecule. Indeed, our results indicate that the
loss of CBX7 expression contributes to cancer progression by
down-regulating E-cadherin expression because of the lack of its
inhibitory effect on HDAC activity on the E-cadherin promoter.
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